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ABSTRACT 
 
TOWARDS THE TOTAL SYNTHESIS OF SPIRASTRELLOLIDE E: 
INVESTIGATIONS INTO ADVANCED SOUTHERN HEMISPHERE FRAGMENTS 
Alexander Sokolsky 
Professor Amos B. Smith, III 
  
 This dissertation describes progress towards the synthesis of spirastrellolide E, a potent 
cytotoxic marine macrolide. In particular, the synthesis of advanced southern hemisphere 
fragments is reported. Chapter 1 details the isolation, structural determination, and biological 
activity of the spirastrellolide family, as well as synthetic efforts towards members of the family. 
Chapter 2 describes the evolution of the Smith group synthetic strategy towards the 
spirastrellolides, details the choice of target for a total synthesis effort, and describes a successful 
first generation approach to a relevant advanced southern hemisphere fragment. Key steps 
involve a convergent Type I Anion Relay Chemistry (ARC) union and a gold catalyzed directed 
spiroketalization. Chapter 3 then revises the overall retrosynthetic analysis by proposing a novel 
strategy for hemisphere union, involving a cross metathesis/epoxidation/epoxide ring opening 
cascade, and describes the synthesis of more than 500 mg of a revised southern hemisphere 
fragment. In addition, the mechanism of the key directed gold catalyzed spiroketalization is 
discussed in detail. A stereochemical rationale for diverging outcomes during spiroketalization is 
described. 
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1 CHAPTER 1 
1.1  Isolation and Structural Determination of Spirastrellolide A and Congeners 
  In 2003, the Anderson group reported that the extracts of the sponge spirastrella 
coccinea displayed potent activity in a cell assay testing for mitotic arrest.1 The major bioactive 
component of this extract was isolated and termed spirastrellolide A. The authors originally 
proposed structure 1.1 (Figure 1-1) based on extensive 2D NMR analysis; however, in a 
subsequent report,2 the authors revised the skeletal connectivity based on improved mass 
spectral data;  structure 1.2 ultimately proved to be correct (vide infra). 
 
Figure 1-1 Original and revised structure of spirastrellolide A (1.2) 
 At the time of their initial report, Anderson and coworkers were able to identify the 
relative stereochemistry of the southern hemisphere spiroketal and one of the northern 
hemisphere rings based on ROESY spectroscopy. With the revision of the skeletal connectivity, 
the group was next able to clarify further the stereochemistry by determining the relative 
stereochemistry of the C(3)-C(7), C(9)-C(24) and C(27)-C(34) fragments (see Figure 1-1 for 
numbering). The relative configuration between the various domains, as well as the 
stereogenicity of the isolated C(46) carbinol, remained undetermined. It was not until the 
Anderson group isolated spirastrellolide B (1.3, Figure 1-2) in 2007 from the same sponge
3
 that 
advances were made on this structural dilemma. Spirastrellolide B differs from A  both by lack of 
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a chlorine atom at C(28) and saturation of the C(15)-C(16) bond. The lack of unsaturation in the 
macrocyclic core of spirastrellolide B permitted degradation via oxidative side chain removal, 
which, in turn, led to the formation of derivative 1.4, which lacked the flexible side chain and 
permitted the growth of X-ray quality crystals for structural analysis.  
 
Figure 1-2 Conversion of spirastrellolide B to a derivative for X-ray characterization 
 Structural determination via X-ray analysis of 1.4 defined the relative and absolute 
stereochemistry of the spirastrellolide core. The final stereochemical hurdle was the 
stereogenicity of the remote C(46) carbinol, which had been removed during oxidative cleavage 
of the side chain. This issue was finally addressed by the Anderson group's isolation of 
spirastrellolides C-G later in 2007.4 The structures of these novel macrolides (1.5 - 1.9, Figure 1-
3) were shown to be very similar to that of spirastrellolides A and B, importantly, careful oxidative 
cleavage of the side chain in spirastrellolide D (1.6) permitted correlation to (R)-dimethyl malate, 
which unambiguously determined the last unknown structural detail at C(46).  
 From the initial isolation, spirastrellolide A (1.2) was recognized to have a very intriguing 
biological profile. In their original report,1 Anderson and coworkers noted the potent activity (IC50 
100 ng/mL) in their anti-mitotic assay, but no effect on tubulin polymerization, a feature not 
typically observed for other natural products possessing anti-mitotic activity.5 
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Figure 1-3 Spirastrellolides C-G 
 In addition, spirastrellolide A (1.2) was observed to accelerate entry of cells into mitosis 
from other stages of the cell cycle. This behavior lead the authors to suspect inhibition of Ser/Thr 
phosphotases,6 which was confirmed by in vitro assays. Importantly, spirastrellolide A (1.2) 
inhibits PP2A selectively (IC50 1 nM) over PP1 (IC50 50 nM) and PP2C (IC50 >1 µM). 
Spirastrellolides C-E show similar activity.4 In addition, spirastrellolides A and B isolated from a 
different sponge by Matsunaga and coworkers7 revealed activity against HeLa cells (20 and 40 
nM, respectively).     
1.2 Early Approaches to Spirastrellolide Fragments for Structural Determination 
 The combination of intriguing biological activity and breath-taking structural complexity of 
spirastrellolide A (1.2) attracted the attention of a large number of synthetic chemists. Initial 
attempts focused on identifying the relative configuration of the fragments, in particular the C(3)-
C(7) and C(9)-C(27) fragments, as their union would comprise an advanced southern hemisphere 
for a potential total synthesis. A number of groups thus targeted flexible approaches that would 
permit the synthesis of multiple diastereomers, with the eventual goal of correlating the 1H and 
13C NMR signals of synthetic analogues with the NMR chemical shifts reported for the natural 
product. In particular, the Paterson8 and De Brabander9 groups made notable early contributions 
in this vein. Their respective approaches are outlined below. 
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The Paterson Approach 
 In 2005, the Paterson group reported approaches to the southern hemisphere8 of the 
putative stereostructure of spirastrellolide A. Their approach (Scheme 1-1) featured a convergent 
strategy uniting a C(1)-C(16) alkyne (1.11) with a C(17)-C(25) aldehyde (1.12). 
 
Scheme 1-1 The Paterson approach to southern hemisphere stereochemical determination 
 The C(1)-C(16) alkyne 1.11 was further divided to isolate the C(1)-C(9) fragment (1.13), 
which was prepared as two enantiomers. In the forward sense, intermediate 1.14 could be taken 
forward to two enantiomeric methyl ketones (1.13), which could be transformed into two epimeric 
alkynes 1.18 in a 6 steps sequence (only one diastereomer shown in Scheme 1-1). The two 
diastereomeric alkynes were then coupled to aldehyde 1.12 and after two steps subjected to acid-
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catalyzed spiroketalization with concomitant protecting group loss. Unfortunately, comparison of 
the two diastereomers to the natural product proved inconclusive.  
The De Brabander Approach 
 In 2006, the De Brabander group reported a similar approach, also targeting two 
diastereomers of the C(1)-C(22) southern hemisphere varying in the stereogenicity of the C(3) 
and C(7) centers.9  Their synthesis is outlined in Scheme 1-2.  
 
Scheme 1-2 The De Brabander approach to southern hemisphere stereochemical determination 
 The two enantiomers of methyl ketone 1.23 were synthesized from commercial 
dihydropyran in a 6 step sequence. The stereogenicity of C(7) was set by choice of a suitable 
allylation reagent in the synthesis of 1.22, while the desired cis relative configuration was 
achieved by a diastereoselective Michael addition to provide 1.23. Each congener was next 
coupled to the C(11)-C(22) aldehyde 1.24 through an aldol condensation. Diastereoselective 
reduction and terminal PMB removal then furnished two possible C(1)-C(22) diastereomers. 
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Unfortunately, comparison of the NMR chemical shifts of these less elaborate congeners also did 
not lead to good agreement with the natural product. The authors attributed the discrepancies to 
possible conformation effects in the fully elaborated macrolide. 
1.3  Other approaches to spirastrellolide fragments  
 A number of other groups have reported approaches to various fragments of the 
spirastrellolides, which have not, to date, culminated in total syntheses. These are summarized 
below in chronological order of the first publication. 
The Hsung Approach 
 In 2005,10 the Hsung group reported the first in a series of papers outlining a strategy 
towards the C(11)-C(23) fragment of spirastrellolide A (1.2) based on their tethered ketal RCM 
strategy.11 After originally pursuing the incorrect diastereomer at C(22), the group settled on the 
route shown in Scheme 1-3.12-13  
 
Scheme 1-3 The Hsung approach to the C(1)-C(23) southern hemisphere fragment 
 Key intermediate 1.28, available in 11 steps from diethyl tartrate, underwent addition of 
vinylmagnesium bromide followed by ketalization with a functionalized alcohol to provide 
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intermediate 1.29, which formed the desired unsaturated spiroketal 1.30 upon ring-closing 
metathesis (RCM), under the action of the second generation Grubbs catalyst. Addition of the 
C(1)-C(11) fragment 1.32 to 1.31 via a Mukiyama aldol, reduction and protection then furnished 
the fully elaborated C(1)-C(23) fragment 1.34.  
 In 2014, the Hsung group also published an approach towards the northern hemisphere 
DEF ring system,14 as shown in Scheme 1-4. 
 
Scheme 1-4 Hsung approach to the northern hemisphere skeleton 
 In a similar fashion to their southern hemisphere synthesis, key intermediate 1.35 was 
condensed with alcohol 1.36 to form the corresponding ketal (1.37). Ring-closing metathesis, 
reduction of the resulting olefin and oxidative cyclization then provided a DEF ring system similar 
to that of the spirastrellolides.  
The Forsyth Approach 
 In 2006, the Forsyth group reported a strategy towards the C(26)-C(40) fragment 
(northern hemisphere).15 As seen in Scheme 1-5, straightforward construction of intermediate 
1.44 was followed by tandem sequential hetero-Michael additions of the requisite pendant 
alcohols onto the ynone and equilibration to the thermodynamic bis-spiroketal isomer to yield the 
desired core 1.45. 
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Scheme 1-5 The  Forsyth approach to the C(26)-C(40) northern hemisphere fragment 
 Notably, the authors were not able to incorporate readily the chlorine substituent at C(28) 
due to competitive epoxide formation with the C(29) hydroxyl under the highly basic conditions 
(c.f. potassium tert-butoxide) of the double hetero Michael addition (1.44 → 1.45). 
The Phillips Approach 
 In 2008, the Phillips group reported a highly convergent synthesis of the C(1)-C(23) 
fragment of the southern hemisphere of spirastrellolide B (which differs from A in the absence of 
the C(15)-C(16) unsaturation - see Scheme 1-6 for numbering). The synthesis begins with the 
straightforward construction of two complex fragments 1.47 and 1.49. The two fragments were 
then united through a novel intermolecular Kulinkovich cycloproponation and the resulting 
cyclopropyl alcohol fragmented under radical conditions to furnish ketone 1.50, which represents 
the full carbon skeleton of the southern hemisphere. Acid catalyzed spiroketalization completed 
the synthesis of 1.51. 
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Scheme 1-6 The Phillips approach to a C(1)-C(23) southern hemisphere fragment 
The Chandrasekhar Approach 
 Later in 2008, the Chandrasekhar group also published results towards a spirastrellolide 
B synthesis, focusing on the C(9)-C(25) fragment (Scheme 1-7).16 
 
Scheme 1-7 The Chandrasekhar approach to a C(9)-C(25) southern hemisphere fragment 
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 The group built up the C(17)-C(25) aldehyde 1.53 from glucose, then coupled the 
aldehyde to the C(9)-C(15) alkyne 1.56, followed by acid catalyzed spiroketalization to furnish 
1.58. Of particular note is the intriguing protecting group scheme used for the C(22)-C(25) 
domain, featuring an acetal masked hemiketal. 
The Brimble Approach 
 In 2010, the Brimble group reported studies directed towards the northern hemisphere of 
the spirastrellolide family;17 full details soon followed.18 The strategy centered on two key dithiane 
couplings: first, between dithiane 1.59 and epoxide 1.60; then, after a series of functional group 
manipulations, the derived aldehyde 1.62 and the dithiane 1.63. The resulting fragment, 1.64, 
representing the full C(25)-C(40) segment, was subjected to dithiane removal (Scheme 1-8) with 
concomitant cyclization to provide 1.65. Northern hemisphere fragment 1.66 was then available 
via a straightforward Barton reduction.   
 
Scheme 1-8 The Brimble approach to the C(25)-C(40) northern hemisphere fragment 
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The Rajesh Approach 
 Finally, in 2014, the Rajesh group published studies aimed at the southern hemisphere of 
spirastrellolide B (Scheme 1-9).19  
 
Scheme 1-9 The Rajesh approach to a C(1)-C(23) 
 The group constructed key fragments 1.68, 1.70, and 1.72. Intermediates 1.70 and 1.72 
were then coupled via an aldehyde alkynylation; fragment 1.68, in turn, was appended via 
selective cross metathesis to form the full C(1)-C(23) carbon skeleton of the spirastrellolide B 
southern hemisphere, albeit without spiroketal formation. 
1.4 Total Syntheses of Members of the Spirastrellolide Family 
 As the above approaches to various fragments of spirastrellolide congeners were being 
reported, the Paterson8,20–22 and Furstner23–25 groups focused on the total synthesis of 
spirastrellolide A (1.2), with occasional reports of their progress. These efforts culminated in 
successful approaches towards spirastrellolide congeners - the synthesis of spirastrellolide A 
(1.2) was achieved first by Paterson26–29 followed a few years later by Furstner.30 In the 
intervening years, the Furstner group achieved the first31,32 and second33 generation synthesis of 
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spirastrellolide F (1.7). Finally, the Paterson group published a second generation synthesis of 
spirasterellolide A (1.2).34 The evolution and eventual success of these approaches are outlined 
below.  
The Paterson Synthesis of Spirastrellolide A (1.2) 
 In 2005, the first reports from the Paterson laboratory targeted at spirastrellolide A (1.2) 
synthesis began to appear. The southern hemisphere approach was mentioned previously as an 
attempt to clarify the structural ambiguities present in the stereochemical information, still present 
at the time of their original report. The C(26)-C(39) northern hemisphere approach is summarized 
in Scheme 1-10.  
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Scheme 1-10 Synthesis of the C(27)-C(39) northern hemisphere fragment 1.83 
 The chlorine substituent at C(28) was installed at a very early stage by an 
enantioselective chloroallyl boration. The resulting allyl chloride 1.76 was taken on to 
phosphonate fragment 1.77, which was then coupled to ketal fragment 1.81 utilizing a Horner-
Wadsworth-Emmons olefination/conjugate reduction sequence. With the full carbon skeleton in 
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place, acid catalyzed spiroketalization provided the fully functionalized northern hemisphere 1.83, 
albeit in low yield due to the chemical instability of spiroketalization precursor 1.82. 
 In an attempt to improve this route, Paterson realized that both fragments featured an 
asymmetric hydroxylation to set carbinol stereocenters possessing the same absolute 
configuration. The strategy towards the northern hemisphere was therefore amended in a manner 
that the two dihydroxylations were performed simultaneously at a late stage, thereby installing 
sensitive functionality (i.e., the acid-sensitive ketal) towards the end of the route. In addition, the 
group decided to move away from the δ lactone protecting group due to problems associated with 
stability. After some optimization, the group settled on a revised route shown in Scheme 1-12. 
Thus, construction of a structurally simpler chloride 1.87 by similar chemistry as employed in the 
first generation route was followed by a double asymmetric dihydroxylation, and then by an acid 
catalyzed spiroketalization to furnish the fully protected northern hemisphere fragment 1.89. 
 
Scheme 1-11 An improved route to the northern hemisphere fragment 
 Although these original approaches to the spirastrellolide A (1.2) fragments were 
published in 2005-6, it was not until two years later that the group disclosed two communications 
describing the total synthesis of spirastrellolide A (1.2).26,27 The reason for this delay was made 
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clear with the publication of the full account in 2012 on the total synthesis spirastrellolide A in the 
Paterson laboratory.28,29 The latter publications detail the difficulties associated with the union of 
the northern and southern hemispheres of spirastrellolide A (1.2; Scheme 1-12 A). In particular, 
approaches that attempted to unite the two fully elaborated hemispheres via chemistry that does 
not generate additional unsaturation, (i.e., to avoid late stage chemoselectivity difficultes with the 
olefination present in the southern hemisphere spiroketal) proved unsuccessful due to the 
chemical instability of the northern hemisphere. Olefination proved similarly unsuccessful. As 
seen in Scheme 1-12,  even very simple building blocks (1.91 and 1.92) did not lead to successful 
bond formation presumably due to the steric encumbrance of the northern hemisphere. 
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Scheme 1-12 Hemisphere union attempts 
 It was at this stage that the Paterson group moved away from a synthetic strategy relying 
on the union of two fully elaborated hemispheres towards a more flexible strategy that built the 
southern hemisphere stepwise after initial addition of the C(17)-C(25) or C(17)-C(24) fragment to 
a fully elaborated northern hemisphere. Even with this revised synthetic plan, hemisphere union 
proved challenging, with a planned Julia olefination to forge the C(25)-C(26) bond proving 
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unsuccessful due to steric hinderence associated with the U-shaped northern hemisphere 
(Scheme 1-12 B). Fortunately, moving the site of fragment union one bond away from the 
northern hemisphere core to C(24) provided better results, with the C(24)-C(25) bond formation 
now being achieved by an sp2-sp3 Suzuki cross coupling (vide infra).     
 With these strategic considerations in mind, the revised Paterson retrosynthetic analysis 
is shown in Scheme 1-13. Initial removal of the sidechain leads to the macrocyclic core of 
spirastrellolide A (1.95), which was further disconnected by a retro-macrolactonization to provide 
the spirastrellolide A seco acid (1.96). A retro-spiroketalization/reduction/alkynylation sequence to 
install the southern hemisphere would then permit disconnection to aldehyde 1.98. The key 
C(24)-C(25) bond would then be forged by an sp2-sp3 Suzuki cross coupling between vinyl iodide 
1.100 and northern hemisphere fragment 1.99.  
 
Scheme 1-13 Revised retrosynthetic analysis 
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 To implement this analysis, the authors required a large supply of advanced material, 
particularly challenging in the case of the northern hemisphere; thus the route to the earlier 
fragment 1.99 was revised, this time with the goal of improved scalability. The final route for the 
requisite Paterson northern hemisphere precursor 1.107 is summarized in Scheme 1-14. 
 
Scheme 1-14 Revised northern hemisphere synthesis 
 Key changes include a modified aldehyde substrate for chloroallylboration (1.101) for the 
preparation of key methyl ketone 1.103. After aldol coupling with aldehyde 1.86, an improved 
synthesis of diketone 1.87 was implemented, which, while longer, permitted for significantly 
improved material throughput. Double asymmetric Shaprless dihydroxylation and spiroketalization 
as before now led to gram quantities of the northern hemisphere fragment precursor 1.107.  
 The southern hemisphere route at this juncture consisted of two fragments (1.99 and 
1.100, Scheme 1-13) to be installed in a stepwise fashion. To this end, vinyl iodide fragment 
1.100 was constructed via a nine step sequence, utilizing an Evans glycolate aldol with sensitive 
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aldehyde 1.109 (Scheme 1-15). Installation of the final stereocenter was then accomplished via 
diastereselective chelation-controlled reduction of the ketone available from the Grignard reaction 
of Weinreb amide 1.111 with allylmagensium bromide.  
 
Scheme 1-15 Synthesis of vinyl iodide 1.100 
 The remaining segment of the southern hemisphere (1.119) was constructed via a route 
adapted from previous iterations of the Paterson fully elaborated southern hemisphere syntheses 
(Scheme 1-16). Construction of tetrahydropyran containing aldehyde 1.116 was followed by a 
diastereselective aldol reaction to construct the carbon skeleton 1.117. Functional group 
manipulation then furnished the key alkyne fragment 1.119.  
 
Scheme 1-16 Revised synthesis of southern hemisphere fragment 
 Finally, the stannane ester 1.122 required for elaboration of the spirastrellolide side chain 
was prepared in a straightforward manner (Scheme 1-17). 
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Scheme 1-17 Synthesis of the side chain 
 With the fragments readily available, the group turned to their assembly. The first order of 
business was the addition of the C(17)-C(24) vinyl iodide 1.100 to the northern hemisphere 1.99 
(Scheme 1-18). To this end, northern hemisphere alcohol 1.89 was converted to the 
corresponding terminal olefin. Hydroboration of this olefin with 9-BBN for the proposed Suzuki 
reaction, followed by the addition of 1.100 in the presence of catalytic PdCl2(dppf), Ph3As as 
ligand and aqueous cesium carbonate as the base furnished the desired coupled product 1.123 in 
83% yield (!), validating the hypothesis that moving the site of bond formation away from the 
crowded northern hemisphere would increase the ease of bond formation. This observation will 
become important to our own synthesis of a spirastrellolide southern hemisphere. 
 
Scheme 1-18 Suzuki cross coupling with southern hemisphere fragment 
 With the key bond formed, elaboration continued (Scheme 1-19). To set the 
stereocenters at C(23)-C(24), the Paterson group utilized a directed hydroboration/oxidation to 
furnish the desired stereodiad with 3:1 diastereoselectivity. The authors note that they believe the 
conformation of the molecule, rather than local substrate control, was responsible for this 
outcome. The hydroboration/oxidation sequence also conveniently converted the terminal olefin 
in 1.123. to the corresponding alcohol. After routine protecting group manipulation, selective 
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oxidation and addition of the remaining southern hemisphere fragment (1.114) permitted 
spiroketalization to provide the full core carbon skeleton of spirastrellolide A (1.126).  
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Scheme 1-19 Elaboration of the southern hemisphere 
 Macrolactonization of the seco-acid derived from 1.126 was next achieved employing the 
Yamaguchi protocol (Scheme 1-20) to furnish 1.28. Global deprotection/reprotection then set the 
stage for the attachment of the side chain, which was achieved using a cross metathesis reaction 
with a symmetrical allyl carbonate, followed by π-allyl palladium chemistry to install the remaining 
carbons in the form of vinyl stannane 1.122. Thus, the first total synthesis spirastrellolide A (1.2) 
methyl ester was achieved. The group later published a second generation approach,34 which 
improved on several of the fragment union steps, but did not significantly alter the overall 
strategy.  
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Scheme 1-20 Comletion of spirastrellolide A (1.2) 
 The Furstner Total Synthesis of Spirastrellolide F 
 The Furstner group had also embarked on a total synthesis of spirastrellolide A (1.2) 
soon after the isolation report. As such, their approach also centered around disconnection of the 
molecule into fragments of known relative stereochemistry. This consideration is reflected in the 
original retrosynthetic analysis adopted by the Furstner group, shown in Scheme 1-21. 
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Scheme 1-21 Furstner group retrosynthetic analysis 
 With the above retrosynthetic approach in mind, the group reported approaches to the 
southern hemisphere spiroketal through union of 1.131 and 1.132 and northern hemisphere bis 
spiroketal fragment 1.133 (Scheme 1-21). The southern hemisphere synthesis is outlined in 
Scheme 1-22. 
 
Scheme 1-22 Synthesis of an advanced southern hemisphere fragment 
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 First, two key fragments were constructed: dithiane 1.136 and tetrahydropyranyl methyl 
ketone 1.139. Union of dithiane 1.136 to the diethyl tartrate derived aldehyde 1.142 was followed 
by a deprotection/acid catalyzed spiroketalization sequence to furnish advanced aldehyde 1.144 
as a single diasteromer, which could be readily coupled with fragment 1.139 to furnish the 
southern hemisphere 1.145. 
 Attention then turned to the northern hemisphere (Scheme 1-23). A similar 
chloroallylboration reaction as employed by Paterson to set the stereocenter of the C(28) chlorine 
substituent was performed to start the synthesis. The resulting allylic chloride was transformed 
into cyanohydrin 1.149 through a series of straightforward manipulations.  
 
Scheme 1-23 Synthesis of the northern hemisphere 
 As a coupling partner for the cyanohydrin TMS ether 1.149, Furstner et al. constructed an 
oxazole bearing an alkyl iodide side chain via a [3+2] cycloaddition of 1.150 and 1.151. After 
standard functional group manipulations, union of fragments 1.153 and 1.149 generated the full 
carbon skeleton of the northern hemisphere (1.154), which was then converted to the desired 
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bisspiroketal by first reductive cleavage of the oxazole, revealing the β-hydroxy ketone moiety, 
and then by acid catalyzed spiroketalization to furnish 1.155. Furstner and coworkers also 
encountered the instability of the five membered ring in the bisspiroketal, as well as the 
corresponding ketal precursors, to acidic and basic conditions; furan formation predominated in 
all but the mildest of settings.  
 Fragments 1.145 and 1.155 were eventually available in significant amounts to initiate 
studies to unite the two hemispheres. The first approach chosen by Furstner and coworkers 
entailed esterification of the two hemispheres, followed by ring closing metathesis. However, in 
line with the results observed by the Paterson group, no bond formation was observed under a 
large variety of conditions, presumably due to the steric bulk of the northern hemisphere. The 
group therefore decided to construct ester 1.157 (Scheme 1-24), featuring a partially 
deconstructed northern hemisphere.  
 
Scheme 1-24 Attempted ring closing metathesis 
 This congener indeed underwent ring closing metathesis, lending credence to the 
suggestion that steric bulk was the determining factor for difficulties associated with the original 
plan. Unfortunately, attempted formation of the bisspiroketal after formation of the macrocyclic 
core was met with failure (i.e, decomposition). The group therefore moved to the relay ring 
closing metathesis approach developed by Hoye,35 with the expectation of using the relay trigger 
to transfer the ruthenium carbene to the hindered northern hemisphere olefin. However, after 
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preparing the necessary substrate 1.158 (Scheme 1-25), the group found that only the ring 
expanded analogue 1.159 could be isolated. 
 
Scheme 1-25 Preparation of a ring expanded analogue 
 At this stage, a reexamination of the overall strategy was required. A new retrosynthetic 
analysis was thus devised, similar in many ways to the ultimately successful strategy employed 
by Paterson (Scheme 1-26).  
 
Scheme 1-26 Revised retrosynthetic analysis 
 Bond construction between the two hemispheres was moved to the C(24)-C(25) bond, 
and a Suzuki cross coupling reaction was chosen as the key bond-forming reaction. In contrast to 
the Paterson approach, the Furstner group elected to use a southern hemisphere vinyl triflate as 
the coupling partner to the northern hemisphere. It was also at this stage that the Furstner group 
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switched from pursuing spirastrellolide A (1.2) to the simpler spirastrellolide F (1.8), which differs 
from 1.2 in the absence of unsaturation at C(15)-C(16).  
 The new retrosynthetic analysis required an amended southern hemisphere 1.173, the 
synthesis of which is outlined in Scheme 1-27.  
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Scheme 1-27 Revised southern hemisphere synthesis 
 With the relative stereochemistry of the spirastrellolides unambiguously assigned at this 
stage, the requirement for strategic bond unions between regions of unknown stereochemistry 
was no longer in play, so a more convergent approach was possible. Thus, a Marshall 
propargylation between aldehyde 1.161 and an enantiopure propargylic mesylate furnished 
homo-propargylic alcohol 1.162, which, after oxidation to 1.163, was in turn coupled to fragment 
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1.164 via a Mukiyama aldol reaction. Functional group interconversion then furnished alkyne 
1.166. The challenging stereotetrad in fragment 1.170 also relied on a Mukiayama aldol reaction 
to construct intermediate alkyne 1.168, which was converted to the desired aldehyde 1.170 in five 
steps. Aldehyde 1.170 and alkyne 1.166 were then coupled and subjected to spiroketalization 
under acidic conditions after oxidation state adjustment. Finally, installation of the vinyl triflate 
completed the new southern hemisphere fragment (1.173). 
 With both hemispheres (1.155 and 1.173) available in large amounts, the envisioned key 
Suzuki cross coupling reaction was evaluated. As expected from the studies of Paterson, both the 
cross coupling and subsequent macrolactonization operations proved facile (Scheme 1-28); the 
olefin hydrogenation to set the stereocenter at C(24), however, proved extremely challenging.  
 
Scheme 1-28 Completion of spirastrellolide F 
 Through an unfortunate combination of circumstances, both faces of the terminal olefin 
are shielded: one by the adjacent ketal, the other by the northern hemisphere bis spiroketal. The 
authors eventually found that an analogue of Crabtree's catalyst employed under forcing 
conditions (c.f. 200 bar H2 pressure) provided the desired product 1.175. At this stage, the 
synthesis intercepted nicely with the spirastrellolide A (1.2) synthesis of Paterson and coworkers; 
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subsequent manipulations were thus performed in a straightforward manner to permit completion 
of the first total synthesis of spirastrellolide F (1.8).  
The Second Generation Furstner Synthesis of Spirastrellolide F (1.8) 
 In 2011, the Furstner group published a second generation approach to spirastrellolide F 
(1.8) based on an alkyne metathesis/spiroketalization approach (Scheme 1-29). Furstner 
hypothesized that the earlier union of advanced southern and northern hemispheres was not the 
ideal route for the synthesis of spirastrellolide congeners. Earlier retrosynthetic analyses had 
focused on such a disconnection to isolate fragments of the spirastrellolides that at the time 
possessed unknown relative configuration. With the relative configuration established 
unequivocally after the first generation syntheses of the Paterson and Furstner groups, an 
alternative approach could now be investigated.  
 In particular, in their second generation synthesis, the Furstner group chose to 
disconnect the southern hemisphere spiroketal at a late stage via a gold catalyzed ring closure, 
leading back to alkynyl diol 1.178 (Scheme 1-29). Application of the Furstner group's signature 
alkyne ring closing metathesis methodology would permit 1.178 to arise from the appropriate bis 
alkyne 1.179. Dialkyne 1.179, in turn, could be readily assembled from three fragments (1.155, 
1.181, 1.180) via an esterification and a variant of the Suzuki cross coupling reaction that proved 
successful in the spirastrellolide F synthetic venture. Importantly, the fragments required for the 
revised analysis could be readily prepared from intermediates synthesized previously en route to 
spirastrellolide F, with northern hemisphere fragment 1.155 remaining unchanged and fragment 
1.181 available by a minor modification of the established synthetic procedure.   
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Scheme 1-29 Second generation retrosynthetic analysis of spirastrellolide F 
 The requisite acid 1.180 (Scheme 1-30) was available by a simple three step 
homologation of intermediate 1.165 (Scheme 1-27), followed via conversion of the primary TBS-
protected carbinol to the corresponding carboxylic acid. 
 
Scheme 1-30 Synthesis of a modified alkyne fragment 
 With these intermediates in hand, construction of spirastrellolide F (1.8) proceeded by 
Suzuki cross coupling of the northern hemisphere 1.155 with fragment 1.81 (Scheme 1-29) 
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employing conditions developed previously and in turn esterification with fragment 1.180 to 
furnish 1.179 (Scheme 1-31).  
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Scheme 1-31 Completion of a second generation synthesis of spirastrellolide F 
 Alkyne metathesis proceeded smoothly utilizing methods developed earlier in the 
Furstner laboratory. Generation of the two pendant hydroxyls from the corresponding PMB ethers 
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then provided 1.178, which was set up for a gold catalyzed spiroketalization, which was 
conveniently accomplished using a cationic JohnPhos ligated gold species. At this stage, the 
second generation route interecepted the first generation route. The group decided, however, to 
install the side chain in a different fashion, now relying on a Julia-Kociencki olefination with the 
appropriate sulfone (1.185) to complete the second generation Furstner synthesis of 
spirastrellolide F (1.8).    
The Furstner Synthesis of Spirastrellolide A (1.2) 
 In 2013, the Furstner group, employing the lessons learned from the spirastrellolide F 
(1.8) synthesis reported completion of a total synthesis of spirastrellolide A (1.2)30 (Scheme 1-32). 
The strategy and general retrosynthesis were not significantly different from those used in their 
earlier approaches. However, due to the presence of unsaturation in the southern hemisphere 
spiroketal, a somewhat different approach to the southern hemisphere was envisioned, with the 
unsaturation at C(15)-C(16) masked as a dithiane. 
 Towards this end, a Mukiyama aldol between tetrahydropyran possessing a TMS enol 
ether (1.163) and dithiane aldehyde 1.186 (Scheme 1-32), followed by an Evans-Tischenko 
reduction and protecting group manipulations lead smoothly to the fully protected dithiane 1.187, 
which was coupled to aldehyde 1.142 to complete the carbon skeleton 1.188. Spiroketalization 
and conversion of the eastern terminus to the desired vinyl triflate next provided 1.190, which was 
in turn converted to acid 1.191 in four steps, ready for union with the northern hemisphere.  
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Scheme 1-32 Synthesis of an advanced southern hemisphere for spirastrellolide A (1.2) 
 The fragment union steps once again followed the precedent set in the spirastrellolide F 
synthesis (Scheme 1-31) and is shown in more detail in Scheme 1-33. Thus, Suzuki cross 
coupling as before furnished coupled product 1.193, which similarly underwent a 
macrolactonization/diastereoselective reduction sequence to 1.194. At this stage, the C(16) 
ketone was converted to the corresponding olefin by triflation and, in turn, a palladium catalyzed 
reduction, to provide spiro-olefin 1.195. Coupling of the side chain was then performed via a 
Julie-Kocienski olefination of the derived aldehyde 1.196 with sulfone 1.197. Global deprotection 
then furnished spirastrellolide A methyl ester (1.2) in a modest yield (32% over two steps).  
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Scheme 1-33 Completion of the Furstner synthesis of spirastrellolide A (1.2) 
1.5 Summary of Smith Group Approaches to Spirastrellolide Fragments at the 
Outset of Thesis Research 
 The Smith group has had a long-standing interest in the spirostrellolide family of natural 
products. Their intriguing cytotoxicity addressed the Smith group's interest in the construction of 
complex anti-cancer natural products, while the polyketide architecture seemed nearly perfect for 
exploiting Type II Anion Relay Chemistry (ARC), which was first reported by Smith et al. as a new 
synthetic paradigm in 2006.36 As such, studies in pursuit of a total synthesis of spirastrellolide A 
(1.2) commenced in 2004 soon after the original isolation of the natural product and the early 
development of ARC.  
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Approach Towards the Southern Hemisphere of Spirastrellolide A (1.2) 
 The first subtarget to succumb to synthesis in the Smith group was the southern 
hemisphere of spirastrellolide A (1.2), performed by graduate student Dae-Shik Kim and post-
doctoral fellow Dr. Helmar Smits.37,38 At the time, difficulties associated with a cross metathesis 
approach towards hemisphere union were unknown, so the target chosen was 1.196, containing 
a terminal alkene. The Smith retrosynthetic analysis to this target is shown in Scheme 1-33 A.  
 
Scheme 1-34 Retrosynthetic analysis towards an advanced southern hemisphere fragment 
 Attachment of the C(1)-C(9) and C(23)-C(25) fragments was envisioned to occur at a late 
stage, via dithiane addition to the termini of spiroketal-containing fragment 1.199. This fragment, 
in turn, was seen to arise from linear precursor 1.200, which was viewed as an excellent 
candidate for Type II Anion Relay Chemistry. This original approach, however, proved 
problematic given that the bifunctional linchpin 1.202 was recalcitrant to nucleophilic attack, a fact 
that is now understood to arise from a preferred conformation which embeds the epoxide into the 
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dithiane ring. A revised retrosynthesis was therefore implemented (Scheme 1-33 B), utilizing the 
simpler linchpin 1.206, with the expectation that the methyl substituent could be installed at a later 
point in the synthesis. 
 This synthetic analysis was indeed converted to practice: deprotonation of dithiane 1.203, 
addition to linchpin 1.206 and, after gegen-ion promoted Brook rearrangement, trapping with 
epoxide 1.201 furnished the three component adduct 1.205 in 77% yield (Scheme 1-34).  
 
Scheme 1-35 Synthesis of advanced spiroketal 1.204 
 Double dithiane removal utilizing the mercury conditions of Corey and Erickson39 
provided diketone 1.207, which, upon anti reduction led to partial hemiketalization; this mixture 
was subsequently treated with aqueous perchloric acid to permit complete spiroketalization, via a 
Ferrier reaction, that yielded 1.208 as a single diastereomer. After protection, the unsaturated 
spiroketal 1.204 was obtained in 34% yield over the 6 steps. Unfortunately, upon repeated 
attempts to install directly the C(14) methyl group success was not achieved. A three step 
sequence was therefore implemented (Scheme 1-35) involving allylic oxidation, displacement of 
the resulting hydroxyl group with bis(phenylsulfonyl)methane with inversion of configuration via a 
Mitsunobu40 reaction, and reduction. Frasier-Reid epoxidation41 to provide the key intermediate 
epoxide 1.199. Treatment of this epoxide with the potassium anion of dithiane 1.197 proceeded 
smoothly to furnish coupled product 1.211. 
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Scheme 1-36 Synthesis of advanced fragment 1.211 
 Standard functional group manipulations then led to aldehyde intermediate 1.212 
(Scheme 1-37). All that remained to complete a potentially viable southern hemisphere skeleton 
was installation of the C(23)-C(25) fragment by dithiane addition to the aldehyde terminus of 
1.212 (Scheme 1-36).  
 
Scheme 1-37 Installation of the C(23)-C(25) fragment and completion of synthesis 
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 Unfortunately, all attempts to achieve the correct stereochemistry at C(22) proved futile, 
with most conditions favoring the undesired isomer. Repeated attempts to reverse the 
diastereoselectivity of the addition lead, at best, to a 1:1 mixture of isomers. Ultimately, a three 
step oxidation/reduction sequence permitted the conversion of the undesired diastereomer to the 
correct diastereomer at C(22) (1.214, Scheme 1-36). An additional three steps then completed 
the synthesis of the proposed spirastrellolide A (1.2) southern hemisphere 1.196.  
Approach Towards the Northern Hemisphere of Spirastrellolides B (1.3) and E (1.6) 
 In 2012, post-doctoral scholar Dr. Xiaozhao Wang in the Smith group achieved the 
synthesis of the northern hemisphere of spirastrellolide family members lacking a chlorine 
substituent.42 Retrosynthetically, the key step was the unraveling of the central [5,6,6]-
bisspiroketal to a simple monoketal 1.216 via an alkyne bisfunctionalization tactic (Scheme 1-37). 
The requisite ketal 1.216 in turn, was envisioned to be constructed in a straightforward manner 
from the three fragments 1.217-9. 
 
Scheme 1-38 Retrosynthetic analysis of an advanced northern hemisphere fragment 
 In a forward sense, addition of the lithium anion of 1.218 to epoxide 1.217 furnished the 
two component adduct 1.220 (Scheme 1-37). A three step conversion to the corresponding 
methyl ketone then provided 1.222, which was poised for a Mukiyama aldol reaction with 
aldehyde 1.219. The resulting product was obtained both in high yield and diastereomeric purity 
(>19:1). Protection of the free hydroxyl as the MOM ether then provided 1.223, substrate for the 
planned spiroketalization.  
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Scheme 1-39 Synthesis of spiroketalization precursor 1.223 
 Unfortunately, when 1.223 was converted to a mixture of ketals by the removal of the two 
PMB groups with DDQ, and subsequently treated with Au(I)Cl in THF, a low yield of a spiroketal 
that did not possess the desired [5,6,6] framework was isolated. Instead, the product, identified by 
extensive NMR studies, proved to be the related [5,5,7] bisspiroketal system (1.227, Scheme 1-
40). Closer inspection revealed that alkyne activation by gold lead to nucleophilic attack at the 
incorrect C(9) terminus of the alkyne bond. Selective removal of only the C(14) PMB group under 
carefully controlled conditions, followed by alkyne activation in protic solvent lead exclusively to 
ketone 1.226, demonstrating that attack by nucleophiles was favored at C(9). This intermediated 
could also be converted to 1.227 by removal of the remaining PMB group and acid-catalyzed 
cyclization. 
 
Scheme 1-40 Formation of an unexpected [5,5,7]-bisspiroketal 
 While the [5,5,7] system was of interest from the point of view of spirastrellolide A 
analogues, an approach towards the original [5,6,6] bisspiroketal was still clearly required. 
Reasoning that the attack of the C(14) hydroxyl onto the activated alkyne was slow relative to 
38 
 
attack of the C(7) hemiketal oxygen or external attack by solvent, a system where both of these 
pathways were disfavored was eventually identified (Scheme 1-41).     
 
Scheme 1-41 Completion of the advanced northern hemisphere fragment 
 That is, while desired product formation under gold catalysis could not be achieved, 
platinum catalysis in the form of Ziese's salt43 permitted alkyne functionalization at the desired 
C(10) acetylenic carbon to form ketal 1.230 as a mixture of diastereomers. This observation is 
consistent with the results of de Brabander and coworkers, which highlight the higher selectivity 
of platinum for 6-endo cyclizations relative to gold in such systems.44 Removal of the remaining 
hydroxyl protecting group then provided the desired [5,6,6] system 1.212 under acid catalysis, 
thereby completing the synthesis of the advanced northern hemisphere fragment of the 
spirastrellolide family. Thus, by 2010, the Smith group had acess to  both northern and southern 
hemisphere fragments of several members of the spirastrellolide family. 
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2 CHAPTER 2 
2.1 Identification of a New Spirastrellolide  Synthetic Target 
 
 In Chapter 1, in addition to a general overview of earlier spirastrellolide synthetic 
approaches and total syntheses, the successful completion by the Smith group of advanced 
intermediates for both the northern and southern hemispheres of spirastrellolide congeners was 
described. With approaches to both hemispheres established, the focus shifted to completion of a 
total synthesis of one of the spirastrellolide congeners. At this stage, a target needed to be 
defined. At the outset of Smith group efforts in the spirastrellolide field, as early as 2003, 
spirastrellolide A was the presumed target, as no others had yet been reported. Over the years, 
however, approaches to fragments relevant to spirastrellolides A, B, and E had been described. 
In addition, the synthesis of spirastrellolides A (1.2) and F (1.8) had been achieved by the 
Paterson and Furstner groups, respectively.1-3 After careful analysis of the approaches available 
to the Smith group, it became clear that spirastrellolides B and E were our most appropriate 
targets, as our northern hemisphere route lacked chlorine at C(28) (see Figure 2-1 for 
numbering). We therefore chose the more complex spirastrellolide E (1.6), possessing a southern 
hemisphere spiroketal olefin, as our target. No synthesis of this congener has been reported to 
date.  
 
Figure 2-1 Spirastrellolides A,B and E 
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2.2 Examination of Smith Group Southern Hemisphere Approach 
 
 With this decision made, we examined the relevant synthetic routes to advanced northern 
and southern hemisphere fragments in preparation for the synthesis of ample material for 
hemisphere union studies. This analysis quickly identified the Smith southern hemisphere route 
(Scheme 2-1) as problematic from the point of view of rapid material advancement, as the 
sequence led only to a 0.2% overall yield, requiring a 33 step longest linear sequence.  
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Scheme 2-1 Summary of first generation southern hemisphere route 
 Careful examination of the published southern hemisphere route revealed a number of 
areas where significant improvements could be achieved. First, the inability to install the C(14) 
methyl group during the Type II ARC reaction required a costly three step sequence to correct 
(c.f., 2.5 → 2.6). Second, the configuration at C(22) in 2.8 could not be established 
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stereoselectively after many attempts; at best a 1:1 ratio of the two diastereomers resulted upon 
addition of dithiane 2.10, with most conditions providing the undesired diastereomer as the major 
product. The conversion of the undesired diastereomer 2.11 to the desired configuration (i.e., 
2.12) also necessitated a three step sequence to correct (i.e., oxidation to the corresponding 
ketone, reduction with concomitant cleavage of the primary pivalic ester and reprotection of the 
free primary alcohol).  
 A final consideration in revising the Smith southern hemisphere target lay in the 
information gathered by the Paterson and Furstner groups on the way to their successful total 
syntheses of spirastrellolide congeners.4,5 Specifically, attempts to unite the advanced southern 
and northern hemisphere fragments at the C(25)-C(26) linkage led to repeated failures due to the 
considerable steric hindrance imparted by the U-shape nature of the northern hemisphere bis-
spiroketal (vide supra).  As such, the original southern hemisphere fragment (2.13, Scheme 2-1), 
which possesses a terminal olefin poised for C(25)-C(26) bond formation via olefin metathesis, 
was deemed to have a very low chance of success. A strategy that forms the nearby C(24)-C(25) 
bond, as in previous successful syntheses of Paterson and Furstner, would be clearly preferable.  
2.3 Revision of Synthetic Strategy and Choice of New Spirastrellolide Target 
 
  With these considerations in mind, a retrosynthetic analysis for spirastrellolide E was 
proposed (Scheme 2-2). For the hemisphere union strategy, we elected to pursue the method of 
Paterson, uniting hemispheres 2.14 and 2.15 via a Suzuki cross coupling between an sp3 
boronate derived from a northern hemisphere alkene and a vinyl iodide present in an advanced 
southern hemisphere fragment. Importantly, we chose to move away from a stepwise hemisphere 
construction strategy, as employed by Paterson, and attempt to unite an advanced southern 
hemisphere fragment 2.15, with the expectation of improving the convergence of the route. Such 
a disconnection would lead back to C(28)-C(40) northern hemisphere fragment 2.14, readily 
available from 2.17, the result of our earlier northern hemisphere efforts, and 2.15, a revised C(1)-
C(24) southern hemisphere fragment. 
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Scheme 2-2 Second generation retrosynthetic analysis 
 Next, we turned to the development of a retrosynthesis for the new C(1)-C(24) southern 
hemisphere fragment 2.15. Encouraged by the success of our northern hemisphere synthesis, 
which crafted the central [5,6,6] spiroketal via a metal-catalyzed bis-cyclization of the 
corresponding alkyne, we envisioned that the central [6,6] spiroketal core of the southern 
hemisphere could similarly arise from cyclization of two pendant hydroxyls onto a central alkyne 
moiety (Scheme 2-3). A major concern, however, was the regioselectivity of the addition. Clearly, 
for our purposes, we required the attack of the C(21) hydroxyl on the C(15) acetylynic carbon 
(blue arrow, Scheme 2-3). However, both our own efforts on the northern hemisphere, as well as 
the efforts of many other researchers,6 have revealed strong directing effects of the specific 
conditions on the regioselectivity of metal-catalyzed spiroketalizations, with mixtures formed in a 
large number of cases.  
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Scheme 2-3 Possible modes of nucleophilic attack for a gold catalyzed spiroketalization 
 We were therefore drawn to the method of Aponick and coworkers (Scheme 2-4),7 in 
which a substrate propargylic alcohol directs the regioselectivity of a gold-catalyzed cyclization in 
2.19 by the formation a hydrogen bond between an incoming hydroxyl and the C(3) propargyl 
hydroxyl in only one of the four possible hydroxyl approaches (Scheme 2-4, green arrow). 
Conveniently from the perspective our proposed spirastrellolide synthetic strategy, rather than 
providing the expected saturated spiroketal, an unsaturated ketal is formed instead (2.22). The 
mechanism of this transformation will be discussed in greater detail in Chapter 3, However, in 
basic terms, addition of the C(9) hydroxyl of 2.19 to the gold-activated alkyne forms a vinyl gold 
complex (2.20), which readily eliminates with loss of a ligated gold hydroxide complex, leading to 
an intermediate allene. At this stage, two pathways to the product are possible. The allene can 
isomerize to the corresponding oxocarbenium (Path a), followed by a non-catalyzed addition of 
the remaining hydroxyl. Alternatively, gold catalyzed addition of a hydroxyl to a gold-activated 
allene followed by protodeauration could also lead to the desired spiroketal (Path b).   
 
Scheme 2-4 Alcohol directed spiroketalization method of Aponick 
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 The expected reaction course for our proposed substrate 2.23 is shown in Scheme 2-5. 
Thus, by analogy to the simple system reported by Aponick, we expected selective attack of the 
C(21) hydroxyl onto the C(17) terminus of the alkyne, proceeding via hydroxyl directed transition 
state 2.24, to produce vinyl gold intermediate 2.25, which after a second cyclization event, would 
furnish southern hemisphere fragment 2.15, or a close derivative.  
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Scheme 2-5 Expected spiroketalization of intermediate 2.23 
 From the retrosynthetic perspective, applying the gold catalyzed spiroketalization 
transformation to the southern hemisphere target 2.15 would lead to intermediate 2.23 (Scheme 
2-6), which in turn can be further simplified into two complex fragments: aldehyde 2.27 and 
alkyne 2.26.  
 
Scheme 2-6 Retrosynthetic analysis of revised southern hemisphere 
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 Alkyne 2.26 is very similar to a fragment of the Paterson synthesis of spirastrellolide A 
(1.2),8 whereas aldehyde 2.27 is an ideal substrate to demonstrate the versatility of Anion Relay 
Chemistry (ARC).9 In particular, we envisioned a Type I ARC union of epoxides 2.29 and 2.30 
around the central TES-dithiane linchpin 2.28. Notably, by changing the bonds formed via the 
ARC union protocol, the problematic C(14) methyl group is now installed as part of an appropriate 
epoxide. Also notable is installation of the C(22) hydroxyl in a stereoselective manner (vide infra). 
2.4 Synthesis of the Requisite Fragments for ARC Union 
 
 With this route in mind, we began by preparing the requisite epoxides for the key 
strategic ARC union with the help of Martin Cattoen, a French summer exchange student. 
Epoxide 2.29, a known compound,10 was readily prepared by a modification of the reported 
procedure (Scheme 2-7). 
 
Scheme 2-7 Synthesis of epoxide 2.29 
 To this end, commercially available (S)-diethyl malate was first methylated 
diastereoselectively exploiting the procedure of Seebach,11 to provide a 67% yield of an 
inseparable mixture of diastereomers in ratios ranging from 5:1 to 8:1 in favor of the desired 
isomer. Next, exhaustive reduction of the diester led to the triol, which, without purification, was 
treated with benzaldehyde dimethyl acetal in the presence of PPTS to provide intermediate 2.32. 
We found that use of stoichiometric PPTS, rather than the catalytic amount called for in the 
original procedure,10 gave optimal results. At this stage, the minor diastereomer could be 
separated, providing the desired benzilidene ketal as a single compound in 63% yield over the 
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two steps. Regioselective opening of ketal 2.32 was best achieved with lithium aluminum hydride 
in the presence of aluminum trichloride in a dichloromethane/diethyl ether mixture at reflux.12 
Finally, Frasier-Reid epoxidation13 provided the desired epoxide 2.29 in near quantitative yield. 
Overall, epoxide 2.29 could be constructed in 6 steps and 38% overall yield from (S)-diethyl 
malate. The sequence also proved scalable, with a single 25 g batch of (S)-diethyl malate 
providing more than 6 grams of the desired epoxide.   
 The second epoxide 2.28 for the ARC union could also be constructed readily on large 
scale (Scheme 2-8). Here, we chose to modify a route first reported by de Brabander.14 Starting 
with commercially available 3,4-dihydropyran, hydration under mild acidic conditions furnished 
lactol 2.34, which could be reacted with freshly prepared ethyl (triphenylphosphoranylidene) 
acetate15 to form α,β-unsaturated ester 2.35 as an inconsequential mixture of olefin isomers 
(typically 10-12:1 as determined by NMR). Notably, choice of the ethyl ester provided critical in 
securing improved yields over the remainder of the synthetic sequence. Oxidation followed by 
Brown allylation16 then furnished the desired homoallylic alcohol 2.37 as a single enantiomer in 
70% yield over 2 steps. Importantly, the reaction could be run >20 g scale to provide the desire 
product in 61% yield over 2 steps. Cyclization of alcohol 2.37 initially proved variable, as under 
the catalytic potassium tert-butoxide conditions, competitive formation of the tert-butyl ester was 
observed. Maintaining the reaction temperature below ─60 °C and quenching the reaction by 
dropwise addition of a saturated aqueous ammonium chloride solution, while maintaining the 
temperature at -60 °C permitted the preparation of chromatographically homogeneous material. 
When these precautions were taken, the cyclized product 2.38 could be formed in >95% yield on 
>10 g scale and importantly was of sufficient purity to be used in the next sequence of steps; 
namely, reduction of the ester and protection of the resulting primary hydroxyl as the TBS ether. 
The overall yield of 2.39 for the three operations from 2.37 was 82%. 
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Scheme 2-8 Synthesis of epoxide 2.28 
 Dihydroxylation of the terminal olefin next provided the diol 2.40 in 97% overall yield as a 
3:1 to 6:1 mixture of diastereomers, which could be separated by careful column chromatography 
to provide an improved diastereomeric ratio (c. 10-12:1) of the desired diastereomer. The 
stereochemistry of the major product was ultimately obtained by analysis of a later intermediate 
(vide infra, Scheme 3-7). Frasier-Reid epoxidation13 then provided epoxide 2.30 in preparation for 
the ARC union. Overall, epoxide 2.30 could be synthesized in 9 steps and 27% overall yield on 
multigram scale.  
2.5 ARC Union and Further Elaboration 
 
 With both ARC epoxides in hand, optimzation of the Type I Anion Relay Chemistry union 
began (Table 2-1). In a first trial, excess TES-dithiane (1.3 equiv) was deprotonated with n-
butyllithium at room temperature for 5 minutes, then cooled to -45 °C and reacted with epoxide 
2.29 in a 1:1 molar ratio. After 1 hour at this temperature, epoxide 2.30 was added as a solution 
in ether, followed by HMPA (2 equivalents) as a solution in ether. Pleasingly, this protocol 
provided a 50% yield of the desired three component adduct 2.41 (Table 2-1).  
 While this initial protocol proved successful in providing the desired product, there were a 
few drawbacks. First, addition to epoxide 2.29 was incomplete as evidenced by the observation of 
quenched intermediate 2.42 in the NMR spectrum of the unpurified reaction mixture. Second, 
because intermediate 2.42 was used in excess, none of the reaction components could be 
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recycled. As a consequence, the use of excess of 2.29 to assure complete conversion of 
intermediate 2.42 was unattractive. We therefore decided to use only one equivalent of epoxide 
2.29, but to use epoxide 2.30 in excess, as such a protocol would permit the unreacted epoxide 
2.30 to be recovered and reused.  
 
Table 2-1 Optimization of the key ARC Union protocol 
 When this modified protocol was implemented (Table 2-1, Entry 2), the desired product 
was isolated in 40% yield, with 21% of unreacted 2.42 after quenching the reaction mixture. 
Pleasingly, more than 50% of the unreacted epoxide 2.30 could be recovered by simple column 
chromatography. We next examined a variety of reaction factors. A temperature of ─45 °C proved 
optimal for the first epoxide addition, as lower temperatures lead to poor conversion (Entry 3). 
The optimal solvent proved to be a mixture of ether:THF (3:1) for the first step and 9:1 ether: THF 
mixture overall (Entry 4-7). That is, at lower temperatures and solvent polarities, incomplete 
addition of the relative non-nucleophilic TES-dithiane anion to epoxide 2.29 was observed; at 
higher solvent polarities the highly basic anion of 2.42 was more readily quenched. Thus, 
identification of the ideal solvent polarity over the course of the ARC protocol proved highly 
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beneficial. With the optimized solvent combination, a 60% yield of the desired product could be 
obtained. Increasing the amount of epoxide 2.30 to 2 equivalents provided a consistent 62% yield 
of the desired product 2.41 (Entry 8). Interestingly, the amount of HMPA, proved less important 
(Entry 9-10).    
 It should be noted that the yields in Table 2-1 are approximate due to the formation of an 
inseparable and very difficult to characterize product, which, based on later observations (vide 
infra), is believed to be the semi-symmetrical product 2.43 (Figure 2-1), which forms upon 
addition of intermediate 2.42 to excess epoxide 2.30. The proton NMR signals of this product 
overlap with those of the product, so assignment of the exact relative amounts proved difficult; 
nonetheless, between 10-20% of 2.43 was typical. It was later discovered that this byproduct 
could be removed by conducting the addition to epoxide 2.30 below 0 °C. Performing the reaction 
under these conditions lead to a 63% yield of coupled product 2.41 as a single compound.  
 
Figure 2-2 Proposed byproduct from ARC union 
 With three component adduct 2.41 in hand, we continued construction of the key 
aldehyde 2.27 (Scheme 2-9). First, dithiane removal was examined. The conditions for this 
transformation, as well as subsequent chemistry of the resulting ketone en route to 2.27,  were 
established by Dr. Xiaozhao Wang, who found that NBS in the presence of silver perchlorate and 
2,6-lutidine17 provided a reliable 70-75% yield of hydroxy ketone 2.44. Stereoselective anti-
Gribble-Evans18 reduction then provided the desired diol in 70% yield as a single diastereomer. At 
this stage, byproduct 2.43 could be separated as the corresponding diol. Continuing with the 
synthesis, bis-TBS protection of the diol was required. Upon reaction of the diol with TBSOTf in 
the presence of 2,6-lutidine, however, the C(13) TES group migrated to the adjacent carbinol (c.f., 
2.45, Scheme 2-9). The resulting products proved difficult to separate. It was therefore decided to 
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revise the protecting group scheme employing the MOM blocking group; this transformation was 
readily achieved with MOMBr in the presence of tetrabutylammonium iodide and Hunig's base at 
elevated temperatures in dichloroethane as solvent. However, from the perspective of the total 
synthesis of spirastrellolide E (1.6), we recognized that such a protecting group scheme would 
not be ideal, as the MOM group would be the last protecting group to be removed. Such 
deprotections are notoriously difficult, particularly in late stage settings. Nevertheless, we were 
eager to validate some of the later chemistry and chose to proceed with the MOM-based route. 
To this end, removal of the primary benzyl group and oxidation to the corresponding aldehyde 
provided advanced fragment 2.27 in preparation for alkynylation.  
 
Scheme 2-9 Successful synthesis of aldehyde 2.27 
 The coupling partner for the proposed alkynylation was next constructed based on the 
synthesis of a similar fragment by the Paterson group in their approach to spirastrellolide A (1.2).8 
Notably, the C(22) stereocenter, which had proven problematic in our previous spirastrellolide A 
and B southern hemisphere synthesis, is set with excellent selectivity (vide infra). The first task 
was the preparation of the sensitive aldehdye 2.48. The Paterson group had synthesized 2.48 by 
performing a titanium mediated hydromagnesiation19,20 of 2-butyn-1-ol, followed by an iodine 
quench (Scheme 2-10). In our hands, this procedure proved difficult to scale up due to formation 
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of an unidentified side product, which proved impractical to separate. In addition, yields tended to 
be variable. We therefore turned to a two step procedure involving protection of 2-butyn-1-ol as 
the corresponding TES ether, followed by a hydrozirconation/iodination protocol.21 Careful 
oxidation of the resulting product with Dess-Martin periodinane then provided aldehyde 2.48. 
Yields for the sequence, however, remained low, due partially to the sensitivity of the final product 
to light and concentration, as well as the volatility of the intermediates.  
 
Scheme 2-10 Synthesis aldehyde 2.48 for aldol reaction 
 Nevertheless, the desired aldehyde 2.48 could be obtained on multi-gram scale and then 
reacted with the boron enolate of acylated oxazolidinone 2.50 (Scheme 2-11) to furnish the 
desired syn isomer 2.51 as a single diastereomer in 82% yield. Removal of the auxillary by 
formation of the Weinreb amide proceeded smoothly. However, the desired product and the 
auxillary proved inseparable. Subsequent protection of the free hydroxyl as the TES ether 
permitted separation of the desired product 2.53 from the auxillary, which had now been 
converted to the TES-amide 2.54 under the reaction conditions. Importantly, the valuable auxillary 
2.55 could then be recovered by following a literature procedure.22  
 
Scheme 2-11 Synthesis of Weinreb amide 2.53 
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 Next, Grignard addition of bromide 2.57 to 2.53 (Scheme 2-12) was planned. The desired 
bromide could be constructed in a straightforward manner from commercially available 3-butyl-1-
ol involving TMS protection of the terminal alkyne, followed by the Appel conditions to install the 
primary bromide (Scheme 2-12).  
 
Scheme 2-12 Successful synthesis of alkyne fragment 2.26 
 The bromide was originally purified by distillation, however, this lead to no conversion in 
the subsequent Grignard reaction due to the co-distillation of bromoform, a byproduct from the 
Appel reaction. When column chromatography was employed as the method of purification, the 
desired Grignard reaction proceeded in >90% yield. The resulting ketone 2.59 was then reduced 
diastereoselectively to the corresponding alcohol employing zinc borohydride, and the alcohol 
methylated with Meerwein's salt. Finally, removal of the TMS group was achieved employing 
potassium carbonate in ethanol, which lead to partial removal of the secondary TES ether. 
Reprotection provided alkyne 2.26 in 77% yield over 2 steps.  
 With both the aldehyde and alkyne fragments available, the critical alkynylation could 
now be explored (Figure 2-3). First, however, the stereochemistry of the resulting propargylic 
carbinol must be considered with respect to spiroketalization. In principle, this carbinol center 
would be removed to form the requisite unsaturation present in the spiroketal. A search of the 
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literature, however, suggested that the spiroketalization reaction would not be as simple and 
depends strongly on the configuration of the carbinol stereocenter to be removed.  
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Figure 2-3 Proposed alkynylation 
 In their original publication,7 Aponick and coworkers demonstrated that when syn and anti 
2.62 were subjected to a mixture of JohnPhos ligated gold (I) chloride and silver triflate, the 
resulting cationic gold catalyst displayed strikingly different reactivities with the anti and syn  
isomers (Scheme 2-13 A). 
 
Scheme 2-13 Literature examples of spiroketalization efficiency depending on substrate stereochemistry 
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 The anti product gave the desired spiroketal 2.63 in high yield; the syn product, on the 
other hand, gave a complex mixture of spiroketals, with the desired product (2.63) a minor 
component. Similarly, in a more complex setting, the Forsyth group23 reported that compound 
2.66 (Scheme 2-13, B) behaved differently in a related gold catalyzed spiroketalization. Once 
again, the anti isomer underwent clean reaction to furnish the desired product (2.67), while the 
syn isomer lead to a mixture of spiroketals, with the [5,7] saturated spiroketal favored as a nearly 
1:1 mixture of diastereomers.  
 With this precedent in mind, it seemed clear that the propargylic stereocenter would 
comprise an important factor in the reactivity and selectivity of our proposed gold catalyzed 
spiroketalization process. However, the details of the impact were unknown; and as such, we 
chose to prepare both diastereomers varying at C(15) and subject each to gold catalysis. A non-
selective alkynylation was therefore pursued. Treatment of alkyne 2.26 with 1 equivalent of 
lithium diisopropylamide in THF, followed by cannulation into a solution of aldehyde 2.27 in THF 
smoothly provided a 75% combined yield of a mixture of diastereomers (1.7:1), with the syn 
product favored slightly (Scheme 2-14). Choice of base (i.e., LDA) proved critical to the success 
of this reaction, as the use of the more basic n-butyllithium led to exclusive lithium-halogen 
exchange prior to alkynylation.  
 
Scheme 2-14 Alkynylation and unsuccessful spiroketalization attempts 
 With both alkyne isomers in hand, removal of the PMB group with DDQ provided 
spiroketalization precursors syn and anti 2.70, which were both subjected to gold catalysis. 
Unfortunately, the conditions of Aponick7, Forsyth23, Trost24 or several modifications thereof, 
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provided none of the desired spiroketal. The problem appeared to lie in the necessity for mildly 
acidic conditions to remove the C(13) TES ether during the reaction. Unfortunately, we were 
forced to use methanol at least as a cosolvent, with PPTS as a mild acid. Under these conditions, 
regardless of the gold source, slow decomposition of the substrate was observed.  
2.6 A Second Approach to Southern Hemisphere 2.15 
 
 Undaunted, we reasoned that the use of a substrate possessing differential protection at 
the C(13), C(21) and C(22) hydroxyls would be more amenable to reaction optimization due to 
the possibility of isolating a triol spiroketalization precursor 2.71, which would not require any 
additional functional group manipulations during spiroketalization (Scheme 2-15). 
 
Scheme 2-15 Revised strategy for spiroketalization 
 We therefore chose 2.71 as our new target (Scheme 2-16). Notably, in addition to the 
differential protection at C(13) and C(21), we chose to return to TBS protection at the C(9) and 
C(11) carbinols due to the aforementioned difficulties expected with selective MOM group 
removal at the late stages of the synthesis (vide supra).  
 Analysis of 2.71 is illustrated in Scheme 2-16. Spiroketalization and alkynylation were still 
envisioned as the end game, now requiring aldehyde 2.72. Importantly, this aldehyde could be 
constructed from the identical ARC components as our original intermediates by simply changing 
the order of addition, followed by dithiane removal and stereoselective reduction of the resulting 
ketone. This tactic serves as another illustration of the remarkable flexibility and utility of the ARC 
union protocol.   
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Scheme 2-16 Revised retrosynthetic analysis 
 In the forward direction, ARC union with inverted order of addition proceed equally well 
under the conditions developed previously, providing intermediate 2.74 in 68% yield (Scheme 2-
17). Dithiane removal was similarly successful with the optimal conditions from the first route. 
With the resulting product 2.75 readily available, simultaneous reduction of the hydroxy ketone 
and differentiation of the resulting diol was required. The Evans-Tischenko reduction25 with 
benzaldehyde was chosen to fulfill these goals. This strategy would permit the formation of a 
benzoate at C(13), a group that could be removed orthogonally with respect to both the C(21) 
PMB ether and the C(22) TES ether after union with 2.72 (Scheme 2-20). 
 
Scheme 2-17 Implementation of an ARC protocol utilizing reversed order of addition 
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 After considerable optimization, we found that the reduction of 2.75 was best conducted 
via the portionwise addition of a freshly prepared samarium diiodide solution over the course of 8 
hours in the presence of 15 equivalents of freshly distilled benzaldehyde, providing the desired 
anti-diol 2.76 in 84% yield as a single observable isomer. We were surprised to observe the 
formation of a second product, initially suspected to be the C(11) diastereomer. However, after 
careful separation and extensive NMR structural investigation, the byproduct was identified as 
2.78 after TBS protection to assist purification. This byproduct has its origins in the initial ARC 
step where, at higher temperatures, excess TBS-dithiane can attack two equivalents of the 
excess epoxide 2.29 to form semi-symmetrical adduct 2.77, which is inseparable both at this 
stage and after dithiane removal.  
 Identification of 2.77 as a byproduct of the ARC step led us to reconsider the conditions 
for the ARC union in both the inverted and regular order of addition (vide supra). We reasoned 
that the symmetrical adduct was arising after introduction of epoxide 2.29 (Scheme 2-18). That is, 
immediately after Brook rearrangement the anion 2.42-Li is present in significantly larger 
quantities and should react with epoxide 2.29 significantly faster. We therefore reasoned that by 
lowering the temperature of the second epoxide addition, the rate of product formation would not 
be significantly influenced, while the rate of formation of byproduct 2.77 would decrease 
sufficiently such that double addition would not take place. 
 
Scheme 2-18 Formation of byproduct 2.77 
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 Indeed, when the second epoxide addition was maintained below 0 °C, the ARC product 
was isolated as a single compound in a similar yield as before. Importantly, when this 
chromatographically pure compound was carried through to the Evans-Tischenko reduction, a 
single diastereomer was obtained in 84% yield. The remaining hydroxyl was next protected as the 
TBS ether to yield 2.79 (Scheme 2-19). Removal of the primary benzyl group and careful 
oxidation with Dess-Martin periodinane (DMP)26 then provided aldehyde fragment 2.72. Two 
details are of note. First, oxidation to the aldehyde proved highly sensitive, as conditions other 
than DMP resulted in exclusive elimination of the benzoate to form the corresponding α,β-
unsaturated congener, a fact that foreshadowed future difficulties (vide infra). Second, the 
decision to move away from TES protection at C(13) was highly beneficial in terms of yield - 
whereas in our previous sequence (see Scheme 2-9) yields were generally low due to partial loss 
of the labile C(13) TES ether, the late stage manipulations in Scheme 2-17 proceeded in 
uniformly high yield.  
 
Scheme 2-19 Completion of aldehyde 2.72 
 Aldehyde 2.72 available from the above sequence was next coupled with the previously 
constructed alkyne 2.26, again utilizing a non-selective alkynylation protocol (Scheme 2-20). The 
diastereomers were readily separated by standard column chromatography and each isomer 
subjected to a two stage deprotection sequence, involving DIBAL-H mediated removal of the 
benzoyl group, following by oxidative removal of the PMB group. On small scale, this sequence 
readily provided samples of spiroketalization precursors syn-2.80 and anti-2.80. Note that the syn 
and anti designations are assigned here to match the syn and anti designations in the Aponick 
and Forsyth  cases described in Scheme 2-13. 
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Scheme 2-20 Synthesis of two spiroketalization precursors 
 With the appropriate precursors in hand, we moved on to the critical gold catalyzed 
spiroketalization step (Scheme 2-21). Pleasingly, when anti-2.81 was treated with cationic 
JohnPhos ligated gold complex 2.82,27 a new product was isolated in 81% yield, which, after 
extensive 1D and 2D NMR analysis, proved to be the desired spiroketal 2.15. 
 
Scheme 2-21 Successful completion of a second generation C(1)-C(24) southern hemisphere fragment 
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 The stereochemistry of the spiroketal core was confirmed by observation of a key nOe 
between the C(13) and C(21) protons (Figure 2-2); a similar nOe was observed by Patterson in a 
related system.28  
 
Figure 2-4 Key observed nOe confirming spiroketal stereochemistry 
 Conversely, when syn-2.81 (Scheme 2-21) was subjected to the same spiroketalization 
conditions, none of the desired spiroketal was identified. Unfortunately, poor purity and instability 
to silica gel precluded the full structural characterization of this compound, though based on 
results that will be described in Chapter 3, we can now assign the structure to be 2.83 (Scheme 
2-21).  
 In conclusion, the first synthesis of the proposed southern hemisphere fragment for 
spirastrellolide E, namely C(1)-C(24) spiroketal 2.15, has been achieved, proceeding in 19 steps 
(longest linear sequence) and a 2% overall yield. An account of the synthesis of 2.15 was 
published in a 2015 Tetrahedron Letters Special Issue to honor and remember Henry 
Wasserman, Yale University (1948-2013).29 
 
Figure 2-5 Southern hemisphere 2.15 
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3 CHAPTER 3 
 
 Chapter 2 described the successful completion of a synthetic approach to the 
unsaturated southern hemisphere relevant to spirastrellolide E, a congener of the spirastrellolide 
family of antitumor agents. Upon completion of this sequence, our thoughts turned: 1) to 
optimization of the sequence with the ultimate goal of scaling up to 1 gram of the southern 
hemisphere for completion of spirastrellolide E (1.6), and 2) to the steps necessary for completion 
of a total synthesis of spirastrellolide E.     
3.1 Examination and Further Revision of the Hemisphere Coupling Strategy 
 
 With southern hemisphere 3.2 complete and the northern hemisphere 3.1 being 
constructed by Dr. Roberto Forrestieri, thoughts first turned to the steps necessary to complete a 
total synthesis (Scheme 3-1). The initial plan was to involve a Suzuki cross coupling between 
southern hemisphere 3.2 and a boronate (3.1) derived from the northern hemisphere. Such a 
cross coupling would provide intermediate 3.3, based on the precedent of both the Furstner1 and 
Paterson2 groups. Next, the installation of the C(23) and C(24) hydroxyl and methyl substituents 
with control of stereochemistry would be required.  
 
Scheme 3-1 Examination of proposed hemisphere union 
 Examination of intermediate 3.3, however, reveals an earlier underappreciated potential 
chemoselectivity problem - namely, the functionalization of the C(24)-C(25) olefin in the presence 
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of unsaturation in the southern hemisphere [6,6]-spiroketal. A review of the previous strategies to 
install the C(24-25) stereodiad was not promising. Thus, the Paterson group used a 
hydroboration/oxidation sequence to chemo- and stereo-selectively functionalize the C(24)-C(25) 
olefin prior to spiroketal formation (Scheme 3-2 A). Such a reaction applied to 3.3 would almost 
certainly not be selective (Scheme 3-2 B), as the C(15)-C(16) olefin is expected to be both more 
sterically accessible and more electron rich. Indeed, it is perhaps as a result of this observation 
that the Paterson group elected to construct the southern hemisphere in a stepwise fashion.  
 
Scheme 3-2 Problematic application of Paterson conditions to intermediate 3.3 
 The Furstner synthesis alternatively utilized a difficult hydrogenation of an exo-olefin in 
their spirastrellolide F synthesis (Scheme 3-3 A), which would not be suitable for intermediate 3.3 
due to the more hindered nature of the internal C(23,24) olefin. In Furstner's synthesis, even the 
relatively unhindered exo olefin required very forcing conditions. The lack of oxygenation at C(23) 
in our proposed intermediate 3.3, also raised a chemoselectivity concern with the more sterically 
accessible C(15)-C(16) olefin (Scheme 3-3 B). Undoubtedly, similar concerns led the Furstner 
group to first construct spirastrellolide F (1.8), lacking unsaturation in the southern hemisphere, 
and to mask the corresponding olefin in their spirastrellolide A (1.2) synthesis as a dithiane. 
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Scheme 3-3 Furstner approach to setting C(24)-C25) stereodiad 
 It quickly became clear that a new hemisphere coupling strategy would be required. We 
reasoned that masking and/or protecting the C(15)-C(16) olefin would be counterproductive, as 
spiroketal construction in 3.3 was the cornerstone of our southern hemisphere synthetic strategy. 
Instead, we sought a method that would permit functionalization of a C(24)-C(25) olefin 
chemoselectively. We were particularly intrigued by the possibility of using the C(23) hydroxyl, 
which we expected could be selectively deprotected, as a directing group for selective 
manipulation of the C(24)-C(25) olefin. Of the possible directed functionalizations, we chose the 
Sharpless asymmetric epoxidation3 due to the mild conditions and broad functional group 
compatibility. Although such a late stage oxidation is of considerably high risk, there are a large 
number of examples of the Shaprless epoxidation used in very complex settings. Figure 3-1 
reveals a striking example from the Paterson synthesis of laulimalide A,4 in which a single olefin, 
out of a possible 7 olefins, was selectively epoxidized. 
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Figure 3-1 Application of highly selective Sharpless asymmetric epoxidation to laulimalide 
 With these considerations in mind, a revised hemisphere union, as outlined in Scheme 3-
4, would be required. We reasoned that the C(25) methyl group could arise from the opening of 
an appropriate epoxide (3.12), which, in turn, would derive from a directed Sharpless asymmetric 
epoxidation of the appropriate allylic alcohol. In this manner, both the epoxidation and 
subsequent epoxide opening would be controlled by the C(23) hydroxyl. The requisite allylic 
alcohol (3.13) would result from a cross metathesis or ring closing metathesis of new northern 
and southern hemispheres 3.14 and 3.15.  
 
Scheme 3-4 Revised retrosynthetic analysis for spirastrellolide E 
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 We further reasoned that the difficulties with olefin metathesis at the C(25)-C(26) bond 
encountered by Paterson and Furstner would not be as relevant in our system, as the site of 
metathesis was now two bonds removed from the bulky northern hemisphere. Finally, we were 
cognizant of the potential incompatibility of typical conditions for nucleophilic methylation of 
epoxides with such an advanced system. Nevertheless, we were encouraged by a number of 
reports of such reactions in complex settings.5,6 In addition, we recognized that a number of 
possible substrates were amenable to the proposed strategy. In particular, applying the 
epoxidation/ring opening sequence after macrocyclic ring closure would also be possible and 
could address potential pitfalls encountered in the acyclic case of 3.13, as the spirastrellolide 
skeletons are well known to adapt distinctly different conformations upon macrocycle formation.1.2 
 To pursue such a revised hemisphere union plan, a new southern hemisphere target 
would be required, possessing a terminal olefin. As the terminal carbon atom of the olefin would 
be lost during the olefin metathesis upon hemisphere union, the revised target was envisioned to 
be a C(1)-C(23) fragment (i.e,, 3.15). Pleasingly, the retrosynthesis of this fragment, illustrated in 
Scheme 3-5, closely resembles our approach chosen for the previous southern hemisphere 
target (2.15, Scheme 2-6). Thus, spiroketalization and alkynylation leads back to aldehyde 3.17, 
which was used in the previous synthesis (i.e., 2.73), and a modified alkyne (3.18). Synthesis of 
alkyne 3.18 would thus be accomplished by a simple modification of the existing route, employing 
an Evans aldol reaction between the previously synthesized acylated oxazolidinone 3.19 (2.50 in 
Chapter 2) and acrolein.  
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Scheme 3-5 Retrosynthetic analysis of modified southern hemisphere 
 In a forward direction (Scheme 3-6), the planned Evans aldol reaction proceeded 
smoothly. Given that acrolein is a commodity chemical, it could be used in large excess (4-10 
equiv).  
 
Scheme 3-6 Synthesis of revised alkyne 3.18 
 Employing these conditions, the desired aldol product 3.20 was isolated in 61% yield 
(91% brsm) as a single diastereomer. Importantly, the unreacted 3.19 could be readily recycled. 
Moreover, 10 grams of 3.20 could be readily prepared in one run. Conversion to the 
corresponding Weinreb amide and TES protection, followed by Grignard addition as before then 
led to ketone 3.22.  
 At the stage of the requisite diastereoselective reduction of 3.22, we observed a reduced 
yield due to an alternate pathway involving attack of the product hydroxyl group onto the alkyne 
moiety. The products of this reaction were tentatively assigned as a mixture of 3.24 and 3.25, 
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which proved inseparable by column chromatography. However, after some optimization, the 
desired alcohol 3.23 could be obtained in a 61% yield by maintaining the reaction temperature 
below -60 °C. Pleasingly, methylation and removal o f the alkynyl TMS group completed the 
synthesis of the new alkyne fragment 3.18. Importantly, use of 3.18 as the new alkyne fragment 
removed the least efficient step in the previous synthesis, namely the preparation of aldehyde 
2.48 (Scheme 2-10) for the key aldol reaction. As an added bonus, the lack of hindrance near the 
TES carbinol in 3.23 permitted the alkynyl TMS group to be removed in an excellent yield of 94% 
without affecting this previously sensitive TES. As a result, the new alkyne fragment 3.18 could 
now be prepared in 22% overall yield from 3.19 in 7 steps on multigram scale.  
 With the new alkyne fragment readily available, alkynylation with aldehyde 3.17 (Scheme 
3-7), previously prepared in the synthesis of 2.15 (Scheme 2-19) was performed, resulting, as 
before, in a ~1.5:1 ratio of the diastereomeric alcohols, syn-3.26 and anti-3.26, (89% combined 
yield), which were readily separated  by column chromatography (Scheme 3-7). Attempts to 
remove the benzoyl group as before, via DIBAL-H reduction, on the larger scales involved in this 
route led to erratic results, with incomplete conversion observed in most cases.  
 
Scheme 3-7 Alknylation and improved procedure for benzoyl group removal 
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 Reoptimization of this process led to the identification and use of freshly prepared ethyl 
magnesium bromide7 as the ideal reagent for the deprotection, proving reproducible 80-95% 
yields of the desired diols syn-3.27 and anti-3.27. At this stage, we were able to confirm the 
assignment of the stereochemistry present in these diols utilizing the method of Rychnovsky8 by 
converting anti-3.27 to the corresponding bis acetonide 3.28, via treatment with 
dimethoxypropane in the presence of PPTS (Scheme 3-8). The presence of acetonide methyl 
peaks corresponding both to a syn acetonide (25, 25 ppm; C(9-11) diol) and an anti acetonide 
(19, 30 ppm; C(13-15) diol) suggested the stereochemistry as shown for 3.28 (Scheme 3-8).  
Finally, PMB removal employing excess DDQ (10 equiv)  provided triols syn-3.29 and anti-3.29.  
 
Scheme 3-8 Synthesis of revised spiroketalization precursors 
 The stage was now set for spiroketalization. Using the previously optimized conditions, 
anti-3.29 readily underwent cyclization to furnish the desired spiroketal 3.15 in 81% yield 
(Scheme 3-9). This transformation completed the synthesis of the revised C(1)-C(23) southern 
hemsiphere fragment of spirastrellolide E in a longest linear sequence of 19 steps and an overall 
yield of 7.5%, a marked improvement over the route to 2.15 (Chapter 2), which had proceeded 
with an overall yield of 2% over the same number of steps. Moreover, with an improved route to 
alkyne fragment 3.17 available, the revised route proved to be significantly more scalable. 
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Scheme 3-9 Synthesis of a revised southern hemisphere fragment for spirastrellolide E 
 The anti-3.29 isomer, on the other hand, again provided a different product under the 
same reaction conditions. This time, however, we discovered that performing the reaction in 
methanol, instead of THF, permitted the isolation of spectroscopically pure material after simple 
filtration through a pad of silica gel to remove the gold catalyst. The pure sample, in turn 
permitted application of a series of detailed 1D (1H, 13C NMR and DEPT) and 2D (COSY, HSQC, 
NOESY, TOCSY) NMR studies. With NMR interpretation unhampered by extraneous signals, the 
structure of the byproduct could now be assigned as 3.30 (Figure 3-2).  
 
Figure 3-2 Product from attempted spiroketalization of syn-3.29 
3.2  Mechanistic Considerations for the Formation of 3.15 and 3.30 
 
 With the product of the minor diastereomer identified, a rationale for the formation of this 
compound could now be proposed. We will however first present a mechanism for the key 
spiroketalization reaction in more detail.  
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 Figure 3-3 outlines the catalytic cycle as proposed by Aponick and coworkers in their 
original publication9 for systems that do not possess stereogenicity. In this system, there are two 
possible cycles, depending on which hydroxyl first attacks the gold-activated alkyne. In both 
cases, upon gold complexation with the triple bond, the attack of a hydroxyl group leads to a vinyl 
gold intermediate (3.32 or 3.36, Figure 3-3), depending on which hydroxyl attacks. In the case of 
the exo vinyl gold species 3.32, elimination of gold hydroxide leads to allene 3.33, most likely 
bound by gold. At this stage, both isomerization to vinyl gold (I) complex 3.34, followed by a non-
catalyzed spiroketalization or direct oxyalkylation of a gold-activated allene are both possible to 
furnish 3.35. For endo vinyl gold (I) species 3.36, rearrangement to the oxocarbenium ion (3.37) 
precedes elimination to provide 3.38, which then undergoes a non-catalyzed addition of the 
pendent carbinol to the oxocarbenium ion.  
 
Figure 3-3 Catalytic cycle proposed by Aponick and coworkers 
 This model accounts for observations made for many of the systems outlined in the 
original Aponick report, but does not provide information for situations in which stereogenicity is 
present, nor does it account for the role played by the directing carbinol in determining the 
regioselectivity of the reaction. The only published analysis of such a system comes from the 
work of Forsyth on the okadaic acids.10 As mentioned in Chapter 2, a similar stereochemistry-
dependent spiroketalization was observed in their work. The rationale proposed is shown in 
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Figure 3-4. The authors invoke a kinetic preference for the 5-exo oxy-auration of the C(30) 
carbinol, attacking the C(33) terminus of the alkyne after complexation of the gold species. In the 
syn isomer of 3.39, this would lead to transtion state A, which possesses a five-membered ring 
with all substituents in the equatorial orientation. Conversely, a similar 5-exo course of events in 
anti-3.39 would lead to transition state B, in which the C(32) hydroxyl group is now in an axial 
configuration. As a consequence, transition state C, featuring a 6-endo attack of the C(38) 
hydroxyl on the C(33) terminus of the alkyne, predominates. It appears unlikely, however, that a 
switch in the orientation of one hydroxyl group would lead to such drastic results, as the A-value 
for a hydroxyl group (~0.5 kcal/mol) is not sufficiently large for a full reversal of the course of the 
reaction. 
 
Figure 3-4 Forsyth analysis of spiroketalization 
 Additional clues for deciphering the mechanism can be found in a publication by 
Aponick11 describing his detailed mechanism, supported by calculations, of the gold-catalyzed 
cyclization of mono-allylic diols. The Aponick system differs from the one under study in our case 
only in the substitution of an alkene for the alkyne, and attack of only one hydroxyl (Scheme 3-
10); it is therefore reasonable to expect that the conclusions reached by Aponick are at least 
partially applicable to the cyclization of mono-propargylic triols.      
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Scheme 3-10 Cyclization of mono-allylic diols 
 Aponick's main conclusions are summarized in Figure 3-5. Of particular importance is the 
presence of a hydrogen bond between the allylic alcohol and the incoming nucleophilic carbinol, 
which is proposed to provide considerable stabilization to the favored transition state both by 
promoting attack of the carbinol on the weakly electrophilic alkene and facilitating the subsequent 
elimination to form a new olefin (3.46 to 3.47, Figure 3-5). The authors note that transition states 
that do not possess such a hydrogen bond are uniformly 5-10 kcal/mol higher in energy. 
OO H
Me
Me3PAu
OO H
Me
Me3PAuOH
HO
R
OO H
Me
Me3PAu
OO H
Me
Me3PAuO
H
R
=
OO H
Me=
(R, E)-3.42 3.42 3.45
3.463.47(S)-3.43
H H
HH
H
 
Figure 3-5 Reaction course for (R, E)-3.42 
 Also important is an examination of how the mechanism changes for the (R, Z)-3.42 
(Figure 3-6). This systems differs only in the orientation of the olefin, which, in combination with a 
preset stereochemical configuration of the allylic carbinol, is similar, in principle, to the syn and 
anti effects for the diols in our system. Figure 3-6 illustrates that in this case, the system 
maintains a conformation that permits the molecule to maintain the key hydrogen bond described 
above.  
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Figure 3-6 Reaction course for (R, Z)-3.42 
 This observation is critical, as it suggests that the hydrogen bond between the incoming 
hydroxyl nucleophile and the directing carbinol is the dominant structural element in determining 
the three-dimensional structure of both the intermediates and transition states en route to 
products 3.43 and 3.44. 
 Finally, an early report by de Brabander and coworkers12 on the reactivity and selectivity 
of non-directed metal catalyzed spiroketalizations should be mentioned. The de Brabander group 
examined protected derivatives of simple alkynyl diol 3.51 (Figure 3-7).  
 
Figure 3-7 Alkyne diol 3.51 derivatives examined by de Brabander 
 Protection of one hydoxyl, as in 3.52, permitted observation of the preferred mode of 
attack between 6-exo and 7-endo, whereas protection of the alternative hydroxyl, as in 3.53, 
permitted observation of competition between 5-exo and 6-endo addition. In each case, initial 
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metal-catalyzed oxyalkylation was followed in the same pot by a subsequent acid-catalyzed 
deprotection and spiroketalization to provide a mixture of spiroketals; their relative ratios were 
then used to infer the original selectivity of oxy-auration.  
 Thus, for alcohol 3.52, 6-exo and 7-endo modes are possible. As seen in Table 3-1, gold 
and palladium provide a mixture of the two possible products, while platinum is selective for 6-exo 
cyclization.  
 
Table 3-1 Selectivities in the cyclization of 3.52 
 Protecting the other terminus allows for discrimination between a 5-exo and 6-endo 
pathway. Table 3-2 demonstrates that platinum once again prefers formation of the six membered 
ring, while gold shows a preference for 5-exo attack.  
THPO
OH
[M]
O
HO
O
HO
O O
5-exo
O O
6-endo
H
5-exo 6-endo3.53
Entry
1
2
3
4a
Catalyst (mol%)
[Cl2Pt(CH2CH2)]2 (1)
PdCl2(PhCN)2 (3)
MeAuPPh3/AgPF6
MeAuPPh3/AgPF6
Time (h)
0.5
3
0.5
13
Yield (%)
70
95
92
73
Ratio 5-exo:6-endo
1:11
2:1
3.7:1
6.6:1  
Table 3-2 Selectivities in the cyclization of 3.53 
 Combining the observations of the work described above, a mechanistic picture for our 
spiroketalization can be proposed. With two nucleophilic carbinols and two termini of the alkyne, 
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there are four possible initial oxy-aurations for each enantiopure diastereomer (Figure 3-7). For 
the sake of clarity, the non-participating western portion is abbreviated as Rw and the eastern 
portion as Re.  
 Formation of a seven membered ring by attack of the C(21) carbinol onto the C(16) 
terminus of the alkyne (light red arrow) is a possibility as evidenced by the de Brabander study 
mentioned above. However, such a configuration would not permit the key hydrogen bond 
identified by Aponick to form.   
 
Figure 3-8 Possible modes of cyclization for 3.29 
 Attack of the C(13) carbinol onto the C(17) terminus (light blue arrow) similarly does not 
permit for the formation of the key hydrogen bond; furthermore, the de Brabander study identifies 
5-exo attack as the more likely course relative to 6-endo cyclization for cationic gold catalysts. 
This leads to two possible modes of attack for each diastereomer (bold red and blue arrows in 
Figure 3-8).  
 Figure 3-9 examines these options with the corresponding transition states. For 
diastereomer anti-3.29, attack of the C(21) alcohol onto the C(17) terminus leads to transition 
state 3.54 (Figure 3-9 A), which possesses both a favorable hydrogen bond and all substituents 
in the equatorial position, leading, ultimately, to 3.15, as observed. Conversely, attack of the 
C(13) carbinol onto the C(16) terminus (Figure 3-9 B; transition state 3.56), lacks this hydrogen 
bond, as the lone pair of the incoming nucleophile is perpendicular to the lone pair of the C(15) 
carbinol, and thus not observed. In diastereomer syn-3.29, C(21) carbinol attack onto the C(17) 
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terminus leads to transition state 3.58 (Figure 3-9 C). In order to maintain the favorable hydrogen 
bond, either the Rw or Re substituent has to be axial. Alternatively, a non-constrained system, 
which could adopt a fully equatorial orientation, lacks the beneficial hydrogen bond. Finally, attack 
of C(13) onto C(16) of the alkyne (Figure 3-9 D; transition state 3.59) predominates 
experimentally to furnish, ultimately, 3.30, although this transition state also does not possess the 
stabilizing hydrogen bond.  
 
Figure 3-9 Analysis of possible transition states for isomers of 3.29 
 To understand the preference for transition state 3.59 (Figure 3-9 D) over other modes of 
attack lacking a hydrogen bond, it is instructive to look at the alternatives (Figure 3-10). There are 
two other possibilities for attack of a carbinol onto the alkyne without formation of a hydrogen 
bond, namely C(13) hydoxyl onto C(17) or  the C(21) hydroxyl onto C(16) (Figure 3-10 A and B). 
As mentioned above, attack of C(13) onto the C(17) terminus can be excluded, as de Brabander 
has demonstrated that 5-exo attack is preferred in unbiased systems. The lack of attack of C(21) 
onto the C(16) terminus of the alkyne in a 7-endo fashion, is harder to explain, as this course of 
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action is allowed, as again shown by de Brabander. However, the fact that syn-3.29 stops at the 
formation of the five membered ring product 3.30 suggests that seven membered ring formation 
is comparatively difficult. A possible transition state 3.62 is shown in Figure 3-10 B. Examination 
of a hand-held model of 3.62 confirms that formation of a hydrogen bond between the incoming 
C(21) oxygen and the C(15) carbinol is not favorable, but does not identify any unfavorable 
interactions. It is reasonable to assume, however, that, while formation of a seven membered ring 
may be somewhat competitive with six membered ring formation, five membered ring formation is 
significantly more facile, allowing attack of C(13) to be favored kinetically.   
 
Figure 3-10 Examination of non-hydrogen bonded transition states for syn-3.29 
 This transition state analysis, we believe, helps to explain the course of the 
spiroketalization observed for both diastereomers (i.e., anti-3.29 and syn-3.29). By combining the 
observations and conclusions of the Forsyth, Aponick and de Brabander groups a fuller picture of 
the spiroketalization is now available.  
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3.3 Epilogue: Optimization of Material Throughput for the Second Generation 
Route to Southern Hemisphere 3.15 
 
 At this stage, all that remained to complete a highly effective synthesis of the southern 
hemisphere of spirastrellolide E was a solution to the material throughput issue, namely, the fact 
that only one diastereomer of intermediate 3.29 provided the desired spiroketal, while the other 
provided a product that was not directly useful for advancing southern hemisphere material for a 
total synthesis of spirastrellolide E (1.6) (Scheme 3-11). This section will summarize recent 
attempts to rectify this drawback at various stages of the synthetic route.  
 
Scheme 3-11 Material throughput problem at 3.29 
 Our first attempt to address this issue came upon the completion of the synthesis of the 
original C(1)-C(24) southern hemisphere (2.15), described in Chapter 2, when the original 
dependence of spiroketalization on the propargylic stereocenter was discovered. We reasoned 
that the simplest solution was to simply produce only one diastereomer of the propargylic alcohol 
via an enantio- or diastereo-selective alkynylation. However, a diastereoselective alkynylation 
seemed less promising, as the 1.5:1 ratio of products (Scheme 2-20) suggested the lack of 
substrate bias. Such an observation is to be expected, as alkynes, due to their rod-like shape, 
often provide poor stereoselectivities in the Felkin-Ahn model for addition to α-chiral aldehydes. 
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Nevertheless, we reasoned that by making the lithium species more sterically bulky, the 
diastereoselectivity would be improved. Table 3-3 summarizes these attempts.  
 We first attempted to use additives such as LiBr,13 HMPA14 and TMEDA15 (Entries 2-4). 
While the exact function of lithium bromide is unclear, HMPA and TMEDA are likely to create a 
bulkier lithium acetylide by formation of a chelate with the metal. Unfortunately, while these 
conditions provided better d.r. in the literature examples, in our case, elimination of the benzoate 
moiety to form α,β-unsaturated aldehyde 3.64 (Table 3-3, top) was observed instead. 
 
Table 3-3 Attempts at improving alkynylation diastereselectivity 
In general, conditions possessing either amine bases or Lewis acids favored this pathway. We 
next turned to a system reported by Trost15 using titanium as the metal (Entry 5); while 
conversion was observed, the d.r. did not improve.  
 We next moved to reagent controlled transformations, encouraged by results from our 
laboratory15 employing the Carreira alkynylation.17 Efforts towards this goal are summarized in 
Table 3-4. Application of the conditions that ultimately proved successful in the Smith group (+)-
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18-epi-latrunculol synthetic venture16 (Entry 1) to our system lead to promising results, with a 23% 
yield of a single diastereomer isolated after 3 days of reaction time. However, elimination to 3.64 
was once again observed, with the aldehyde ultimately undergoing elimination over the 3 days. 
We reasoned that the cause of the elimination was the excess of the zinc metal present in the 
reaction mixture. 
 
Table 3-4 Attempts an enantioselective alkynylation 
 Unfortunately, switching to the standard stoichiometric alkynylation conditions17 lead to 
no reaction, even at 55 °C; only slow elimination o f the starting aldehyde was observed (Entry 2). 
After examining in more detailed the reaction temperature, equivalents of the metal, ligand and 
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base for the generation of the alkynyl zinc species (Entry 3-5), we settled on conditions reported 
by Carreira in the total synthesis of bafilomycin A1,18 which in our hands provided a 35% yield of 
the desired isomer, again as a single diastereomer. Encouraged, we reexamined temperature, 
stoichiometry, choice of base, order and speed of addition (Entries 6-11), but to our dismay, no 
conversion was observed, with partial elimination the only observable byproduct. Lack of 
reproducibility is a well-known issue in Carreira alkynylation.19 In fact, a test reaction with 
isopropylaldehyde was found not to be reproducible after initial success, so fresh bottles of the 
main reagents were used. In addition, Zn(OTf)2, which seems to be the main culprit in the lack of 
reproducibility, was prepared using the methods of Corey20 and Laprete,21 the latter using 
complete water and oxygen free conditions. These attempts did not produce any improvement. 
We also tried a number of other enantioselective alkynylations, including the Shibasaki method22 
using indium (Entries 13-14) and the method of Marshall19 utilizing titanium (Entry 12). No desired 
product was observed in either case. 
 Undaunted, we turned to a later stage of the synthesis for the potential convergence of 
the two alkynylation diastereomers. In particular, we reasoned that the undesired product syn-
3.26 could be converted into the desired anti-3.26 either by a Mitsunobu inversion or by an 
oxidation/reduction sequence (Scheme 3-12). Attempts to perform a Mitsunobu inversion were 
hampered by poor conversion, even under forcing conditions. Alternatively, while oxidation of 
syn-3.26 was facile, the ensuing reduction was once again hampered by elimination to furnish the 
α,β-unsaturated ketone 3.67.  
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Scheme 3-12 Attempts of conversion of syn-3.26 to anti-3.26 
 We next reasoned that perhaps conditions could be found where the fully elaborated 
spiroketalization precursor syn-3.29 could be converted into the desired spiroketal. An 
examination of a range of conditions (Table 3-5) did not identify conditions for this transformation, 
with most conditions providing only 3.30, or decompositions when other metals were used.  
 
Table 3-5 Attempts to convert syn-3.29 to the desired spiroketal 
 At this stage, we postulated that the conversion of syn-3.29 into the desired spiroketal 
was being hindered by the hydrogen bond between the incoming C(21) hydroxyl and the C(15) 
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carbinol, as described above. Thus, removal of this possibility, or, alternatively, blocking the C(13) 
hydroxyl from attack would alleviate the difficulties we were observing. At the same time, the 
Aponick group published a paper with very similar logic,23 in which an acetonide blocking group 
was used to block attack of the undesired alcohol onto the alkyne. Importantly, the Aponick group 
demonstrated that a mixture of diastereomers 3.68 underwent the spiroketalization with equal 
efficiency, together or separately (Scheme 3-13). 
 
Scheme 3-13 Aponick cyclization of acetonide alkynes 
 Excited by this possibility, we constructed both the required acetonide 3.70 and the 
related carbonate 3.71 (Scheme 3-14). To date, however, conditions to convert either of these 
congeners into the desired spiroketal have not been found. Studies in this direction continue. 
 
Scheme 3-14 Synthesis of acetonide 3.70 and carbonate 3.71  
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3.4 Summary  
 
 Chapter 3 has described our efforts to develop a viable synthesis for the southern 
hemisphere of spirastrellolide E methyl ester (1.6). Pleasingly, in the area of the overall 
spirastrellolide synthetic venture, a revised hemisphere union strategy was designed and 
validated, in conjunction with completion of a large scale synthesis (c. 500 mg) of the required 
southern hemisphere fragment (3.15). This sequence now proceeds in a 7.5% overall yield with a 
longest linear sequence of 19 steps. Also, in the area of the southern hemisphere, identification of 
the byproduct from spiroketalization (3.30) has lead to efforts to understand the origin and to 
determine appropriate conditions to minimize the formation of this byproduct.  
 
Figure 3-11 Southern hemisphere 3.15 
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4 CHAPTER 4 Experimental 
4.1 General Methods 
 Reactions were carried out in oven- or flame-dried glassware under a nitrogen 
atmosphere, unless otherwise noted.  All solvents were reagent grade.  Diethyl ether, 
dichloromethane, THF, and toluene were obtained from a Pure Solve TM PS-400. Triethylamine 
and diisopropylamine were distilled from calcium hydride under ambient pressure. HMPA was 
distilled from calcium hydride under reduced pressure (~0.1 mm Hg).  N,O-
dimethylhydroxylamine hydrochloride was azeotroped with benzene three times before use. NBS 
was recrystallized from water before use in dithiane deprotections. Reactions were magnetically 
stirred and monitored by thin layer chromatography (TLC) with 0.25 mm E. Merck precoated silica 
gel plates.  Spots were visualized by dipping the plate in an ethanol solution of anisaldehyde or 
potassium permanganate and heating.  In aqueous work-up, all organic solutions were dried over 
sodium sulfate, and filtered prior to rotary evaporation at water aspirator pressure.  Flash 
chromatography was performed with silica gel 60 (particle size 0.040 – 0.062 mm) supplied by 
Silicycle and Sorbent Technologies.  MPLC purification was performed using an apparatus 
comprised of a solvent pump (Waters 510 HPLC pump, 10 mL/min), injection loop (5 mL), column 
(11 mm ID x 300 mm, ACE glass) packed with Silasorb silica gel (18-32 micron particle size, 60 Å 
pore size), and a refractive index detector (Waters R401).  Yields refer to chromatographically 
and spectroscopically pure compounds, unless otherwise stated.  All reagents were purchased 
from commercial vendors and used as received, unless otherwise noted. Benzaldehyde and 
diiodomethane were distilled before use.  n-butyllithium (2.5 M in hexanes) was titrated with 
diphenylphosphoric acid before use.  Infrared spectra were recorded on a Jasco Model FT/IR-480 
Plus spectrometer.  1H and 13C NMR spectra were recorded on a Bruker AMX-500 spectrometer.  
Chemical shifts for 1H and 13C NMR spectra are reported as δ values relative to the internal 
chloroform (δ 7.27 ppm for 1H and δ 77.16 ppm for 13C) or benzene (δ 7.16 ppm for 1H and δ 
128.1 for 13C).  High resolution mass spectra were measured at the University of Pennsylvania 
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Mass Spectrometry Service Center on either a VG Micromass 70/70 H or VG ZAB-E 
spectrometer. Optical rotations were measured on a Jasco P-2000 polarimeter. 
4.2 Experimental Details Relevant to Chapter 2 
Synthesis of Epoxide 2.27 
 
Scheme 4-1 Synthesis of epoxide 2.29 
Compound 2.31. To a -78 °C solution of diisopropylamine (19.3 mL , 138 
mmol, 2.1 eq) in THF (130 mL) was added n-BuLi (56.6 mL, 138 mmol, 2.5 M 
in hexanes, 2.1 eq) dropwise and the mixture was stirred at -78 °C for 40 min. A solution of 
diethyl malate (12.5 g, 65.7 mmol, 1.0 eq) in THF (13 mL) was then added dropwise, and the 
mixture stirred for 1.5 h at 0 °C, then recooled to  -78 °C. A dark red color indicates successful 
formation of the dianion.  Methyl iodide (6.13 mL, 98.5 mmol, 1.5 eq) was then added dropwise 
and the reaction mixture gradually warmed to room temperature overnight, then quenched with 
sat. aqueous sodium bicarbonate. The mixture was diluted with ethyl acetate and the layers 
separated. The aqueous layer was extracted five times with ethyl acetate and the combined 
organics were washed with water and brine, dried over Na2SO4 and concentrated. The residue 
was purified by column chromatography (4:1 Hexanes:Ethyl acetate) to yield the title compound 
(9.15 g, 68%, 7:1 d.r.) as a slightly yellow oil. The spectral data of this compound were in 
agreement with literature reports.1 
Compound 2.32. A modification of a published procedure was followed.2 To a 
suspension of lithium aluminum hydride (8.5 g, 223 mmol, 4.0 eq) in THF (220 mL) 
EtO2C
CO2Et
OH
O O
HO
Ph
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at 0 °C was added a solution of diester 2.31 (11.4 g, 55.8 mmol, 1 eq) in THF (30 mL) dropwise 
over 30 minutes. The reaction was heated to reflux for 3h, then cooled to 0 °C and quenched by 
the successive addition of H2O (8.5 mL), 15% NaOH (8.5 mL) and H2O (27 mL). The resulting 
mixture was stirred under reflux for 2h, then dried over magnesium sulfate, filtered over Celite 
and concentrated to provide the crude triol (6.01 g, 90%) 
 A portion of the resulting residue (3.7 g, 31 mmol, 1.0 eq)  was dissolved in 
dichloromethane (100 mL) and p-TsOH (6 g, 31 mmol, 1.0 eq) and benzaldehyde dimethyl acetal 
(6.2 mL, 40 mmol, 1.3 eq) were added. The reaction mixture was stirred at room temperature 
overnight, then quenched with triethylamine until smoking was no longer observed and 
concentrated. The residue was purified by flash column chromatography (3:1 → 2:1 
Hexanes:Ethyl Acetate) to yield the title compound (4.5 g, 63% over 2 steps).  
1H NMR (CDCl3, 500 MHz): δ = 7.51 (dd, J = 1.6, 7.7 Hz, 2 H), 7.42 - 7.34 (m, 3 H), 5.55 (s, 1 H), 
4.16 (dd, J = 4.9, 11.3 Hz, 1 H), 3.87 (dd, J = 2.5, 11.9 Hz, 1 H), 3.72 (dd, J = 6.3, 12.1 Hz, 1 H), 
3.62 (ddd, J = 2.4, 5.0, 7.3 Hz, 1 H), 3.55 (t, J = 11.3 Hz, 1 H), 2.14 - 2.03 (m, 1 H), 0.84 (d, J = 
6.7 Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 138.4, 129.2, 128.5, 126.3, 101.4, 83.5, 72.8, 63.4, 
30.0, 12.3.; IR (film): ṽ = 3436, 2958, 1456, 1391 cm-1; HRMS (ESI): Calc. for C12H17O3 [M
+ + H] 
209.1178. Found 209.1180. []
 = +9.5 (c =1 in CH2Cl2) 
 
Compound 2.29. To a solution of AlCl3 (5.8 g, 43 mmol, 3.1 eq) in diethyl ether 
(50 mL) was added a slurry of lithium aluminum hydride (1.6 g, 43 mmol, 3.1 
eq) in diethyl ether (40 mL) dropwise. The solution was diluted with dichloromethane (100 mL), 
then stirred at reflux for 30 minutes. A solution of 2.32 (3 g, 14 mmol) in dichloromethane (40 mL) 
was then added and the mixture stirred for an additional 1 h at reflux. The reaction mixture was 
cooled to 0 °C and quenched by the successive slow addition of water (1.6 mL), 15% sodium 
hydroxide (1.6 mL) and water (5.4 mL), then stirring at reflux for 2 h. After cooling, Celite and 
O
OBn
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magnesium sulfate were poured into the reaction mixture, which was then filtered and the filtrate 
concentrated. The resulting 2.33 was sufficently pure to be carried onto the next step. 
 To a 0 °C suspension of NaH (60% dispersion in min eral oil, 1.7 g, 41.4 mmol, 3.0 eq) in 
THF (100 mL) was added the above solution of 2.33 in THF (50 mL). The reaction mixture was 
stirred for 1 h at 0 °C, then triisopropyl sulfonyl  imidazole (6.9 g, 20.7 mmol, 1.3 eq) was added as 
a solid in one portion and stirring was continued for an additional 1 h. The reaction was quenched 
with sat. aqueous ammonium chloride and diluted with diethyl ether. The layers were separated 
and the aqueous layer extracted 3 times with diethyl ether. The combined organics were washed 
with water and brine, dried over Na2SO4 and concentrated. The residue was taken up in diethyl 
ether and filtered through a plug of cotton and the filtrate reconcentrated. Purification by flash 
column chromatography (9:1 Hexanes:Ethyl Acetate) yielded the title compound (2.5 g, 94% over 
2 steps) as a colorless oil. 
1H NMR (CDCl3, 500 MHz): δ = 7.40 - 7.30 (m, 5 H), 4.55 (s, 2 H), 3.70 (dd, J = 
3.0, 10.9 Hz, 1 H), 3.64 - 3.56 (m, 3 H), 3.53 (q, J = 9.0 Hz, 1 H), 2.03 (dtd, J = 
4.0, 7.1, 8.4 Hz, 1 H), 0.91 (d, J = 7.0 Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 137.6, 128.7, 
128.1, 127.9, 76.4, 74.8, 73.7, 64.9, 35.7, 13.8; IR (film): 3388, 2877, 1454, 1363 cm-1; HRMS 
(CI): Calc. for C12H19O3 [M
+] 211.1334. Found 211.1326; []
 = +18 (c = 1 in CH2Cl2).  
.  
1H NMR (CDCl3, 500 MHz): δ = 7.37 - 7.33 (m, 4 H), 7.31 - 7.27 (m, 1 H), 4.53 (d, 
J = 1.2 Hz, 2 H), 3.53 (dd, J = 5.4, 9.1 Hz, 1 H), 3.48 (dd, J = 6.0, 9.3 Hz, 1 H), 
2.91 (td, J = 3.4, 6.9 Hz, 1 H), 2.75 (t, J = 4.5 Hz, 1 H), 2.55 (dd, J = 2.8, 5.0 Hz, 1 H), 1.72 (spt, J 
= 6.5 Hz, 1 H), 1.02 (d, J = 7.0 Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 138.6, 128.5, 127.7, 
73.3, 72.9, 54.4, 45.9, 36.8, 13.3; IR (film): ṽ = 2858, 1454, 1361 cm-1; HRMS (CI): Calc. for 
C12H16O2 [M
+] 192.1150. Found 192.1141; []
 = ─ 7.4 (c = 1 in CH2Cl2). 
 
 
 
OH OBn
HO
O
OBn
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Construction of epoxide 2.28 
 
Scheme 4-2 Synthesis of epoxide 2.30 
 
Compound 2.34. To a 0 °C solution of pyran (25 mL, 0.28 mmol) wa s added 0.2 N 
aqueous HCl (60 mL) dropwise. The reaction mixture was stirred at 0 °C for 15 min., 
then at room temperature for 1 h. The resulting solution was then extracted with 3x100 mL 
dichloromethane. The combined organics were washed with sat. aqueous sodium bicarbonate 
and brine, dried over Na2SO4 and concentrated. The crude product was distilled (0.01 torr) to 
yield the title compound (19.9 g, 71%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 4.95 - 4.87 (m, 1 H), 4.08 - 3.96 (m, 1 H), 3.55 (td, J = 5.8, 11.5 
Hz, 1 H), 2.88 (s, 1 H), 1.96 - 1.74 (m, 2 H), 1.61 - 1.45 (m, 4 H); 13C NMR (CDCl3, 126 MHz): δ = 
94.6, 64.0, 32.1, 25.4, 20.4; IR (film): ṽ = 3390, 2942, 1442 cm-1; HRMS (ESI): Calc. for C5H9O 
[M-H+] 101.0603. Found 101.0605;  
 
Compound 2.35. To a solution of triphenylphosphine (68.7 g, 262 mmol, 1.0 
eq) in ethyl acetate (400 mL) was added a solution of ethyl bromoacetate (29 
mL, 262 mmol, 1.0 eq) in ethyl acetate (100 mL). The reaction was stirred at 
reflux for 3 h until the solution solidified. The white precipitate was filtered and washed with ethyl 
acetate. The crude product was dissolved in dichloromethane and transferred to a separatory 
funnel. Sodium hydroxide (21 g, 526 mmol, 2.0 eq) in water (300 mL) was added and the mixture 
shaken vigorously. The layers were separated and the aqueous layer extracted with additional 
O OH
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dichlromethane. The combined organics were washed with brine and dried over sodium sulfate. 
Concentration provided ethyl (triphenylphosphoranylidene)acetate (86.8 g, 95%) as a white solid, 
which was used without further purification in the Wittig olefination. 
 To this ylide in THF (1 L) was added a solution of 2.34 (19.9 g, 194 mmol) in THF (100 
mL) dropwise. The mixture was then heated to reflux overnight, then cooled down and 
concentrated. The solid residue was stirred in a 7:3 mixture of ether:petroleum ether (50 mL) for 
1h, then filtered to remove the triphenylphosphine oxide byproduct. The solid was washed with 
ether and the filtrate was concentrated. The residue was purified by flash column chromatograph 
(2:1 → 1:1 Hexanes:Ethyl Acetate) to yield the title compound as an oil in an inconsequential 14:1 
ratio of E:Z olefin isomers (28.2 g, 84% total yield).  
1H NMR (CDCl3, 500 MHz): δ = 6.96 (dt, J = 15.6, 7.0 Hz, 1 H), 5.82 (dt, J = 15.7, 1.3 Hz, 1 H), 
4.53 - 4.60 (m, 1 H), 4.18 (q, J = 7.1 Hz, 2 H), 3.81 - 3.89 (m, 1 H), 3.74 (dt, J = 9.3, 6.3 Hz, 1 H), 
3.46 - 3.54 (m, 1 H), 3.39 (dt, J = 9.9, 6.0 Hz, 1 H), 2.24 (q, J = 7.0 Hz, 2 H), 1.75 - 1.88 (m, 1 H), 
1.67 - 1.72 (m, 1 H), 1.47 - 1.66 (m, 8 H), 1.28 (t, J = 7.1 Hz, 3 H); 13C NMR (CDCl3, 126 MHz) δ 
= 166.8, 148.9, 121.7, 62.6, 60.3, 32.2, 32.0, 24.4, 14.4; IR (film): ṽ = 3429, 2936, 1720, 1656, 
1439 cm-1. HRMS (ESI): Calc. for C9H16O3Na [M
+ + Na] 195.0997, found 195.0991. 
 
Compound 2.36. To a suspenstion of PCC (42.4 g, 196 mmol, 1.3 eq) and 
Celite (40 g) in dichloromethane (500 mL) was added a solution of 2.35 (28.2 g, 
164 mmol, 1.0 eq) in dichloromethane (100 mL) and the reaction mixture stirred 
for 4 h at room temperature. The reaction mixture was purified directly by flash column 
chromatography (3:1 Hexanes:Ethyl Acetate) to yield the title compound (22.9 g, 82%) as a 
colorless oil. 
1H NMR (CDCl3, 500 MHz): δ = 9.77 (s, 1 H), 6.85 - 6.99 (m, 1 H), 5.83 (d, J = 15.9 Hz, 1 H), 4.18 
(q, J = 7.2 Hz, 2H), 2.48 (t, J = 7.2 Hz, 2 H), 2.25 (q, J = 7.2 Hz, 2 H), 1.81 (quin, J = 7.2 Hz, 2 H), 
O
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1.28 (td, J = 7.1, 1.9Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 201.7, 166.5, 147.6, 122.4, 60.4, 
43.1, 31.4, 20.5, 14.4; IR (film): ṽ = 2951, 2843, 2726, 1720, 1656, 1438, 1318, 1275 cm-1.  
 
Compound 2.37. To a solution of [(+)-ipc2]BOMe (9.6 g, 30.3 mmol, 1.5 eq) in 
diethyl ether (80 mL) at -78 °C was added allylmagn esium chloride (2 M in 
THF, 12.8 mL, 25.7 mmol, 1.3 eq) dropwise. The reaction mixture was stirred 
at -78 °C for 10 minutes, then warmed to room tempe rature and stirred an additional 1h, then 
recooled to -78 °C. A solution of compound 2.36 (4.0 g, 23.3 mmol, 1.0 eq) in diethyl ether (50 
mL) was then added dropwise and the reaction mixture gradually warmed to room temperature 
overnight. The resulting mixture was cooled to 0 °C  and quenched with successive addition of 
methanol (55 mL), pH 7 buffer (35 mL) and 30% H2O2 (35 mL). The mixture was allowed to stir 
for 24 h at room temperature, then diluted with diethyl ether. The layers were separated and the 
aqueous layer extracted with additional diethyl ether. The combined organics were dried over 
Na2SO4 and concentrated. The residue was purified by flash column chromatography (3:1 → 1:1 
Hexanes:Ethyl Acetate) to yield the title compound (4.2 g, 85%) as a colorless oil.   
 
1H NMR (CDCl3, 500 MHz) δ = 6.96 (dt, J = 15.7, 6.9 Hz, 1 H), 5.82 (d, J = 16.4 Hz, 2 H), 5.15 (s, 
1 H), 5.10 - 5.13 (m, 1 H), 4.18 (q, J = 7.1 Hz, 2 H), 3.67 (br. s, 1 H), 2.26 - 2.35 (m, 1 H), 2.23 (q, 
J = 7.3 Hz, 2 H), 2.10 - 2.19 (m, 1 H), 1.86 (s, 1 H), 1.59 - 1.71 (m, 1 H), 1.46 - 1.58 (m, 3 H), 
1.28 (t, J = 7.1 Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 167.1, 149.2, 134.7, 121.7, 118.5, 70.6, 
70.6, 60.4, 42.1, 36.2, 32.2, 24.2, 14.4; IR (film): ṽ = 3437, 2933, 1725, 1656, 1437, 1273 cm-1; 
HRMS (ESI): calc. for C12H21O3 [M
+ + H] 213.1491, found 213.1496. []
 = -5.48 (c 1.00, 
CH2Cl2). 
 
Compound 2.39. To a solution of 2.37 (8 g, 37.7 mmol, 1.0 eq) in THF 
(160 mL) at -78 °C was added t-BuOK (1 M in THF, 22.6 mL, 22.6 
mmol, 0.6 eq). The reaction mixture was then gradually warmed to -60 °C and stirred until starting 
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material had been consumed as determined by TLC analysis (1h). The mixture was then re-
cooled to -78 °C and quenched slowly with sat. aque ous ammonium chloride.  After dilution with 
ethyl acetate, the layers were separated and the aqueous layer extracted with ethyl acetate. The 
combined organics were washed with brine, dried over Na2SO4 and concentrated to provide 2.38 
of sufficient purity to be taken onto the next step without further purification. 
 To a suspension of LAH (1.68 g, 44.3 mmol, 1.2 eq) in diethyl ether (170 mL) at 0 °C was 
added the above solution of 2.38 in diethyl ether (115 mL). The reaction was stirred at this 
temperature for 1h, then quenched by the successive addition of H2O (1.7 mL), 15% NaOH (1.7 
mL), and H2O (5.1 mL). The resulting suspension was stirred at room temperature for 2 h, then 
filtered and the resulting solid was washed liberally with diethyl ether. The filtrated was dried over 
Na2SO4 and concentrated.  
 The crude residue was dissolved in dichloromethane (80 mL) and cooled to 0 °C. 
Imidazole (868 mg, 75 mmol, 2 eq), DMAP (225 mg, 0.38 mmol, 0.1 eq), and TBSCl (8.3 g, 54.8 
mmol, 1.3 eq) were added successively as solids and the reaction mixture warmed to room 
temperature and stirred for 1h, then quenched with water and diluted with dichloromethane. The 
layers were separated and the aqueous layer extracted with dichloromethane. The combined 
organics were dried over Na2SO4 and concentrated. The residue was purified by flash column 
chromatography (20:1 Hexanes:Ethyl Acetate) to yield the title compound (8.77 g, 84% over three 
steps) as a colorless oil.  
 
1H NMR (CDCl3, 500 MHz): δ = 5.74 - 5.87 (m, 1 H), 5.06 (d, J = 18.0 Hz, 
1 H), 5.00 (d, J = 9.7 Hz, 1 H), 4.15 (q, J = 7.1 Hz, 2 H), 3.73 - 3.82 (m, 1 
H), 3.34 - 3.43 (m, 1 H), 2.50 - 2.59 (m, 1 H), 2.36 - 2.43 (m, 1 H), 2.25 - 2.33 (m, 1 H), 2.10 - 
2.19 (m, 1 H), 1.84 (d, J = 13.5 Hz, 1 H), 1.49 - 1.69 (m, 3 H), 1.26 (t, J = 7.1 Hz, 4 H), 1.16 - 1.24 
(m, 1 H); 13C NMR (CDCl3, 126 MHz): δ = 171.9, 135.2, 166.4, 77.7, 74.7, 60.6, 41.9, 40.9, 31.3, 
30.8, 23.5, 14.3; IR (film): ṽ = 2936, 2860, 1742, 1642, 1437, 1346, 1288 cm-1. HRMS (ESI): Calc. 
for C12H20O3 [M
+] 212.1212, found 212.1418.  
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1H NMR (CDCl3, 500 MHz): δ = 5.89 - 5.79 (m, 1 H), 5.05 (dd, J = 1.5, 
17.2 Hz, 1 H), 5.01 (td, J = 0.9, 10.2 Hz, 1 H), 3.79 - 3.73 (m, 1 H), 3.71 - 
3.65 (m, 1 H), 3.43 (dtd, J = 1.4, 5.2, 14.9 Hz, 1 H), 3.30 (dtd, J = 1.8, 6.4, 11.0 Hz, 1 H), 2.33 - 
2.26 (m, 1 H), 2.17 - 2.10 (m, 1 H), 1.84 - 1.78 (m, 1 H), 1.72 - 1.42 (m, 6 H), 1.18 (s, 3 H), 0.89 
(d, J = 0.6 Hz, 10 H), 0.05 (d, J = 2.6 Hz, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 135.5, 116.4, 77, 
74.5, 59.7, 41.2, 39.7, 31.9, 31.4, 26.1, 23.8, 18.5, -5.2, -5.2; IR (film): ṽ = 2933, 2857, 1643, 
1472, 1439, 1387, 1254, 1198 cm-1; HRMS (ESI): Calc. for C16H33O2Si [M
+ + H] 285.2250. Found 
285.2260; []
 = ─ 19 (c = 1 in CH2Cl2).  
 
Compound 2.40. To a rapidly stirring mixture of K2OsO4·2H2O (9.1 
mg, 0.027 mmol, 0.01 eq), (DHQD)2PYR ( 65 mg, 0.073 mmol, 0.03 
eq), K2CO3 (1.02 g, 7.38 mmol, 3.0 eq), and K3Fe(CN)6 (2.43 g, 7.38 mmol, 3.0 eq) in H2O/t-
BuOH (8 mL/11 mL) at 0 °C was added a solution of 2.39 (700 mg, 2.46 mmol, 1.0 eq) in t-BuOH 
(3 mL). The reaction mixture was stirred at 0 °C ov ernight, then quenched by the addition of 
Na2SO3 (1.55 g, 12.3 mmol, 5.0 eq) and stirring for 4 h at room temperature. The mixture was 
diluted with H2O/ethyl acetate and the layers separated. The aqueous layer was extracted with 
ethyl acetate and the combined layers dried over Na2SO4 and concentrated to give the crude diol 
as a ~6:1 mixture of diastereomers. Column chromatography (2:1 → 3:2 → 1:2 Hexanes:Ethyl 
Acetate) could improve the diastereomeric ratio to ~8-12:1. This mixture was used in the next 
step. An analytically pure sample of the major diastereomer was obtained by purification with an 
MPLC (elution with 3:2 hexanes:ethyl acetate). 
Major isomer: 
 1H NMR (CDCl3, 500 MHz): δ = 3.98 - 3.93 (m, 1 H), 3.72 - 3.66 (m, 2 H), 3.59 (dd, J = 3.8, 11.1 
Hz, 2 H), 3.57 - 3.52 (m, 1 H), 3.49 (dd, J = 5.8, 13.1 Hz, 1 H), 1.86 - 1.80 (m, 1 H), 1.75 - 1.63 
(m, 3 H), 1.63 - 1.48 (m, 4 H), 1.33 - 1.19 (m, 2 H), 0.90 (s, 9 H), 0.07 (s, 3 H), 0.06 (s, 3 H); 13C 
NMR (CDCl3, 126 MHz): δ = 78.7, 75.1, 72.2, 66.8, 59.6, 39.5, 39.2, 32.2, 31.5, 26.1, 26.1, 23.5, 
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18.4, -5.2, -5.2; IR (film): ṽ = 3390, 2930, 2857 cm-1; HRMS (ESI):  Calc. for C16H34O4NaSi [M
+ + 
Na] 341.2124. Found 341.2119; []
 = ─ 5.2 (c = 1 in CH2Cl2). 
  
Epoxide 2.30. To a 0 °C suspension of sodium hydride (60% 
dispersion in mineral oil, 900 mg, 22.4 mmol, 3.0 eq) in THF (25 mL) 
was added a solution of 2.40 (2.38 g, 7.47 mmol, 1.0 eq) in THF (50 mL) and the reaction mixture 
stirred at 0 °C for 0.5 h. Triisopropylsulfonyl imi dazole (3.86 g, 11.2 mmol, 1.5 eq) was then 
added as a solid in one portion and stirring was continued for an additional 1h at 0 °C. The 
reaction mixture was then quenched with sat. aqueous ammonium chloride and diluted with 
diethyl ether. The layers were separated and the aqueous layer extracted 3x75 mL diethyl ether. 
The combined organics were washed with water and brine, dried over Na2SO4 and concentrated. 
The residue was taken up in diethyl ether and filtered through a plug of cotton, then 
reconcentrated to yield an oil, which was purified by flash column chromatography (9:1 
Hexanes:Diethyl Ether) to yield the title compound (2.19 g, 97%) as a colorless oil.  
 
1H NMR (CDCl3, 500 MHz): δ = 3.79 - 3.66 (m, 2 H), 3.57 - 3.50 (m, 1 H), 3.50 - 3.43 (m, 1 H), 
3.09 (sxt, J = 4.2 Hz, 1 H), 2.79 (dd, J = 4.1, 5.0 Hz, 1 H), 2.49 (dd, J = 2.8, 5.1 Hz, 1 H), 1.87 - 
1.81 (m, 1 H), 1.78 (ddd, J = 4.8, 9.1, 14.2 Hz, 1 H), 1.74 - 1.45 (m, 7 H), 1.22 (s, 2 H), 0.90 (s, 10 
H), 0.06 (s, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 75.4, 74.5, 59.8, 50.0, 47.5, 40.1, 39.8, 32.1, 
31.8, 26.1, 26.1, 23.8, 18.5, -5.2, -5.2; IR (film): ṽ = 2930, 2857, 1471 cm-1; HRMS (ESI): Calc. for 
C16H32O3NaSi [M
+ + Na] 323.2011. Found 323.2009; []
 = ─ 8.5 (c = 3 in CH2Cl2). 
 
ARC Union and Further Transformations to Aldehyde 2.25 
ARC Adduct 2.41. To a solution of TES-dithiane 2.26 
(67 mg, 0.286 mmol, 1.1 eq) in 1:1 THF:Diethyl Ether 
(0.6 mL) was added n-butyllithium (2.5 M in hexanes, 
125 µL, 0.312 mmol, 1.2 eq) dropwise and the reaction mixture stirred at room temperature for 15 
O OTBS
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min, then cooled to -55 °C. A solution of epoxide 2.29 (50 mg, 0.260 mmol, 1.0 eq) in diethyl 
ether (0.6 mL) was added dropwise and the reaction mixture stirred for 1h at -45 °C. Completion 
of the first addition was verified by TLC (9:1 Hexanes:Diethyl ether). The reaction mixture was 
cooled to -78 °C. A solution of epoxide 2.30 (156 mg, 0.520 mmol, 2.0 eq) in diethyl ether (0.6 
mL) was added slowly, followed by a solution of HMPA (70 µL, 0.39 mmol, 1.5 eq) in diethyl ether 
(0.6 mL) and the reaction mixture was taken out of the dry ice/acetone bath and allowed to warm 
to 0 °C and stir 1 h. The reaction was quenched wit h sat. aqueous ammonium chloride and 
diluted with ethyl acetate. The layers were separated and the aqueous layer extracted with 2x5 
mL ethyl acetate and the combined layers washed with water (2x10 mL) and brine, then dried 
over Na2SO4 and concentrated. The residue was purified by flash column chromatography (5% to 
10% diethyl ether in hexanes, then 9:1 → 7:1 Hexanes:Ethyl Acetate; alternatively the residue 
could be purified by MPLC, 9:1 Hexanes:Ethyl Acetate) to yield the title compound as a colorless 
oil (118 mg, 62%) along with recovered epoxide 2.30 (55 mg, 70% of theoretical recovery) and 
quenched intermediate 2.41 (18 mg, 16%).  
 
1H NMR (CDCl3, 500 MHz): δ = 7.37 - 7.32 (m, 4 H), 7.31 - 7.28 (m, 1 H), 4.51 (d, J = 11.7 Hz, 2 
H), 4.41 - 4.34 (m, 2 H), 3.79 - 3.67 (m, 2 H), 3.60 - 3.55 (m, 1 H), 3.53 (d, J = 2.4 Hz, 1 H), 3.48 - 
3.40 (m, 2 H), 3.37 (dd, J = 5.9, 9.8 Hz, 1 H), 2.85 - 2.75 (m, 3 H), 2.74 - 2.65 (m, 1 H), 2.23 - 
2.11 (m, 3 H), 2.02 - 1.96 (m, 2 H), 1.92 - 1.85 (m, 2 H), 1.84 - 1.78 (m, 1 H), 1.73 - 1.60 (m, 2 H), 
1.58 - 1.47 (m, 5 H), 1.34 - 1.17 (m, 2 H), 0.99 (t, J = 8.6 Hz, 9 H), 0.95 (d, J = 7.0 Hz, 3 H), 0.90 
(s, 9 H), 0.67 (q, J = 7.5 Hz, 6 H), 0.07 (s, 3 H), 0.06 (s, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 
138.7, 128.4, 127.6, 75.0, 74.7, 73.2, 73.2, 71.0, 65.7, 59.9, 52.6, 47.5, 44.1, 41.7, 40.9, 39.9, 
31.9, 31.7, 26.7, 26.3, 26.2, 25.1, 23.9, 18.5, 11.2, 7.3, 5.7, -5.1; IR (film): ṽ = 3466, 2933, 1495, 
1252 cm-1; HRMS (ESI): Calc. for C38H70O5NaSi2S2
 [M+ + Na] 749.4101. Found 749.4109; []
 = 
+ 12 (c = 0.5 in CH2Cl2). 
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Compound 2.42 1H NMR (CDCl3, 500 MHz): δ = 7.37 - 7.34 (m, 4 H), 7.31 - 
7.28 (m, 1 H), 4.50 (d, J = 1.9 Hz, 2 H), 4.15 (ddd, J = 3.5, 4.5, 7.7 Hz, 2 H), 
3.40 (dd, J = 6.9, 9.3 Hz, 1 H), 3.29 (dd, J = 6.5, 9.3 Hz, 1 H), 2.93 - 2.76 (m, 
4 H), 2.16 - 2.09 (m, 1 H), 2.09 - 2.04 (m, 1 H), 1.93 - 1.83 (m, 1 H), 1.80 (ddd, J = 4.3, 9.4, 13.8 
Hz, 2 H), 0.99 (t, J = 7.5 Hz, 9 H), 0.94 (d, J = 7.2 Hz, 3 H), 0.65 (q, J = 7.7 Hz, 6 H); 13C NMR 
(CDCl3, 500 MHz): δ = 138.7, 128.4, 127.6, 127.5, 73.3, 72.6, 69.9, 44.4, 39.5, 38.5, 30.8, 30.1, 
26.3, 12.2, 7.2, 5.3; IR (film): ṽ = 2953, 2875, 1455, 1421, 1241 cm-1; HRMS (ESI): Calc. for 
C22H39O2S2Si [M
+ + H] 427.2161. Found 427.2164; []
 = + 16 (c = 1 in CH2Cl2). 
 
Ketone 2.44. To a solution of NBS (27 mg, 0.154 mmol, 
2.0 eq), silver perchlorate (35 mg, 0.169 mmol) and 2,6-
lutidine (36 µL, 0.308 mmol, 4.0 eq) in 10% aqueous acetone (6.9 mL) was added a solution of 
ARC adduct 2.41 (56 mg, 0.077 mmol, 1.0 eq) in acetone (1 mL) and the reaction mixture stirred 
vigorously for ~1 min, then quenched with sat. aqueous sodium bicarbonate (15 mL) and stirred 
for 30 minutes. The mixture was diluted with water and ethyl acetate and the layers were 
separated. The aqueous layer was extracted with 2x15 mL ethyl acetate and the combined 
organics were washed with brine, dried over Na2SO4, filtered through a plug of Celite and 
concentrated. The residue was purified by flash column chromatography (9:1 → 7:1 
Hexanes:Ethyl Acetate) to yield the title compound (45 mg, 82%) as a colorless oil.  
 
1H NMR (CDCl3, 500 MHz): δ =  7.36 - 7.31 (m, 4 H), 7.28 (m, 1 H), 4.47 (q, J = 12.0 Hz, 2 H), 
4.38 - 4.33 (m, 1 H), 4.33 - 4.28 (m, 1 H), 3.69 (m, 2 H), 3.61 - 3.54 (m, 1 H), 3.48 (m, 2 H), 3.42 
(dd, J = 7.1, 9.2 Hz, 1 H), 3.28 (dd, J = 5.6, 9.8 Hz, 1 H), 2.63 - 2.49 (m, 4 H), 2.04 - 1.95 (m, 1 
H), 1.86 - 1.80 (m, 1 H), 1.72 - 1.47 (m, 8 H), 1.22 (s, 3 H), 0.94 (t, J = 8.9 Hz, 12 H), 0.91 (s, 9 
H), 0.59 (q, J = 8.1 Hz, 6 H), 0.07 (s, 3 H), 0.06 (s, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 210.4, 
138.7, 128.5, 127.7, 127.6, 75.0, 74.8, 73.2, 72.4, 70.0, 64.9, 59.7, 51.3, 47.5, 42.4, 39.8, 39.5, 
31.8, 31.6, 26.1, 26.1, 23.8, 18.5, 12.8, 7.1, 5.1, -5.2; IR (film): ṽ= 3483, 2933, 1708, 1457, 1252, 
H
OTES
OBn
S S
OTBSO
OH OTES
OBn
O
103 
 
1089 cm-1; HRMS (ESI): Calc. for C35H65O6Si2 [M
+ + H] 637.4320. Found 637.4316; []
 = + 10 
(c = 0.5 in CH2Cl2). 
 
Compound 2.46. To a solution of Me4NBH(OAc)3 
(111.5 mg, 0.424 mmol, 6.0 eq) in acetic 
acid/acetonitrile (1:2, 3.6 mL total) at -30 °C was  added 
a solution of ketone 2.44 (45 mg, 70.6 µmol, 1.0 eq). The reaction mixture was stirred at -30 °C 
overnight, then quenched slowly with sat. aqueous sodium bicarbonate and diluted with ethyl 
acetate. The layers were separated and the organic layer dried over Na2SO4 and concentrated. 
The residue was purified by flash column chromatography (5:1 → 3:1 Hexanes:Ethyl Acetate) to 
yield the title compound (31.6 mg, 70%) 
 
To a solution of the resulting diol (46 mg, 72 µmol, 1.0 eq), Hunig's base (205 µL, 1.08 mmol, 15 
eq) and TBAI (29 mg, 72 µmol, 1.0 eq) in dichloroethane (1 mL) was added MOMBr (65 µL, 0.72 
mmol, 10 eq) dropwise and the reaction mixture stirred at room temperature overnight, then 
quenched with sat. aqueous ammonium chloride and diluted with dichloromethane. The layers 
were separated and the aqueous layer extracted with dichloromethane. The combined organics 
were dried over Na2SO4 and concentrated. The residue was purified by flash column 
chromatography (6:1 Hexanes:Diethyl ether) to yield the title compound  (45.7 mg, 85%) as a 
pale yellow oil.  
 
1H NMR (CDCl3, 500 MHz): δ =  7.36 - 7.32 (m, 4 H), 7.30 - 7.26 (m, 1 H), 4.68 (s, 2 H), 4.66 (d, J 
= 2.3 Hz, 1 H), 4.50 (s, 2 H), 4.00 - 3.96 (m, 1 H), 3.92 - 3.86 (m, 1 H), 3.83 - 3.77 (m, 1 H), 3.71 
(dd, J = 6.2, 7.0 Hz, 2 H), 3.48 - 3.39 (m, 3 H), 3.38 (s, 4 H), 3.34 (s, 3 H), 3.28 (dd, J = 7.1, 9.7 
Hz, 1 H), 2.10 - 2.01 (m, 1 H), 1.87 - 1.78 (m, 1 H), 1.75 - 1.67 (m, 3 H), 1.66 - 1.46 (m, 8 H), 1.24 
- 1.13 (m, 2 H), 0.97 (t, J = 9.1 Hz, 9 H), 0.93 (d, J = 6.9 Hz, 3 H), 0.90 (s, 9 H), 0.62 (q, J = 8.6 
Hz, 6 H), 0.06 - 0.04 (s, 6 H); 13C NMR (CDCl3, 126 MHz): δ= 139.2, 138.9, 128.4, 127.6, 127.5, 
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96.7, 96.3, 74.5, 74.1, 73.9, 73.1, 72.8, 72.5, 70.9, 60.0, 55.8, 55.7, 43.1, 42.6, 40.0, 39.6, 39.3, 
32.2, 31.9, 26.1, 23.9, 18.4, 12.4, 7.2, 5.4, -5.2; IR (film): 2930, 1462, 1253 cm-1; HRMS (ESI): 
Calc. for C39H74O8NaSi2 [M
+ + Na] 749.4820. Found 749.4822; []
 = ─ 0.5 (c = 1 in CH2Cl2). 
 
Alcohol 4.1. To a solution of 2.46 (40 mg, 55.4 µmol, 
1.0 eq) in THF (2.5 mL) was added Pd(OH)2 on carbon 
(8 mg, 11.1 µmol, 0.2 eq). The flask was evacuated and backfilled with hydrogen; this was 
repeated three times. The solution was then stirred at room temperature for 30 minutes. The 
reaction mixture was filtered through a pad of Celite and concentrated. The residue was purified 
by MPLC (4:1 Hexanes:Ethyl Acetate) to yield the title compound (28 mg, 80%) as a colorless oil.  
 
1H NMR (CDCl3 500 MHz): δ =  4.72 - 4.64 (m, 4 H), 3.95 - 3.86 (m, 2 H), 3.86 - 3.74 (m, 2 H), 
3.71 (t, J = 6.5 Hz, 2 H), 3.55 - 3.49 (m, 1 H), 3.44 - 3.39 (m, 5 H), 3.38 (s, 3 H), 1.97 - 1.90 (m, 1 
H), 1.85 - 1.77 (m, 2 H), 1.75 - 1.66 (m, 3 H), 1.65 - 1.45 (m, 8 H), 1.24 - 1.14 (m, 2 H), 1.02 (d, J 
= 7.0 Hz, 3 H), 0.98 (t, J = 8.0 Hz, 9 H), 0.89 (s, 9 H), 0.64 (q, J = 7.9 Hz, 6 H), 0.05 (s, 6 H); 13C 
NMR (CDCl3, 126 MHz): δ = 96.8, 96.1, 74.5, 74.1, 73.5, 72.6, 64.9, 59.9, 55.9, 55.8, 43.2, 42.3, 
40.5, 40.0, 39.1, 32.2, 31.8, 26.1, 23.9, 18.4, 13.7, 7.1, 5.2, -5.2; IR (film): ṽ = 3461, 2932, 1465, 
1383, 1253 cm-1; HRMS (ESI): Calc. for C32H68O8Si2Na [M
+ + Na] 659.4350. Found 659.4347; 
[]
 = ─ 7 (c = 1 in CH2Cl2) 
 
Aldehyde 2.25. To powdered 4 Å molecule sieves (30 
mg) and alcohol 4.1 (20 mg, 37.2 µmol, 1.0 eq) in 
dichloromethane (500 µL) were added NMO (7 mg, 55.8 
µmol, 1.5 eq) and TPAP (1.3 mg, 3.72 µmol, 0.1 eq) successively and the reaction mixture stirred 
at room temperature for 45 min, then filtered through a pad of silica gel, eluting with 9:1 
Hexanes:Diethyl ether to afford the title compound (18 mg, 78%) directly as a colorless oil.  
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1H NMR (C6D6, 500 MHz): δ = 9.80 (d, J = 1.5 Hz, 1 H), 4.88 - 4.82 (m, 3 H), 4.80 - 4.78 (m, 1 H), 
4.45 - 4.41 (m, 1 H), 4.28 - 4.21 (m, 1 H), 4.16 - 4.10 (m, 1 H), 3.92 (m, 2 H), 3.61 - 3.55 (m, 1 H), 
3.54 - 3.48 (m, 1 H), 3.42 (s, 3 H), 3.36 (s, 3 H), 2.59 - 2.53 (m, 1 H), 2.03 - 1.67 (m, 8 H), 1.49 - 
1.31 (m, 4 H), 1.28 - 1.20 (m, 2 H), 1.18 (d, J = 7.0 Hz, 3 H), 1.15 - 1.09 (m, 18 H), 0.75 (q, J = 
7.6 Hz, 6 H), 0.23 (s, 3 H), 0.22 (s, 3 H); 13C NMR (CDCl3, 126 MHz): 96.7, 96.2, 74.5, 74.1, 73.4, 
72.5, 70.6, 59.9, 55.9, 55.8, 52.1, 43.1, 42.4, 41.5, 40.0, 32.2, 31.8, 26.1, 23.9, 18.4, 10.0, 7.1, 
5.3, -5.2; IR (film): ṽ = 2934, 2879, 1724, 1461, 1384, 1252 cm-1; HRMS (ESI): Calc. for 
C32H66O8NaSi2 [M
+ + Na] 657.4194. Found 657.4194; []
 = ─ 21 (c = 0.9 in CH2Cl2). 
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Scheme 4-3 Synthesis of alkyne fragment 2.26 
Compound 2.49 To a solution of 2-butyn-1-ol (5.0 g, 71.5 mmol,1.0 eq), 
imidazole (7.3 g, 0.11 mol, 1.5 eq) and DMAP (440 mg, 3.6 mmol, 0.05 eq) in dichloromethane 
(250 mL) was added TESCl (14.5 mL, 85.8 mmol, 1.2 eq). The cloudy reaction mixture was 
stirred for 4 h at room temperature, then quenched with water. The layers were separated and the 
aqueous layer extracted with additional dichloromethane. The combined organic layers were 
TESO
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dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography 
(100% hexanes → 5% diethyl ether in hexanes) to provide the title compound as a colorless free-
flowing liquid (12.77 g, 97%).  
1H NMR (CDCl3, 500MHz) δ = 4.28 (q, J = 2.3 Hz, 2 H), 1.85 (t, J = 2.4 Hz, 3 H), 0.99 (t, J = 8.5 
Hz, 9 H), 0.66 (q, J = 8.6 Hz, 6 H); 13C NMR (CDCl3, 126MHz) δ = 81.0, 77.8, 51.7, 6.8, 4.6, 3.7; 
IR (film): ṽmax = 2953, 2877, 2238 cm
-1; HRMS (ESI): Calc. for C10H21OSi [M
+ + H] 185.1362. 
Found 185.1358.  
Compound 2.47. To a 0 °C solution of Cp 2ZrCl2 (6.97 g, 23.9 mmol, 1.1 eq) in THF 
(56 mL) was added DIBAL-H (1.0 M in hexanes, 24 mL, 24 mmol, 1.1 eq) dropwise 
and the reaction mixture stirred 0.5 h at 0 °C. A s olution of 2.49 (4 g, 21.7 mmol, 1.0 eq) in THF 
(12 mL) was added dropwise and the reaction mixture warmed to room temperature and stirred 
for 1 h, then cooled to - 78 °C. A solution of iodi ne (7.16 g, 28.2 mmol, 1.3 eq) in THF (40 mL) 
was added slowly. The mixture was stirred at - 78 °C for 1.5 h, then quenched with sat. aqueous 
ammonium chloride and warmed to room temperature, then stirred for 1.5 h. The layers were 
separated, the aqueous layer extracted 2x10 mL diethyl ether, and the combined organics 
washed with sat. aqueous Na2S2O3 and brine, dried over Na2SO4 and concentrated. The residue 
was purified by flash column chromatography (3:1 Hexanes:Ether → 3:1 Pentane:Ether → 2:1 
Pentane:Ether) to yield the title compound (2.66 g, 62%) as a volatile oil that was not stored for 
prolonged periods of time due to decomposition.  The spectral data for a diethyl ether solution 
(~25% w/w) of this compound matched the data reported in the literature for the pure compound.3 
Compund 2.48. The entirety of this reaction was performed in the dark. To a 
solution of 2.47 (3.28 g, 16.6 mmol, 1.0 eq) in dichloromethane (60 mL) was added 
Dess-Martin periodinane (9.13 g, 21.5 mmol, 1.3 eq) and the reaction mixture warmed to room 
temperature and stirred for 1 h, then recooled to 0 °C and quenched with sat. aqueous sodium 
bicarbonate (60 mL) and sat. aqueous Na2S2O3 (60 mL). After stirring vigorously at room 
temperature for 1 h, the layers were separated and the aqueous layer extracted with diethyl ether 
OH
I
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(3x20 mL). The combined organics were dried over Na2SO4 and concentrated under reduced 
pressure (c. 200 Torr). The residue was purified by flash column chromatography (9:1 Petroleum 
ether:Diethyl Ether) to yield the title compound (2.24 g, 69%) as a pale yellow oil. Due to 
instability, this compound was kept in the dark, never concentrated fully and used immediately in 
the next step. The spectral data matched those previously reported in the literature.3 
Compound 4.2 Chloroacetic acid (4.72 g, 50 mmol, 1.0 eq) and 4-methoxybenzyl 
alcohol (6.25 mL, 50 mmol, 1.0 eq) were combined in a 500 mL round bottom flask 
and azeotroped twice with benzene, then dried under vacuum. Toluene (180 mL) was added and 
the reaction mixture cooled to 0 °C. Sodium hydride  (4.4 g, 110 mmol, 2.2 eq, 60% in mineral oil) 
was then added portionwise. After addition was complete, the reaction mixture was heated to 
reflux and allowed to stir overnight. The following morning, the mixture was cooled to room 
temperature and quenched with water. The layers were separated and the aqueous layer was 
acidified to pH 1 by the addition of 3 M HCl, then extracted three times with dichloromethane (200 
mL). The combined organics were dried over sodium sulfate and concentrated. The crude residue 
was purified by flash column chromatography (2:1 Hexanes:Ethyl Acetate + 1% formic acid → 1:2 
Hexanes:Ethyl Acetate + 1% formic acid) to yield the title compound (8.51 g, 87%). 
1H NMR (CDCl3, 500MHz) δ = 7.30 (d, J = 7.9 Hz, 2 H), 6.91 (d, J = 8.6 Hz, 2 H), 4.60 (s, 2 H), 
4.12 (s, 2 H), 3.83 (s, 3 H); 13C NMR (CDCl3, 126MHz)  = 159.8, 130.5, 130.0, 128.6, 114.2, 
73.3, 66.4, 55.5; IR (film): ṽmax = 3240, 2937, 2829, 1732, 1612, 1514 cm
-1; HRMS (ESI): Calc. for 
C10H12O4Na [M
+ + Na] 291.0633, found 291.0634. 
Compound 2.50. To a -78 °C solution of 4.2 (2.52 g, 12.8 mmol, 1.0 eq) in THF 
(45 mL) was added triethylamine (2.0 mL, 141. mmol, 1.1 eq) and pivalic 
chloride (1.65 mL, 13.4 mmol, 1.05 eq) dropwise. The reaction mixture was then 
gradually warmed to -20 °C over 1.5 h to form the c orresponding mixed anhydride. In a separate 
flask, a solution of Evans auxiliary (2.5 g, 14.1 mmol, 1.1 eq) in THF (45 mL) was treated with n-
butyllithium (2.5 M in hexanes, 5.9 mL, 14.7 mmol, 1.15 eq) dropwise at -78 °C, then stirred for an 
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additional hour at this temperature. The lithiated auxiliary was then canulated dropwise into the 
flask containing the anhydride. The reaction mixture was allowed to gradually warm to r.t. over c. 
1h, then quenched with sat. aqueous ammonium chloride and diluted with H2O/diethyl ether. The 
layers were separated and the aqueous layer extracted with diethyl ether (2x50 mL). The 
combined organics were washed with 1 M sodium hydroxide and brine, dried over Na2SO4 and 
concentrated. The residue was purified by flash column chromatography (3:1 → 2:1 
Hexanes:Ethyl Acetate) to yield the title compound (3.79 g, 83%) as a white solid.  
M.P. 64-65 °C; 1H NMR (CDCl3, 500 MHz): δ = 7.38 - 7.32 (m, 4 H), 7.32 - 7.28 (m, 1 H), 7.22 (d, 
J = 7.1 Hz, 2 H), 6.91 (d, J = 9.1 Hz, 2 H), 4.74 - 4.67 (m, 3 H), 4.65 (d, J = 12.0 Hz, 1 H), 4.63 (d, 
J = 11.4 Hz, 1 H), 4.28 (t, J = 8.4 Hz, 1 H), 4.23 (dd, J = 4.3, 9.0 Hz, 1 H), 3.82 (s, 3 H), 3.34 (dd, 
J = 2.9, 13.5 Hz, 1 H), 2.83 (dd, J = 9.5, 13.4 Hz, 1 H); 13C NMR (CDCl3, 126 MHz): δ = 170.4, 
159.7, 153.5, 135.1, 130.0, 129.6, 129.4, 129.2, 127.6, 114.1, 73.3, 69.5, 69.5, 67.4, 55.4, 54.9, 
37.9; IR (film): ṽ = 2918, 1779, 1714, 1612, 1585, 1514, 1393 cm-1; HRMS (ESI): Calc. for 
C20H21NO5Na [M
+ + Na] 378.1317. Found 378.1314; []
 = ─ 61 (c = 2 in CH2Cl2). 
Compound 2.51. To a solution of 2.50 (2.53 g, 7.13 mmol, 1.0 eq) and 
triethylamine (1.3 mL, 9.27 mmol, 1.3 eq) in toluene (9.5 mL) at -50 °C was 
added dibutyl boron triflate (1 M in dichloromethane, 7.84 mL, 7.84 mmol, 
1.1 eq) and the reaction mixture stirred at -50 °C for 1.5 h. A solution of aldehyde 2.48 (2.24 g, 
11.4 mmol, 1.6 eq) in toluene (9.5 mL) was then added dropwise at this temperature and the 
reaction mixture was allowed to gradually warm to -30°C and stir at this temperature for an 
additional 1.5 h. The reaction was then quenched by the successive careful addition of methanol 
(6 mL), pH 7 buffer (6 mL) and 30% hydrogen peroxide (6 mL). The mixture was stirred 
vigorously at room temperature for 1h. The layers were separated and the aqueous layer was 
extracted with diethyl ether (3x25 mL). The combined organics were dried over Na2SO4 and 
concentrated. The residue was purified by flash column chromatography (2:1 → 1:1 
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Hexanes:Ethyl Acetate) to yield the title compound (3.23 g, 82%, single diastereomer) as an off-
white foam. 
1H NMR (CDCl3, 500 MHz): δ = 7.37 - 7.32 (m, 4 H), 7.32 - 7.29 (m, 1 H), 7.23 - 7.19 (m, 2 H), 
6.94 - 6.90 (m, 2 H), 6.33 (qd, J = 1.3, 8.9 Hz, 1 H), 5.20 (d, J = 4.3 Hz, 1 H), 4.65 (d, J = 11.2 Hz, 
1 H), 4.63 - 4.58 (m, 2 H), 4.56 (d, J = 11.1 Hz, 1 H), 4.29 (t, J = 8.8 Hz, 1 H), 4.21 (dd, J = 2.2, 
9.1 Hz, 1 H), 3.80 (s, 3 H), 3.18 (dd, J = 3.3, 13.5 Hz, 1 H), 2.67 (dd, J = 9.7, 13.4 Hz, 1 H), 2.43 
(d, J = 1.5 Hz, 3 H); 13C NMR (CDCl3, 126 MHz): δ = 170.0, 160.0, 153.4, 138.4, 135.1, 130.5, 
129.5, 129.2, 127.6, 114.1, 100.2, 79.1, 73.3, 70.5, 67.2, 60.5, 55.8, 55.4, 37.9, 28.9; IR (film): ṽ 
= 3465, 2920, 1778, 1705, 1611, 1513, 1455, 1390, 1354 cm-1; HRMS (ESI): Calc. for 
C24H26NO6NaI [M
+ + Na] 574.0703. Found 574.0702; []
 =-55 (c =1 0.91 in CH2Cl2); []
 = ─ 
55 (c = 0.9 in CH2Cl2). 
Compound 2.53. To a 0 °C suspension of N,O-dimethylhydroxylamine  
hydrochloride (995 mg, 10.2 mmol, 3.0 eq) in THF (9 mL) was added 
trimethylaluminum (2.0 M in toluene, 5.1 mL, 10.2 mmol, 3.0 eq) and the mixture stirred for 30 
minutes at room temperature. The reaction mixture was then cooled to -20 °C and a solution of 
2.51 (1.87 g, 3.40 mmol, 1.0 eq) in THF (9 mL) was added dropwise. The reaction mixture was 
transferred to a 0 °C ice bath and stirred for 1 h.  The reaction was quenched by the careful 
dropwise addition of Rochelle's salt (9 mL), followed by 1 h of vigorous stirring at room 
temperature. The mixture was diluted with water and diethyl ether and the layers were separated. 
The aqueous layer was extracted 3x5 mL dichloromethane and the combined organics dried over 
Na2SO4 and concentrated to yield a crude inseparable mixture of the desired Weinreb amide and 
Evans auxiliary. 
 This mixture was dissolved in dichloromethane (6 mL) and cooled to -78 °C. 2,6-lutidine 
(1.46 mL, 12.6 mmol, 3.7 eq) and TESOTf (1.69 mL, 7.48 mmol, 2.2 eq) were added dropwise 
and the reaction mixture was stirred for 1 h at -78 °C. The reaction was quenched with sat. 
aqueous sodium bicarbonate and warmed to room temperature. The layers were separated and 
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the aqueous layer extracted with dichloromethane (3x15 mL). The combined organics were dried 
over Na2SO4 and concentrated. The residue was purified by flash column chromatography to 
yield the title compound (1.39 g, 74% over 2 steps) and TES-protected Evans auxiliary 2.54 (888 
mg). The auxillary could be recovered by stirring in a TFA/THF/H2O (1:10:2.5) mixture overnight 
following a literature procedure.4  
1H NMR (CDCl3, 500 MHz): δ = 7.28 (d, J = 8.6 Hz, 2 H), 6.87 (d, J = 8.6 Hz, 2 H), 6.21 (dd, J = 
1.5, 9.3 Hz, 1 H), 4.66 (d, J = 12.0 Hz, 1 H), 4.63 (dd, J = 9.8, 6.7 Hz, 1 H), 4.50 (d, J = 12.0 Hz, 1 
H), 3.81 (s, 3 H), 3.49 (br. s., 3 H), 3.17 (s, 3 H), 2.37 (d, J = 1.0 Hz, 3 H), 0.96 (t, J = 8.6 Hz, 9 
H), 0.62 (q, J = 7.9 Hz, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 159.3, 140.4, 130.2, 129.7, 113.8, 
97.6, 72.2, 71.9, 61.4, 55.4, 32.5, 29.8, 28.8, 6.8, 4.9; IR (film): ṽ = 2953, 1670, 1613, 1513, 1458 
cm-1; HRMS (ESI): Calc. for C22H36NO5SiINa [M
+ + Na] 572.1305. Found 572.1307; []
 =+28 (c 
= 1.55 in CH2Cl2). 
 
Compound 2.54: 1H NMR (CDCl3, 500 MHz): δ = 7.35 (t, J = 7.2 Hz, 2 H), 7.28 (tt, 
J = 1.2, 7.4 Hz, 1 H), 7.17 (d, J = 7.0 Hz, 2 H), 4.13 - 4.06 (m, 2 H), 3.91 - 3.83 (m, 
1 H), 3.00 (dd, J = 3.4, 13.5 Hz, 1 H), 2.72 (dd, J = 11.1, 13.5 Hz, 1 H), 1.06 (t, J = 
8.2 Hz, 9 H), 0.94 (q, J = 7.0 Hz, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 161.6, 136.4, 129.3, 
129.1, 129.1, 127.3, 68.1, 57.6, 42.2, 7.0, 7.0; IR (film): ṽmax = 2953, 1670, 1513 cm
-1; HRMS 
(ESI): Calc. for C16H26NO2Si [M
+ + H] 292.1733. Found 292.1730; []
 = ─ 38 (c = 1 in CH2Cl2). 
 
 Compound 2.565 To a -78 °C solution of 3-butyn-1-ol (7.0 g, 100 m mol) in 
THF (400 mL) was added n-butyllithium (88 mL, 220 mmol, 2.2 eq, 2.5 M 
solution in hexanes) and the resulting cloudy mixture stirred 1.5 h at -78 °C. Trimethylsilyl chloride  
(23.8 g, 220 mmol, 2.2 eq) was then added dropwise and the reation mixture warmed to 0 °C and 
stirred and additional 2 h. 2 N HCl (30 mL) was then added dropwise and the reaction mixture 
stirred a final 30 minutes at 0 °C. The mixture was  then extracted directly with diethyl ether 
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(3x200 mL) and the combined extracts dried over sodium sulfate and concentrated to provide the 
title compound, which was used in the next step without any further purification.  
1H NMR (CDCl3, 500MHz) δ = 3.72 (q, J = 6.1 Hz, 2 H), 2.51 (dt, J = 1.3, 6.3 Hz, 2 H), 0.17 (s, 9 
H); 13C NMR (CDCl3, 126MHz) δ = 103.4, 87.2, 61.0, 24.4, 0.2; IR (film): ṽmax = 3348, 2959, 2899, 
2177 cm-1. HRMS (CI): Calc. for C6H11OSi [M
+ - Me] 127.0579, found 127.0564.   
 Compound 2.576 To a -20 °C solution of compound 2.56 (6.46 g, 45.4 mmol, 
1.0 eq) in dichloromethane (70 mL) were added triphenylphosphine (14.3 g, 
54.5 mmol, 1.2 eq) and NBS (8.9 g, 49.9 mmol, 1.1 eq) as solids in one portion. The reaction 
mixture was allowed to warm to room temperature and stir under an argon atmosphere overnight, 
then diluted with diethyl ether (250 mL) and washed with saturated aqueous sodium bicarbonate 
solution and brine. The organics were dried over sodium sulfate and concentrated. The residue 
was suspended in hexanes and stirred for 15 minutes, then filtered and reconcentrated. Flash 
column chromatography (hexanes) provided the title compound a colorless free-flowing liquid 
(4.644 g, 50%).  
1H NMR (CDCl3, 500MHz) δ = 3.44 (t, J = 7.5 Hz, 2 H), 2.79 (t, J = 7.5 Hz, 2 H), 0.17 (s, 9 H); 
13C 
NMR (CDCl3, 126MHz) δ = 103.3, 87.1, 29.3, 24.4, 0.1; IR (film): ṽmax = 2960, 2898, 2178, 1418 
cm-1; HRMS (CI): Calc. for C6H10SiBr [M
+] 188.9735. Found 188.9726. 
Compound 2.59. Grignard reagent derived from 2.57 was prepared 
according to a literature procedure.7 To magnesium turnings (660 
mg, 27.2 mmol, 5.0 eq) in refluxing THF (40 mL) was added dibromoethane (230 µL, 2.72 mmol, 
0.5 eq) and the mixture refluxed an additional 10 minutes. A solution of 2.57 (3.35 g, 16.3 mmol, 
3.0 eq, must be free of trace bromoform from the preceeding Appel reaction) in THF (10 mL) was 
then added dropwise and the reaction mixture refluxed for an additional 1h. In a separate flask, a 
solution of 2.53 (2.99 g, 5.44 mmol, 1.0 eq) in THF (20 mL) was cooled to -78 °C. The solution of 
the Grignard was then cooled to room temperature and transferred to the solution of 2.53 
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dropwise via syringe and the resulting mixture stirred at -78 °C  for 30 min, then at 0 °C for an 
additional 1.5 h. The reaction was quenched with sat. aqueous ammonium chloride and diluted 
with diethyl ether. The layers were separated and the aqueous layer extracted with additional 
diethyl ether. The combined organics were washed with water and brine, dried over Na2SO4 and 
concentrated. The residue was purified by flash column chromatography (9:1 Hexanes:Diethyl 
ether) to yield the title compound (3.06 g, 92%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.26 (d, J = 8.7 Hz, 2 H), 6.92 (d, J = 8.7 Hz, 2 H), 6.26 (qd, J = 
1.4, 8.0 Hz, 1 H), 4.69 (d, J = 11.8 Hz, 1 H), 4.56 (dd, J = 3.9, 7.0 Hz, 1 H), 4.39 (d, J = 11.8 Hz, 1 
H), 3.84 (s, 3 H), 3.68 (d, J = 3.6 Hz, 1 H), 2.93 - 2.77 (m, 2 H), 2.51 - 2.37 (m, 2 H), 2.34 (d, J = 
1.5 Hz, 3 H), 0.92 (t, J = 8.1 Hz, 9 H), 0.54 (q, J = 8.2 Hz, 6 H), 0.15 (s, 9 H); 13C NMR (CDCl3, 
126 MHz): δ = 210.3, 159.7, 140.9, 130.1, 129.0, 114.1, 106.1, 96.9, 86.2, 84.9, 73.5, 71.7, 55.4, 
40.3, 28.5, 13.8, 6.8, 6.8, 6.8, 4.8, 0.2; IR (film): ṽ = 2956, 2912, 2877, 2176, 1718, 1637, 1612, 
1586, 1514, 1250 cm-1; HRMS (ESI): C27H43O4Si2INa [M
+ + Na] 637.1642. Found 637.1639; []
 
=+56 (c = 0.92 in CH2Cl2). 
Compound 2.60. Zinc borohydride solution was freshly prepared by 
adding a solution of zinc chloride (1 M in diethyl ether, 5.5 mL, 5.5 
mmol, 1.0 eq) to a suspension of sodium borohydride (401 mg, 10.6 mmol, 1.93 eq) in diethyl 
ether (30 mL) and stirring the resulting mixture for 2 days. An aliquot of this solution (7 mL, 0.978 
mmol, 1.2 eq) was then added to a -50 °C solution o f 2.59 (500 mg, 0.815 mmol, 1.0 eq) in 
diethyl ether (10 mL). The reaction mixture was stirred at -50 °C for 30 min., then quenched by 
the careful addition of Rochelle's salt. The biphasic mixture was warmed to room temperature 
and stirred vigorously for 1h. The layers were separated and the aqueous layer was extracted 
with diethyl ether. The combined organic phases were dried over Na2SO4 and concentrated. The 
residue was purified by flash column chromatography to yield the title compound (313 mg, 62%) 
as a colorless oil. Performing this reaction on a larger scale resulted  in a significant drop in yield. 
Higher yields (up to 73%) could be obtained on smaller scale (<300 mg).  
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1H NMR (CDCl3, 500 MHz): δ = 7.26 (d, J = 8.8 Hz, 2 H), 6.90 (d, J = 8.9 Hz, 2 H), 6.33 (dd, J = 
1.4, 9.1 Hz, 1 H), 4.58 (q, J = 11.4 Hz, 2 H), 4.54 (dd, J = 4.5, 9.1 Hz, 1 H), 3.89 - 3.84 (m, 1 H), 
3.82 (s, 3 H), 3.31 (dd, J = 4.9, 10.0 Hz, 1 H), 3.17 (d, J = 4.0 Hz, 1 H), 2.42 (d, J = 1.4 Hz, 3 H), 
2.37 (m, 1 H), 1.88 - 1.80 (m, 1 H), 1.65 - 1.57 (m, 1 H), 0.96 (t, J = 8.7 Hz, 9 H), 0.60 (q, J = 8.0 
Hz, 6 H), 0.17 (s, 9 H); 13C NMR (CDCl3, 126 MHz): δ = 159.6, 140.6, 130.1, 129.9, 114.0, 107.4, 
97.5, 84.9, 82.6, 73.6, 71.1, 70.5, 55.4, 32.5, 28.9, 16.2, 6.8, 4.8, 0.4; IR (film): ṽ = 3495, 2955, 
2876, 2172, 1640, 1612, 1586, 1514, 1249 cm-1; HRMS (ESI): Calc. for C27H45O4NaSi2I [M
+ + Na] 
639.1799. Found 639.1804; []
 = ─ 25 (c = 1 in CH2Cl2). 
Compound 2.61. To a solution of 2.60 (1 g, 1.62 mmol, 1.0 eq) in 
dichloromethane (30 mL) were added proton sponge (1.04 g, 4.86 
mmol, 3.0 eq) and trimethyloxonium tetrafluoroborate (720 mg, 4.86 mmol) in one portion and the 
reaction mixture was stirred for 1 h at room temperature. The reaction was then quenched with 
brine and diluted with dichloromethane. The layers were separated and the aqueous phase 
extracted three times with dichloromethane. The combined organic layers were filtered through a 
pad of Celite and concentrated, then redissolved in ether and refiltered. The filtrate was 
concentrated and the residue purified by flash column chromatography (9:1 Hexanes:Diethyl 
ether) to yield the title compound (782 mg, 77%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.28 (d, J = 8.9 Hz, 2 H), 6.88 (d, J = 8.5 Hz, 2 H), 6.23 (d, J = 
9.3 Hz, 1 H), 4.62 (d, J = 10.2 Hz, 2 H), 4.41 (dd, J = 5.2, 9.1 Hz, 1 H), 3.82 (s, 3 H), 3.52 - 3.46 
(m, 2 H), 3.33 (s, 3 H), 2.46 (s, 3 H), 2.42 - 2.30 (m, 2 H), 1.86 - 1.78 (m, 1 H), 1.74 - 1.66 (m, 1 
H), 0.96 (t, J = 7.9 Hz, 9 H), 0.59 (q, J = 8.1 Hz, 6 H), 0.18 (s, 9 H); 13C NMR (CDCl3, 126 MHz): δ 
= 159.3, 142.1, 130.9, 129.6, 113.8, 107.4, 96.6, 84.9, 81.9, 79.6, 73.9, 70.9, 57.7, 55.4, 29.4, 
28.8, 16.3, 6.9, 5.1, 0.4; IR (film): ṽ = 2955, 2876, 2173, 1729, 1640, 1614, 1586, 1514, 1463 cm-
1; HRMS (ESI): Calc. for C28H47O4Si2INa [M
+ + Na] 653.1955. Found 653.1957; []
 =+4.9 (c = 1 
in CH2Cl2). 
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Alkyne 2.26. To a solution of 2.61 (258 mg, 0.409 mmol, 1.0 eq) in 
ethanol (5 mL) was added potassium carbonate (170 mg, 3.0 eq) in one 
portion and the reaction mixture stirred at room temperature for 3  days, then concentrated. The 
residue was dissolved in diethyl ether and washed with water and brine, dried over Na2SO4 and 
concentrated. Crude NMR showed ~30% loss of TES group. 
 The crude residue was dissolved in dichloromethane (5 mL) and cooled to -78 °C. 2,6-
lutidene (95 µL, 0.818 mmol, 2.0 eq) and TESOTf (92 µL, 0.409 mmol, 1.0 eq) were added and 
the reaction mixture stirred at -78 °C for 30 min, then quenched with sat. aqueous sodium 
bicarbonate, warmed to room temperature and diluted with dichloromethane. The layers were 
separated and the aqueous layer extracted with dichloromethane. The combined organics were 
dried over Na2SO4 and concentrated. The residue was purified by flash column chromatography 
(12:1 Hexanes:Diethyl ether) to yield the title compound (176 mg, 77% over two steps) as a 
colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.28 (d, J = 8.9 Hz, 2 H), 6.88 (d, J = 9.0 Hz, 2 H), 6.22 (dd, J = 
1.5, 9.4 Hz, 1 H), 4.64 (s, 2 H), 4.39 (dd, J = 5.8, 9.4 Hz, 1 H), 3.82 (s, 3 H), 3.52 (dd, J = 3.1, 5.8 
Hz, 1 H), 3.46 (td, J = 2.9, 9.2 Hz, 1 H), 3.33 (s, 3 H), 2.46 (d, J = 1.6 Hz, 3 H), 2.37 - 2.25 (m, 2 
H), 1.99 (t, J = 2.7 Hz, 1 H), 1.89 - 1.80 (m, 1 H), 1.69 - 1.63 (m, 1 H), 0.96 (t, J = 8.1 Hz, 9 H), 
0.60 (q, J = 8.0 Hz, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 159.2, 141.8, 130.9, 129.6, 113.8, 
97.0, 84.4, 81.7, 79.8, 74.1, 71.2, 68.8, 57.6, 55.4, 29.3, 28.9, 14.8, 6.9, 5.1; IR (film): 2953, 
2876, 2116, 1638, 1613, 1514, 1462, 1378, 1302, 1248 cm-1; HRMS (ESI): Calc. for 
C25H39O4NaSiI [M
++ Na] 581.1560. Found 581.1553; []
 = ─ 1.7 (c = 1 in CH2Cl2). 
Propargylic alcohols syn-2.23 and anti-2.23. A stock solution of LDA (0.2 M in THF) was 
freshly prepared by adding n-butyllithium (2.5 M in hexanes, 220 µL, 0.5 mmol) to a solution of 
diisopropylamine (70 µL, 0.5 mmol) in THF (2.5 mL) at -78 °C and stirring for 40 minutes. An 
aliquot of this solution (435 µL, 87 µmol, 3.0 eq) was then added to a -78 °C solution of alkyne 
2.24 (48.6 mg, 87 µmol, 3.0 eq) in THF (0.5 mL) and the reaction mixture allowed to gradually 
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warm to -20 °C over ~30 min., then stirred at this temperature for 15 min and recooled to -78 °C. 
In a separate flask, a solution of aldehyde 2.25 (18.4 mg, 29 µmol, 1.0 eq) in THF (0.5 mL) was 
cooled to -78 °C. The solution of alkyne anion was then transferred via cannula to the aldehyde 
solution and the mixture was transferred to a 0 °C ice bath and stirred for 1h, then quenched with 
sat. aqueous ammonium chloride and diluted with H2O/diethyl ether. The layers were separated 
and the aqueous layer extracted 2x5 mL diethyl ether. The combined organic layers were dried 
over Na2SO4 and concentrated. The residue was purified by MPLC (5:1 Hexanes:Ethyl Acetate) 
to yield the title compounds anti-2.23 (15.1 mg, ) and syn-30b (8.8 mg), as well as recovered 
alkyne 2.4 (33.3 mg, ~100%).   
anti-2.23: 1H NMR (CDCl3, 500 MHz): δ = 7.27 
(d, J = 8.1 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 
6.22 (d, J = 9.2 Hz, 1 H), 4.84 - 4.60 (m, 7 H), 
4.40 (dd, J = 5.5, 9.3 Hz, 1 H), 3.95 (m, 1 H), 
3.92 - 3.87 (m, 1 H), 3.82 (s, 4 H), 3.78 - 3.68 (m, 3 H), 3.53 (br. s., 1 H), 3.44 (dd, J = 3.8, 5.4 
Hz, 1 H), 3.41 - 3.35 (m, 8 H), 3.31 (s, 3 H), 2.45 (s, 3 H), 2.30 (t, J = 6.2 Hz, 2 H), 2.07 - 1.98 (m, 
1 H), 1.87 - 1.78 (m, 3 H), 1.74 - 1.64 (m, 4 H), 1.63 - 1.48 (m, 8 H), 1.29 - 1.11 (m, 8 H), 0.97 (td, 
J = 7.9, 13.0 Hz, 18 H), 0.89 (s, 9 H), 0.65 (q, J = 7.9 Hz, 6 H), 0.59 (q, J = 7.9 Hz, 6 H), 0.05 (s, 
6 H); 13C NMR (CDCl3, 126 MHz): δ = 159.2, 142.1, 130.9, 129.6, 113.8, 96.8, 96.8, 96.2, 81.8, 
80.6, 80.0, 74.5, 74.5, 74.1, 73.3, 72.5, 71.1, 63.5, 59.9, 57.6, 55.9, 55.8, 55.4, 43.3, 42.5, 42.3, 
41.4, 40.0, 32.2, 31.8, 29.9, 29.6, 28.8, 26.1, 23.9, 18.4, 15.2, 12.0, 7.0, 6.9, 5.2, 5.1, -5.2; IR 
(film): ṽ = 3455, 2932, 2877, 1613, 1514, 1461, 1379 cm-1; HRMS (ESI): Calc. for 
C57H105O12Si3INa [M
+ + Na] 1215.5856. Found 1215.5857; []
 =+3.3 (c = 1 in CH2Cl2). 
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syn-2.23: 1H NMR (CDCl3, 500 MHz): δ = 7.28 
(d, J = 8.8 Hz, 2 H), 6.88 (d, J = 9.1 Hz, 2 H), 
6.22 (dd, J = 1.4, 9.4 Hz, 1 H), 4.72 - 4.60 (m, 6 
H), 4.39 (dd, J = 5.7, 9.4 Hz, 1 H), 4.24 (d, J = 9.1 Hz, 1 H), 4.18 - 4.13 (m, 1 H), 3.92 - 3.85 (m, 2 
H), 3.82 (s, 3 H), 3.71 (t, J = 6.6 Hz, 2 H), 3.50 - 3.46 (m, 1 H), 3.41 - 3.37 (m, 8 H), 3.31 (s, 3 H), 
2.93 (d, J = 5.4 Hz, 1 H), 2.46 (d, J = 1.3 Hz, 3 H), 2.33 (t, J = 7.0 Hz, 2 H), 1.97 - 1.90 (m, 1 H), 
1.87 - 1.79 (m, 2 H), 1.78 - 1.65 (m, 5 H), 1.54 (m, 8 H), 1.21 - 1.14 (m, 2 H), 1.01 - 0.92 (m, 21 
H), 0.90 (s, 9 H), 0.65 (q, J = 8.0 Hz, 6 H), 0.59 (q, J = 8.0 Hz, 6 H), 0.05 (s, 6 H); 13C NMR 
(CDCl3, 126 MHz): δ = 159.1, 142.1, 130.7, 129.6, 113.8, 96.9, 96.7, 95.7, 85.6, 81.8, 81.0, 79.9, 
77.4, 77.2, 76.9, 74.6, 74.1, 72.4, 71.1, 70.2, 65.4, 60.0, 57.6, 55.9, 55.9, 55.4, 46.3, 43.1, 42.4, 
40.0, 39.0, 32.2, 31.9, 29.8, 29.5, 28.8, 26.1, 23.9, 18.5, 15.4, 15.2, 11.4, 7.2, 6.9, 5.4, 5.1, -5.2; 
IR (film): ṽ = 3455, 2932, 2877, 1613, 1514, 1461, 1379 cm-1; HRMS (ESI): Calc. for 
C57H105O12Si3INa [M
+ + Na] 1215.5856. Found 1215.5857; []
 =+3.3 (c = 1 in CH2Cl2). 
Diols anti-2.70 and syn-2.70. The following procedure of anti-2.70 is representative. To a 
solution of anti-2.23 (15.1 mg, 12.6 µmol, 1.0 eq) in dichloromethane/pH 7 buffer (9:1, 2.4 mL 
total) at 0 °C was added DDQ (28 mg, 0.126 mmol, 10  eq) in one portion and the reaction mixture 
stirred for 1 h at 0 °C, then quenched with sat. aq ueous sodium bicarbonate. The layers were 
separated and the aqueous layer extracted with 2x3 mL dichloromethane. The combined organic 
layers were washed with sodium bicarbonate, dried over Na2SO4 and concentrated. The residue 
was purified (4:1 Hexanes:Ethyl Acetate) to yield the title compound (9.4 mg, 69%) as a colorless 
oil. Yields for syn-2.70 tended to be higher (~85%).   
 
1H NMR (C6D6, 500 MHz): δ = 6.50 (dd, J = 1.5, 
9.3 Hz, 1 H), 4.86 - 4.82 (m, 1 H), 4.82 - 4.72 
(m, 4 H), 4.56 (dd, J = 3.4, 9.3 Hz, 1 H), 4.30 - 
4.26 (m, 1 H), 4.22 - 4.16 (m, 1 H), 4.11 - 4.05 (m, 1 H), 3.86 - 3.76 (m, 2 H), 3.53 - 3.46 (m, 1 H), 
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3.45 - 3.38 (m, 2 H), 3.37 (s, 3 H), 3.33 (m, 4 H), 3.16 (s, 3 H), 2.36 (dt, J = 1.5, 6.6 Hz, 2 H), 2.26 
(d, J = 1.5 Hz, 3 H), 2.17 - 2.09 (m, 2 H), 2.03 - 1.95 (m, 1 H), 1.94 - 1.77 (m, 5 H), 1.76 - 1.57 (m, 
4 H), 1.40 - 1.33 (m, 9 H), 1.15 (m, 1 H), 1.05 (t, J = 7.7 Hz, 9 H), 1.01 (s, 9 H), 0.95 (t, J = 7.7 
Hz, 9 H), 0.72 (q, J = 8.0 Hz, 6 H), 0.56 (dq, J = 2.1, 8.0 Hz, 6 H), 0.13 (s, 3 H), 0.12 (s, 3 H); 13C 
NMR (C6D6, 126 MHz): δ = 142.4, 96.9, 96.8, 96.1, 85.3, 81.9, 79.4, 75.0, 74.3, 74.1, 73.7, 73.4, 
72.7, 69.9, 65.8, 64.0, 60.1, 57.0, 55.6, 55.5, 44.8, 43.8, 43.1, 40.9, 40.4, 32.4, 32.0, 30.3, 30.1, 
29.0, 28.3, 26.1, 24.1, 18.4, 15.4, 14.2, 11.4, 7.2, 6.9, 5.5, 5.2, -5.2; IR (film): ṽ = 3436, 2929, 
1640, 1461, 1251  cm-1; HRMS (ESI): Calc. for C49H97O11Si3INa [M
+ + Na] 1095.5281. Found 
1095.5317; []
 =+27 (c = 0.5 in CH2Cl2). 
Revised Second Generation Route - Synthesis of Revised Alkyne 2.72 
ARC Adduct 2.74. To a solution of TBS-dithiane (1.78 g, 
7.60 mmol, 1.1 eq) in a mixture of diethyl ether (6 mL) 
and THF (6 mL) at room temperature was added n-
butyllithium  (2.4 M in hexanes, 3.45 mL, 8.29 mmol, 1.2 eq) dropwise and the reaction mixture 
stirred at room temperature for 10 minutes, then cooled to -50 °C. A solution of epoxide 2.30 
(2.08 g, 6.91 mmol, 1.0 eq) in diethyl ether (12 mL) was added slowly and the reaction mixture 
stirred for 1h at -45 °C, then cooled to -78 °C. A solution of epoxide 2.29 (1.99 g, 10.36 mmol, 1.5 
eq) in diethyl ether (12 mL) was added slowly, followed by a solution of HMPA (900 µL, 5.18 
mmol, 0.75 eq) in diethyl ether (12 mL). The reaction mixture turns yellow, indicating successful 
Brook rearrangement. The reaction mixture was then removed from the cooling bath, allowed to 
warm to 0 °C and stirred for 1h. The reaction was t hen quenched with sat. aqueous ammonium 
chloride and diluted with ethyl acetate. The layers were separated and the aqueous layer 
extracted with ethyl acetate (3x15 mL). The combined organics were washed with water (2x15 
mL) and brine, dried over Na2SO4 and concentrated. The residue was purified by flash column 
chromatography (9:1 → 7:1 Hexanes:Ethyl Acetate) to yield the title compound (1.14 g, 76%) a 
colorless oil.  
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1H NMR (CDCl3, 500 MHz): δ = 7.35 - 7.32 (m, 4 H), 7.31 - 7.26 (m, 1 H), 4.52 (s, 2 H), 4.24 
(quin, J = 5.6 Hz, 1 H), 4.03 - 3.97 (m, 1 H), 3.73 (d, J = 7.2 Hz, 2 H), 3.64 - 3.55 (m, 2 H), 3.50 
(dd, J = 6.0, 9.2 Hz, 1 H), 3.40 (dd, J = 6.3, 14.1 Hz, 2 H), 2.98 - 2.71 (m, 4 H), 2.33 (ddd, J = 9.5, 
15.8, 24.5 Hz, 2 H), 2.12 - 2.02 (m, 2 H), 1.99 - 1.87 (m, 4 H), 1.84 - 1.72 (m, 2 H), 1.65 - 1.43 (m, 
5 H), 1.25 - 1.14 (m, 2 H), 1.03 (d, J = 6.9 Hz, 3 H), 0.90 (s, 18 H), 0.14 (s, 3 H), 0.11 (s, 3 H), 
0.06 (s, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 138.6, 128.5, 127.8, 127.7, 127.7, 127.6, 74.8, 
74.6, 73.4, 73.0, 71.4, 67.3, 60.3, 51.7, 48.7, 46.7, 44.1, 40.0, 39.7, 32.4, 31.7, 26.9, 26.4, 26.3, 
26.3, 26.1, 24.8, 24.0, 18.5, 18.2, 14.5, -3.4, -4.0, -5.1, -5.1; IR (film): ṽ = 3451, 2929, 2856, 1471, 
1387, 1360, 1254 cm-1; HRMS (ESI): Calc. for C38H70O5NaSi2S2 [M
+ + Na] 749.4101. Found 
749.4103; []
  = + 11 (c = 1 in CH2Cl2). 
Compound 4.3:  1H NMR (CDCl3, 500MHz) δ = 4.15 - 4.12 (m, 1 
H), 4.09 (t, J = 7.1 Hz, 1 H), 3.79 - 3.74 (m, 1 H), 3.72 (s, 1 H), 3.42 
- 3.34 (m, 2 H), 2.90 (tt, J = 3.0, 15.2 Hz, 1 H), 2.84 - 2.77 (m, 3 H), 
2.17 - 2.06 (m, 1 H), 1.92 - 1.86 (m, 1 H), 1.85 - 1.80 (m, 3 H), 1.79 - 1.69 (m, 1 H), 1.66 - 1.57 
(m, 3 H), 1.56 - 1.45 (m, 3 H), 1.25 - 1.16 (m, 2 H), 0.91 (s, 9 H), 0.90 (s, 9 H), 0.13 (s, 3 H), 0.09 
(s, 3 H), 0.06 (s, 6 H); 13C NMR (CDCl3, 126MHz) δ = 74.8, 74.0, 66.0, 60.4, 45.0, 44.1, 43.9, 
40.0, 32.2, 31.8, 30.7, 30.4, 26.2, 26.1, 23.9, 18.5, 18.2, -4.1, -4.3, -5.1; IR (film): ṽmax = 2929, 
2856, 1471, 1387, 1254 cm-1; HRMS (ESI): Cacl for. C26H54O3S2Si2Na [M
+ + Na] 557.2951, found 
557.2958; []
  = ─ 7 (c = 1 in CH2Cl2).  
Ketone 2.75. 10% aqueous acetone (380 mL) was 
added to solid NBS (1.76 g, 9.88 mmol, 2.0 eq; freshly 
recrystallized, slightly yellow NBS gives inferior yields) and silver perchlorate (2.05 mg, 9.88 
mmol, 2.0 eq). The reaction mixture was stirred for 3 minutes. 2,6-lutidine (1.72 mL, 14.82 mmol, 
3.0 eq)was added, followed immediately by a solution of ARC adduct 2.74 (3.59 g, 4.94 mmol, 
1.0 eq) in acetone (10 mL). The reaction mixture was stirred for 1 minute, then quenched with sat. 
aqueous sodium bicarbonate (500 mL) and diluted with ethyl acetate (500 mL) and brine (100 
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mL). The layers were separated and the aqueous layer extracted with ethyl acetate (2x500 mL). 
The combined organics were washed with brine, dried over Na2SO4 and concentrated. The 
residue was purified by flash column chromatography (7:1 → 5:1 Hexanes:Ethyl Acetate) to yield 
the title compound (2.19 g, 70%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.37 - 7.28 (m, 5 H), 4.51 (s, 2 H), 4.39 - 4.32 (m, 1 H), 4.06 - 
4.00 (m, 1 H), 3.75 - 3.67 (m, 2 H), 3.56 - 3.47 (m, 3 H), 3.43 - 3.33 (m, 2 H), 2.68 - 2.53 (m, 4 H), 
1.95 - 1.86 (m, 1 H), 1.85 - 1.69 (m, 2 H), 1.65 - 1.55 (m, 4 H), 1.54 - 1.47 (m, 2 H), 1.18 (dq, J = 
3.7, 13.0 Hz, 2 H), 0.94 (d, J = 6.9 Hz, 3 H), 0.90 (s, 9 H), 0.88 (s, 9 H), 0.09 (s, 3 H), 0.06 (s, 9 
H). 13C NMR (CDCl3, 126 MHz): δ = 210.6, 138.4, 128.5, 127.7, 74.7, 74.0, 73.4, 70.8, 66.1, 60.1, 
52.4, 48.7, 45.0, 40.0, 38.5, 32.3, 31.7, 26.1, 26.1, 23.9, 18.5, 18.1, 13.9, -4.3, -4.5, -5.1; IR (film): 
ṽ = 3485, 2927, 1714, 1472 cm-1; HRMS (ESI): Calc. for C35H64O6NaSi2 [M
+ + Na] 659.4139. 
Found 659.4127; []
 = + 34 (c = 0.5 in CH2Cl2). 
Alcohol 2.76. Samarium iodide (0.1 M in THF) was 
prepared freshly before each reaction by adding freshly 
distilled diiodomethane (500 µL, 1.25 mmol, 0.95 eq) to 
a rapidly stirring suspension of samarium metal (980 mg, 1.3 mmol, 1.0 eq) in THF (62 mL). The 
resulting mixture was stirred overnight and used only if a deep blue color developed after the first 
30-45 minutes. 
To a solution of ketone 2.75 (2.28 g, 3.58 mmol, 1.0 eq) and benzaldehyde (5.5 mL, 53.7 mmol, 
15 eq) in THF (33 mL) at -10 °C was then added an a liquot of the samarium iodide solution (7.1 
mmol, 7.1 mmol, 0.2 eq). An additional aliquot was added after 4 and 8 hours. After the final 
addition, the reaction mixture was allowed to stir at -10 °C overnight, then quenched with sat. 
aqueous sodium bicarbonate and warmed to room temperature. The mixture was diluted with 
water and diethyl ether and the layers separated. The aqueous layer was extracted with diethyl 
ether (2x100 mL) and the combined organics washed with sat. aqueous sodium bicarbonate and 
brine, dried over Na2SO4 and concentrated. The residue was purified by flash column 
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chromatography (9:1 Hexanes:Diethyl ether then 8:1 → 6:1 Hexanes:Ethyl Acetate) to yield the 
title compound as a pale yellow oil (2.153 mg, 81%) as a single detectable diastereomer by 1H 
NMR analysis.  
1H NMR (CDCl3, 500 MHz): δ = 8.02 (dd, J = 1.2, 8.2 Hz, 2 H), 7.58 (t, J = 7.3 Hz, 1 H), 7.44 (t, J 
= 7.7 Hz, 2 H), 7.31 (d, J = 4.7 Hz, 4 H), 7.27 - 7.24 (m, 1 H), 5.44 - 5.39 (m, 1 H), 4.49 (d, J = 
12.5 Hz, 2 H), 4.14 - 4.08 (m, 1 H), 3.83 - 3.76 (m, 1 H), 3.70 (t, J = 6.6 Hz, 2 H), 3.60 - 3.55 (m, 2 
H), 3.42 (dd, J = 6.7, 9.2 Hz, 1 H), 3.39 - 3.28 (m, 2 H), 2.27 - 2.18 (m, 1 H), 1.82 - 1.75 (m, 1 H), 
1.75 - 1.64 (m, 4 H), 1.63 - 1.38 (m, 8 H), 1.21 - 1.12 (m, 2 H), 1.07 (d, J = 6.9 Hz, 3 H), 0.92 - 
0.88 (m, 9 H), 0.72 (s, 9 H), 0.05 (s, 6 H), 0.02 (s, 3 H), -0.05 (s, 3 H); 13C NMR (CDCl3, 126 
MHz): δ = 167.3, 138.5, 133.2, 130.2, 130.0, 128.4, 127.7, 127.6, 74.6, 74.3, 73.7, 73.3, 72.0, 
67.1, 63.9, 60.1, 44.9, 44.6, 40.6, 39.9, 38.1, 32.2, 31.8, 26.1, 25.9, 23.8, 18.5, 18.0, 14.2, -4.4, -
4.6, -5.1; IR (film): ṽ = 3511, 2927, 2855, 1698, 1640, 1453, 1277 cm-1; HRMS (ESI): Calc. for 
C42H71O7Si2 [M
+ + H] 743.4738. Found 743.4732; []
 = ─ 14 (c = 0.4 in CH2Cl2). 
Compound 2.79. To a -78 °C solution of alcohol 2.76 
(358 mg, 0.482 mmol, 1.0 eq) and 2,6-lutidine (560 µL, 
4.82 mmol, 10 eq) in dichloromethane (8 mL) was 
added TBSOTf (420 µL, 2.41 mmol, 5.0 eq) dropwise and the reaction mixture was warmed to 
room temperature and stirred 2h. The reaction was then quenched with sat. aqueous ammonium 
chloride and diluted with dichloromethane. The layers were separated and the aqueous layer 
extracted with dichloromethane. The combined aqueous layers were dried over Na2SO4 and 
concentrated. The residue was purified by flash column chromatograph (14:1 Hexanes:Diethyl 
Ether) to yield the title compound (390 mg, 94% yield) as a colorless oil. 
1H NMR (C6D6, 500 MHz): δ = 8.41 - 8.38 (m, 2 H), 7.44 (d, J = 7.4 Hz, 2 H), 7.32 - 7.27 (m, 5 H), 
7.21 (tt, J = 1.9, 7.4 Hz, 1 H), 5.88 (ddd, J = 1.7, 4.9, 10.0 Hz, 1 H), 4.47 (d, J = 12.0 Hz, 1 H), 
4.42 (d, J = 12.1 Hz, 1 H), 4.39 - 4.32 (m, 1 H), 4.24 - 4.18 (m, 1 H), 3.93 (t, J = 6.6 Hz, 2 H), 3.69 
(tt, J = 1.9, 10.4 Hz, 1 H), 3.60 (d, J = 6.3 Hz, 2 H), 3.46 (dd, J = 4.7, 6.3 Hz, 1 H), 2.66 - 2.57 (m, 
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1 H), 2.31 - 2.25 (m, 1 H), 2.11 (t, J = 6.9 Hz, 2 H), 2.06 - 1.97 (m, 2 H), 1.95 - 1.88 (m, 1 H), 1.82 
- 1.75 (m, 1 H), 1.75 - 1.70 (m, 1 H), 1.67 - 1.60 (m, 1 H), 1.56 - 1.50 (m, 1 H), 1.47 - 1.41 (m, 2 
H), 1.31 - 1.20 (m, 2 H), 1.18 (d, J = 6.9 Hz, 3 H), 1.14 (s, 9 H), 1.13 (s, 9 H), 1.11 (s, 9 H), 0.34 
(s, 3 H), 0.32 (s, 3 H), 0.31 (s, 3 H), 0.24 (s, 3 H), 0.23 (s, 3 H), 0.21 (s, 3 H); 13C NMR (C6D6, 500 
MHz): δ = 165.8, 139.2, 139.1, 132.6, 131.5, 130.0, 128.5, 128.4, 127.5, 74.5, 74.0, 73.6, 73.0, 
72.4, 67.6, 66.8, 60.3, 47.8, 44.9, 40.5, 38.6, 37.6, 32.5, 32.1, 26.2, 26.1, 26.1, 24.0, 18.4, 18.2, 
12.8, -3.6, -3.8, -4.1, -4.3, -5.1, -5.2; IR (film): ṽ = 2929, 2856, 1719, 1471 cm-1; HRMS (ESI): 
Calc. for C48H84O7Si3Na [M
++ Na] 879.5423. Found 879.5396; []
 = + 14 (c = 1 in CH2Cl2). 
Compound 2.78 1H NMR (CDCl3, 500MHz) δ = 8.04 (dd, J = 1.3, 
8.4 Hz, 2 H), 7.55 (tt, J = 1.1, 7.5 Hz, 1 H), 7.42 (t, J = 7.8 Hz, 2 
H), 7.38-7.32 (m, 8 H), 7.31 - 7.26 (m, 2 H), 5.45 (ddd, J = 2.0, 4.5, 
9.9 Hz, 1 H), 4.55 - 4.45 (m, 4 H), 3.94 (tt, J = 3.1, 8.9 Hz, 1 H), 3.88 (td, J = 3.3, 8.8 Hz, 1 H), 
3.53 (dd, J = 6.1, 9.4 Hz, 1 H), 3.38 - 3.33 (m, 2 H), 3.34 - 3.28 (m, 1 H), 2.37 (dq, J = 4.7, 6.6 Hz, 
1 H), 2.07 (s, 1 H), 2.02 (ddd, J = 2.7, 10.1, 14.5 Hz, 1 H), 1.72 (ddd, J = 4.2, 9.0, 13.0 Hz, 1 H), 
1.60 (ddd, J = 2.0, 9.2, 14.5 Hz, 1 H), 1.49 (ddd, J = 2.9, 9.2, 13.6 Hz, 1 H), 0.98 (d, J = 6.9 Hz, 3 
H), 0.91 (s, 12 H), 0.84 (s, 9 H), 0.05 (s, 3 H), 0.03 (s, 3 H), 0.02 (s, 3 H), -0.03 (s, 3 H); 13C NMR 
(CDCl3, 126MHz) δ = 166.2, 138.8, 138.7, 132.8, 131.1, 129.8, 128.5, 128.3, 127.8, 127.6, 127.5, 
127.5, 73.8, 73.1, 73.1, 72.9, 72.4, 70.2, 67.0, 41.2, 39.2, 38.2, 37.4, 26.1, 26.0, 18.1, 18.1, 12.9, 
11.7, -3.9, -4.2, -4.6; IR (film): ṽmax = 3510, 2927, 2855, 1698, 1453 cm
-1; HRMS (ESI): Calc. for 
C44H68O6NaSi2 [M
+ + Na] 771.4452, found 771.4457; []
 = + 0.4 (c = 0.2 in CH2Cl2).  
Aldehyde 2.72. To a solution of 2.79 (431 mg, 0.503 mmol, 1.0 eq) in THF (30 mL) was added 
Pd(OH)2 on carbon (71 mg, 0.100 mmol, 0.2 eq). The head space of the reaction was evacuated 
and back filled with hydrogen gas three times. The reaction mixture was then stirred under a 
balloon of hydrogen for 4h. Upon reaction completion, the mixture was filtered through a pad of 
Celite and concentrated. The crude residue was dissolved in dichloromethane (10 mL). Sodium 
bicarbonate (211 mg, 2.52 mmol, 5.0 eq) was added as a solid, followed by DMP (213 mg, 0.503 
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mmol, 1.0 eq). The reaction mixture was stirred for 1h, then cooled to 0 °C and quenched by the 
addition of a 1:1 mixture of sat. sodium bicarbonate:sat. sodium thiosulfite (20 mL total). After 
stirring for an additional 1h at room temperature, the layers were separated and the aqueous 
layer extracted with additional dichloromethane. The combined organics were dried over Na2SO4 
and concentrated. The crude residue was purified by flash column chromatography (12:1 → 9:1 
Hexanes:Diethyl ether) to afford the title compound as a colorless oil (352 mg, 91% over 2 steps). 
The de-benzylation could also be run utilizing Pd/C in ethyl acetate as solvent with similar results, 
but higher reproducibility due to the greater stability of the catalyst.  
Compound 4.4: 1H NMR (C6D6, 500 MHz): δ =  8.30 - 
8.26 (m, 2 H), 7.21 - 7.16 (m, 3 H), 5.65 (ddd, J = 1.4, 
7.0, 9.9 Hz, 1 H), 4.28 - 4.22 (m, 1 H), 4.06 (q, J = 7.8 Hz, 
1 H), 3.89 - 3.80 (m, J = 3.5 Hz, 2 H), 3.63 - 3.55 (m, 1 H), 3.49 (d, J = 4.7 Hz, 3 H), 2.14 (ddd, J 
= 1.7, 10.3, 14.3 Hz, 1 H), 2.00 (t, J = 7.0 Hz, 2 H), 1.96 - 1.87 (m, 4 H), 1.79 (ddd, J = 2.1, 9.8, 
13.7 Hz, 1 H), 1.70 (dtd, J = 4.7, 6.9, 13.6 Hz, 1 H), 1.66 - 1.60 (m, 1 H), 1.51 (ddd, J = 2.0, 9.4, 
13.9 Hz, 1 H), 1.46 - 1.39 (m, 1 H), 1.35 (br. s., 2 H), 1.22 - 1.14 (m, 2 H), 1.07 (d, J = 6.9 Hz, 3 
H), 1.04 (s, 9 H), 1.03 (s, 9 H), 1.00 (s, 9 H), 0.24 (s, 3 H), 0.21 (s, 3 H), 0.18 (s, 3 H), 0.12 (s, 3 
H), 0.11 (s, 3 H), 0.11 (s, 3 H); 13C NMR (C6D6, 126 MHz): δ = 166.8, 132.9, 131.0, 130.1, 128.6, 
74.5, 73.9, 73.6, 67.5, 66.6, 64.0, 60.4, 47.6, 44.7, 40.6, 40.3, 39.4, 32.5, 32.1, 30.1, 26.2, 24.0, 
18.4, 18.2, 13.3, -3.6, -3.8, -4.2, -4.4, -5.1, -5.2; IR (film): ṽ = 3441, 2928, 2856, 1718, 1472, 
1387, 1275, 1254 cm-1; HRMS (ESI): Calc. for C41H78O7NaSi3 [M
+ + Na] 789.4953. Found 
789.4957; []
 = + 21 (c = 0.5 in CH2Cl2). 
1H NMR (CDCl3, 500 MHz): δ = 9.80 (d, J = 1.5 Hz, 1 H), 
8.06 (ddd, J = 0.1, 1.3, 8.6 Hz, 2 H), 7.59 (tt, J = 1.2, 7.4 
Hz, 1 H), 7.46 (t, J = 7.9 Hz, 1 H), 5.62 (ddd, J = 2.3, 4.6, 
9.8 Hz, 1 H), 3.98 - 3.91 (m, 1 H), 3.86 - 3.78 (m, 1 H), 3.76 - 3.67 (m, 2 H), 3.45 - 3.35 (m, 2 H), 
3.00 - 2.93 (m, 1 H), 2.04 (ddd, J = 2.2, 9.9, 14.3 Hz, 1 H), 1.86 - 1.79 (m, 1 H), 1.78 - 1.64 (m, 3 
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H), 1.62 - 1.46 (m, 7 H), 1.40 - 1.34 (m, 1 H), 1.24 - 1.07 (m, 5 H), 0.89 (s, 18 H), 0.88 (s, 9 H), 
0.08 (s, 3 H), 0.07 (s, 3 H), 0.05 (s, 3 H), 0.04 (s, 3 H), 0.03 (s, 3 H), 0.01 (s, 3 H); 13C NMR 
(CDCl3, 126 MHz): δ = 201.8, 133.3, 130.2, 129.9, 128.6, 74.5, 73.6, 71.5, 66.9, 66.4, 60.2, 50.3, 
46.9, 44.5, 40.2, 39.0, 32.4, 31.9, 26.1, 26.0, 23.9, 18.4, 18.1, 18.1, 9.2, -3.7, -3.9, -4.2, -4.5, -5.1, 
-5.1; IR (film): ṽ=  2929, 2857, 1723, 1472, 1388, 1360, 1255 cm-1; HRMS (ESI): Calc. for 
C41H76O7NaSi3 [M
+ + Na] 787.4797. Found 787.4779; []
 = +10 (c = 0.3 in CH2Cl2). 
Coupled products anti-2.80 and syn-2.80. To a -78 °C solution of alkyne 2.26 (194 mg, 0.348 
mmol, 2.0 eq) in THF (1.75 mL) was added a cold LDA solution (0.5 M in THF, 700 µL, 0.348 
mmol, 2.0 eq)  dropwise and the reaction mixture gradually warmed up to -30 °C and stirred at 
this temperature for 30 min, then recooled to -78 °C and transferred to a solution of aldehyde 
2.72 (133 mg, 0.174 mmol, 1.0 eq) in THF at -78 °C (1.7 5 mL) via cannula. The reaction mixture 
was stirred at -78 °C for 30 min, then gradually wa rmed to -20 °C and quenched with sat. 
aqueous ammonium chloride. After warming to room temperature, the biphasic mixture was 
diluted with water and diethyl ether. The layers were separated and the aqueous layer extracted 
with diethyl ether. The combined organics were dried over Na2SO4 and concentrated. The residue 
was purified by MPLC (9:1 Hexanes:Ethyl acetate) to yield the title compounds anti-2.80 and 
syn-2.80 (191 mg total yield, 1.4:1 d.r., 89%) as well as recovered alkyne 2.26 (97 mg, 100% of 
theoretical).   
anti-2.80: 1H NMR (C6D6, 500 MHz): δ =  8.28 - 
8.24 (m, 2 H), 7.34 (d, J = 8.7 Hz, 2 H), 7.26 (m, 
3 H), 6.83 (d, J = 8.7 Hz, 2 H), 6.45 (dd, J = 1.7, 
9.5 Hz, 1 H), 5.72 (t, J = 8.3 Hz, 1 H), 4.79 - 4.74 (m, 1 H), 4.69 (s, 2 H), 4.47 (dd, J = 5.9, 9.8 Hz, 
1 H), 4.25 (q, J = 7.3 Hz, 1 H), 4.08 (q, J = 8.2 Hz, 1 H), 3.86 (t, J = 6.7 Hz, 2 H), 3.63 - 3.57 (m, J 
= 4.5 Hz, 3 H), 3.52 - 3.46 (m, 1 H), 3.31 (s, 3 H), 3.24 (s, 3 H), 2.85 (d, J = 4.7 Hz, 1 H), 2.50 
(tquin, J = 1.9, 8.4 Hz, 1 H), 2.37 (d, J = 1.4 Hz, 3 H), 2.27 (dt, J = 3.6, 7.2 Hz, 1 H), 2.22 - 2.16 
(m, 1 H), 2.12 - 2.04 (m, 2 H), 2.01 (t, J = 6.5 Hz, 2 H), 1.93 (sxt, J = 7.1 Hz, 1 H), 1.83 - 1.73 (m, 
OMe
PMBO
OTES
I
HO
OBz
TBSO
TBSO
OTBSO
124 
 
2 H), 1.73 - 1.65 (m, 1 H), 1.65 - 1.59 (m, 1 H), 1.54 - 1.47 (m, 1 H), 1.42 (d, J = 6.9 Hz, 3 H), 
1.38 - 1.27 (m, 4 H), 1.21 - 1.06 (m, 3 H), 1.05 - 1.00 (m, 36 H), 0.62 (q, J = 8.0 Hz, 6 H), 0.25 (s, 
3 H), 0.21 (s, 3 H), 0.17 (s, 3 H), 0.15 (s, 3 H), 0.14 (s, 3 H), 0.11 (s, 3 H); 13C NMR (CDCl3, 126 
MHz): 159.2, 142.0, 133.3, 130.9, 130.1, 129.6, 128.6, 113.8, 96.6, 85.5, 81.8, 79.8, 74.6, 74.3, 
74.1, 73.5, 71.1, 67.2, 66.9, 66.3, 62.7, 60.4, 57.6, 55.4, 48.2, 47.1, 44.4, 44.2, 40.4, 39.9, 32.5, 
31.9, 29.6, 28.8, 26.1, 23.9, 18.5, 18.1, 14.9, 10.7, 6.9, 5.1, -3.5, -3.9, -4.3, -4.5, -5.1; IR (film): ṽ 
= 3419, 2928, 2856, 1718, 1613, 1514, 1462, 1381 cm-1; []
 = + 24 (c = 0.5 in CH2Cl2). 
 
syn-2.80: 1H NMR (CDCl3, 500 MHz): δ = 8.08 
(d, J = 7.0 Hz, 2 H), 7.56 (tt, J = 1.1, 7.2 Hz, 1 
H), 7.44 (t, J = 7.8 Hz, 2 H), 7.26 (d, J = 8.6 Hz, 
2 H), 6.87 (d, J = 8.8 Hz, 2 H), 6.20 (dd, J = 1.5, 9.4 Hz, 1 H), 5.47 (dd, J = 5.3, 9.1 Hz, 1 H), 5.50 
- 5.45 (m, 1 H), 4.60 (d, J = 12.0 Hz, 2 H), 4.37 (dd, J = 5.5, 9.4 Hz, 2 H), 3.99 - 3.91 (m, 1 H), 
3.81 (s, 4 H), 3.79 - 3.67 (m, 3 H), 3.44 (dd, J = 3.4, 5.6 Hz, 1 H), 3.41 - 3.37 (m, 2 H), 3.36 - 3.32 
(m, 1 H), 3.28 (s, 3 H), 2.45 (d, J = 1.3 Hz, 3 H), 2.38 (d, J = 6.9 Hz, 1 H), 2.31 - 2.24 (m, 1 H), 
2.22 - 2.08 (m, 2 H), 1.95 (ddd, J = 1.9, 9.9, 14.6 Hz, 1 H), 1.82 - 1.65 (m, 6 H), 1.63 - 1.43 (m, 7 
H), 1.36 - 1.28 (m, 1 H), 1.21 - 1.14 (m, 1 H), 1.08 (d, J = 7.0 Hz, 5 H), 0.94 (t, J = 8.0 Hz, 11 H), 
0.90 (s, 9 H), 0.89 (s, 9 H), 0.87 (s, 9 H), 0.58 (q, J = 7.8 Hz, 6 H), 0.07 (s, 3 H), 0.07 (s, 3 H), 
0.05 (s, 3 H), 0.05 (s, 3 H), 0.02 (s, 6 H); 13C NMR (CDCl3, 126 MHz): δ = 159.3, 142.0, 132.8, 
130.9, 129.9, 129.6, 128.4, 113.8, 96.9, 86.0, 81.7, 80.5, 79.7, 74.5, 74.1, 73.5, 73.0, 71.1, 67.1, 
66.4, 64.6, 60.3, 57.6, 55.4, 47.1, 44.4, 43.4, 40.2, 38.1, 32.4, 31.9, 29.4, 28.8, 26.1, 24.1, 23.8, 
18.5, 18.1, 15.0, 12.2, 6.9, 5.1, -3.7, -3.9, -4.3, -4.4, -5.1; IR (film): ṽ = 3455, 2929, 2856, 1719, 
1613, 1514, 1463, 1381, 1251 cm-1; []
 = +5 (c = 0.5 in CH2Cl2). 
Triols anti-2.81 and syn-2.81. The following procedure for anti-2.81 is representative. To a -78 
°C solution of anti-2.80 (42.5 mg, 32.1 µmol, 1.0 eq) in dichloromethane (500 µL) was added 
DIBAL-H (1.0 M in toluene, 160 µL, 0.160 mmol, 5.0 eq) dropwise and the reaction mixture stirred 
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at -78 °C until complete (~30 minutes). The reactio n was then quenched with sat. aqueous 
sodium bicarbonate and warmed to room temperature. Ethyl acetate was added and the mixture 
poured into a sat. aqueous solution of Rochelle's salt and stirred vigorously at room temperature 
until a clear biphasic solution is obtained (~1h). The layers were then separated and the aqueous 
layer extracted with ethyl acetate. The combined organics were dried over Na2SO4 and 
concentrated. The residue was purified by flash column chromatograph (6:1 → 7:1 Hexanes:Ethyl 
Acetate) to yield the desired diol (30 mg, 77%) as a colorless oil.  
 To a solution of the above diol in dichloromethane/pH 7 buffer (9:1, 11 mL total volume) 
at 0 °C was added DDQ (1 g, 4.5 mmol, 10 eq) as a s olid in one portion and the reaction mixture 
stirred at 0 °C for 45 minutes, then quenched with sat. aqueous sodium bicarbonate and warmed 
to room temperature. The layers were separated and the aqueous layer extracted with 
dichloromethane. The combined organic layers were dried over Na2SO4 and  concentrated. The 
residue was purified by flash column chromatography (3:1 Hexanes:Ethyl Acetate) to yield the 
title compound anti-2.81 (261 mg,60%, 2 steps) as a colorless oil.  
anti-2.81: 1H NMR (C6D6, 500 MHz): δ = 6.52 
(dd, J = 1.5, 9.2 Hz, 1 H), 4.79 (d, J = 5.9 Hz, 1 
H), 4.60 (dd, J = 3.2, 9.2 Hz, 1 H), 4.52 (t, J = 
8.2 Hz, 1 H), 4.40 - 4.36 (m, 1 H), 4.32 - 4.22 (m, 1 H), 4.22 - 4.12 (m, 2 H), 3.90 (q, J = 7.1 Hz, 2 
H), 3.80 (dt, J = 1.8, 6.6 Hz, 1 H), 3.62 (t, J = 10.2 Hz, 1 H), 3.52 (dt, J = 3.2, 7.5 Hz, 1 H), 3.49 - 
3.44 (m, 1 H), 3.41 - 3.36 (m, 1 H), 3.20 (s, 3 H), 2.49 (d, J = 8.1 Hz, 1 H), 2.45 - 2.40 (m, 2 H), 
2.28 (d, J = 1.4 Hz, 3 H), 2.20 (tt, J = 4.7, 9.0 Hz, 1 H), 2.09 - 1.89 (m, 5 H), 1.77 (m, 3 H), 1.70-
1.60 (m, 2 H), 1.52 (ddd, J = 2.5, 9.6, 14.4 Hz, 1 H), 1.45 - 1.40 (m, 1 H), 1.39 - 1.33 (m, 2 H), 
1.20 - 1.11 (m, 1 H), 1.11 - 1.07 (m, 12 H), 1.04 (s, 9 H), 0.97 (t, J = 7.6 Hz, 9 H), 0.92 (s, 9 H), 
0.57 (dq, J = 2.1, 7.9 Hz, 6 H), 0.30 (s, 3 H), 0.29 (s, 3 H), 0.15 (s, 3 H), 0.14 (s, 3 H), 0.09 (s, 3 
H), 0.08 (s, 3 H); 13C NMR (C6D6, 126 MHz): δ = 142.6, 96.9, 85.8, 81.3, 79.5, 75.2, 74.8, 73.6, 
72.6, 70.0, 69.9, 67.3, 66.5, 60.4, 60.1, 57.2, 45.8, 44.9, 44.7, 40.5, 39.8, 32.7, 31.9, 29.0, 28.5, 
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26.3, 26.2, 26.0, 24.1, 20.6, 18.6, 18.4, 18.1, 14.4, 14.2, 13.9, 7.1, 5.3, -3.5, -4.1, -4.3, -4.6, -5.0, -
5.0; IR (film): ṽ = 3441, 2935, 1640, 1464, 1251 cm-1; HRMS (ESI): Calc. for C51H103O9Si4INa [M
+ 
+ Na] 1121.5622. Found 1121.5627; []
 = + 27 (c = 0.37 in CH2Cl2). 
syn-2.81: 1H NMR (C6D6, 500 MHz): δ = 6.52 
(dd, J = 1.4, 9.3 Hz, 1 H), 4.92 (d, J = 6.4 Hz, 1 
H), 4.59 (dd, J = 3.3, 9.3 Hz, 1 H), 4.24 - 4.14 
(m, 3 H), 3.80 (dt, J = 2.2, 6.6 Hz, 2 H), 3.61 (t, J = 10.7 Hz, 1 H), 3.51 - 3.44 (m, 2 H), 3.38 - 3.33 
(m, 1 H), 3.18 (s, 3 H), 2.42 - 2.36 (m, 2 H), 2.28 (d, J = 1.4 Hz, 3 H), 2.18 (ddd, J = 4.4, 9.1, 13.6 
Hz, 1 H), 2.06 - 1.82 (m, 6 H), 1.76 (d, J = 2.6 Hz, 2 H), 1.71 - 1.58 (m, 2 H), 1.52 (ddd, J = 2.0, 
9.9, 11.4 Hz, 1 H), 1.45 - 1.29 (m, 6 H), 1.21 (d, J = 6.8 Hz, 3 H), 1.18 (m, 2 H), 1.06 (s, 9 H), 
1.03 (s, 9 H), 0.97 (t, J = 8.1 Hz, 9 H), 0.94 (s, 9 H), 0.57 (dq, J = 2.2, 7.9 Hz, 6 H), 0.27 (s, 3 H), 
0.26 (s, 3 H), 0.15 (s, 3 H), 0.14 (s, 3 H), 0.11 (s, 3 H), 0.10 (s, 3 H); 13C NMR (C6D6, 126 MHz): δ 
= 142.5, 96.8, 85.9, 81.3, 79.4, 75.0, 74.7, 73.5, 72.3, 69.9, 69.7, 66.5, 66.3, 60.2, 57.0, 45.9, 
45.9, 44.8, 40.4, 39.6, 32.6, 31.8, 28.9, 28.4, 26.2, 26.1, 25.9, 24.0, 18.4, 18.3, 18.0, 14.2, 12.8, 
6.9, 5.2, -3.7, -4.2, -4.4, -4.7, -5.1, -5.1; IR (film): ṽ = 3428, 2928, 2856, 1640, 1462, 1254 cm-1; 
HRMS (ESI): Calc. for C51H104O9Si4I [M
+ + H] 1099.5802. Found 1099.5814; []
 = + 29 (c = 1 in 
CH2Cl2). 
Southern Hemisphere 2.15. Triol anti-2.81 (10.4 mg, 9.46 
µmol, 1.0 eq) was dissolved in dichloromethane (300 µL) over 
activated 4 Å molecular sieves. A stock solution of cationic 
gold catalyst 2.82 (0.01 M in THF) was also prepared. The 
two solutions were degassed by three cycles of freeze/pump/thaw and allowed to warm up to 
room temperature under nitrogen. An aliquot of the catalyst solution (73 µL, 0.095 mmol, 0.1 eq) 
was then added to the reaction mixture, which was stirred for 2h at room temperature, then 
quenched with triethylamine (3 drops). The crude reaction mixture was filtered through a plug of 
silica gel, eluting with diethyl ether. The filtrate was concentrated and the residue purified by flash 
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column chromatography (24:1 Hexanes:Ethyl Acetate) to yield the fully protected southern 
hemisphere (8.3 mg, 81%) as a pale yellow oil.  
1H NMR (C6D6, 500 MHz): δ = 6.81 (dd, J = 1.4, 9.0 Hz, 1 H), 5.55 (dd, J = 2.3, 10.0 Hz, 1 H), 
5.48 (dd, J = 1.3, 10.0 Hz, 1 H), 4.90 (dd, J = 2.3, 9.0 Hz, 1 H), 4.35 - 4.26 (m, 2 H), 3.83 (dt, J = 
2.2, 6.7 Hz, 3 H), 3.75 (dd, J = 2.3, 9.2 Hz, 1 H), 3.59 (t, J = 10.2 Hz, 1 H), 3.52 - 3.44 (m, 2 H), 
3.22 (s, 3 H), 2.41 (d, J = 1.3 Hz, 3 H), 2.25 - 2.17 (m, 1 H), 2.09 - 1.97 (m, 2 H), 1.96 - 1.85 (m, 2 
H), 1.74 - 1.63 (m, 4 H), 1.61 - 1.52 (m, 4 H), 1.50 - 1.26 (m, 6 H), 1.09 (s, 12 H), 1.08 - 1.04 (m, 
18 H), 1.02 (s, 9 H), 0.68 (dq, J = 3.3, 8.3 Hz, 6 H), 0.33 (s, 3 H), 0.32 (s, 3 H), 0.27 (s, 3 H), 0.26 
(s, 3 H), 0.14 (s, 3 H), 0.13 (s, 3 H); 13C NMR (C6D6, 126 MHz): δ = 143.6, 134.1, 129.1, 95.2, 
94.0, 76.2, 74.6, 74.2, 74.1, 72.3, 69.1, 68.1, 67.6, 60.4, 55.4, 48.5, 45.9, 42.3, 40.5, 34.0, 33.3, 
32.4, 32.2, 32.0, 30.1, 28.4, 26.3, 26.2, 26.1, 24.1, 23.8, 23.0, 18.5, 18.4, 18.3, 17.2, 14.3, 7.1, 
5.5, -3.0, -3.6, -3.6, -3.9, -5.1; IR (film): ṽ = 2928, 2856, 1741, 1640, 1462, 1379, 1254 cm-1; []
 
= + 16.5 (c = 0.5 in CH2Cl2). 
Compound 2.83 To a solution of triol syn-2.81 (7.4 mg, 
6.73 µmol, 1.0 eq) in THF (300 µL) over 4 A molecular 
sieves was added the catalyst (1 mg, 1.35 µmol, 0.2 eq). 
After stirring at room temperature for 2 hours, the mixture 
was filtered directly through a plug of silica gel and analyzed by NMR.  
1H NMR (CDCl3, 500MHz) δ = 6.55 (d, J = 9.9 Hz, 1 H), 4.70 (d, J = 9.0 Hz, 1 H), 4.39 (q, J = 7.0 
Hz, 2 H), 4.34 - 4.28 (m, 1 H), 4.27 - 4.23 (m, 1 H), 4.13 - 4.08 (m, 1 H), 3.82 (t, J = 6.8 Hz, 2 H), 
3.63 - 3.54 (m, 2 H), 3.50 - 3.42 (m, 1 H), 3.36 (s, 3 H), 3.27 (q, J = 6.9 Hz, 1 H), 2.46 (d, J = 7.8 
Hz, 2 H), 2.32 (s, 3 H), 2.00 (t, J = 6.1 Hz, 2 H), 1.97 - 1.85 (m, 3 H), 1.77 (t, J = 9.4 Hz, 1 H), 
1.65 (m, 3 H), 1.47 - 1.15 (m, 16 H), 1.16 - 1.10 (m, 2 H), 1.08 (s, 9 H), 1.07 (s, 9 H), 1.02 (s, 9 
H), 0.98 (t, J = 8.0 Hz, 12 H), 0.59 (q, J = 7.8 Hz, 6 H), 0.29 (s, 3 H), 0.26 (s, 9 H), 0.13 (s, 3 H), 
0.12 (s, 3 H); 13C NMR (C6D6, 126MHz) δ = 158.9, 142.8, 98.7, 96.8, 81.9, 80.6, 75.4, 74.7, 73.9, 
70.0, 67.9, 67.1, 65.9, 60.5, 57.3, 48.5, 45.4, 44.2, 42.4, 40.5, 32.8, 32.0, 30.7, 30.2, 29.9, 28.5, 
O
O
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O TBS
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OH
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OH
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26.4, 26.3, 26.2, 24.3, 23.0, 20.4, 9.6, 7.0, 5.3; IR (film): ṽmax = 3454, 2926, 2854, 1733, 1652, 
1578, 1471 cm-1; []
 = + 24 (c = 0.33 in CH2Cl2). 
4.3 Experimental Details Relevant to Chapter 3 
 
Synthesis of Alkyne Fragment 3.18 
 
Compound 3.20 A modification of a literature procedure was followed.8 To a 
solution of compound 3.19 (7.15 g, 20.1 mmol, 1.0 eq) and triethylamine (4.8 
mL, 34.2 mmol, 1.7 eq) in toluene (54 mL) at -50 °C  was added dibutyl boron 
triflate (1 M in DCM, 30.2 mL, 30.2 mmol, 1.5 eq) and the reaction mixture stirred at -50 °C for 1.5 
h, then recooled to -78 °C. A solution of freshly d istilled acrolein (5.4 mL, 80.4 mmol, 4 eq) was 
then added dropwise at this temperature and the reaction mixture was allowed to stir at -78 °C for 
one hour, then warmed up to 0 °C and allowed to sti r an additional 1 h. The reaction was then 
quenched by the successive careful addition of methanol (25 mL), pH 7 buffer (25 mL) and 30% 
hydrogen peroxide (25 mL). The mixture was stirred vigorously at room temperature for 1h. The 
layers were separated and the aqueous layer was extracted with diethyl ether (3x75 mL). The 
combined organics were dried over Na2SO4 and concentrated. The residue was purified by flash 
column chromatography (2:1 → 1:1 Hexanes:Ethyl Acetate) to yield recovered 3.19 (2.38 g, 33%) 
the title compound (5.03 g, 61%, 91% brsm, single diastereomer) as a white solid. 
M.P. = 86-88 °C; 1H NMR (CDCl3, 500 MHz): δ =  7.37 - 7.28 (m, 5 H), 7.20 (d, J = 6.5 Hz, 2 H), 
6.89 (d, J = 9.2 Hz, 2 H), 5.95 (ddd, J = 5.8, 10.5, 17.2 Hz, 1 H), 5.35 (td, J = 1.4, 17.3 Hz, 1 H), 
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5.26 (d, J = 3.8 Hz, 1 H), 5.24 (td, J = 1.3, 10.5 Hz, 1 H), 4.68 - 4.62 (m, 2 H), 4.57 (d, J = 11.3 
Hz, 1 H), 4.40 (dd, J = 1.7, 3.6 Hz, 1 H), 4.23 - 4.16 (m, 2 H), 3.79 (s, 3 H), 3.22 (dd, J = 3.3, 13.5 
Hz, 1 H), 2.71 - 2.62 (m, 2 H); 13C NMR (CDCl3, 126 MHz): δ = 170.5, 159.9, 153.5, 136.6, 135.2, 
130.3, 129.5, 129.2, 129.1, 127.6, 117.2, 114.0, 79.4, 73.8, 73.2, 67.0, 55.7, 55.4, 37.9; IR (film): 
ṽ = 3463, 2935, 1776, 1707, 1612, 1514, 1392 cm-1; HRMS (ESI): Calc. for C23H25NO6Na [M
+ + 
Na] 434.1580. Found 434.1565; []
 =-34 (c =1 in CH2Cl2). 
Compound 4.5. To a 0 °C suspension of freshly azeotroped N,O-
dimethylhydroxylamine hydrochloride (3.58 g, 36.6 mmol, 3.0 eq) in THF (36 
mL) was added trimethylaluminum (2.0 M in toluene, 18.3 mL, 36.6 mmol, 3.0 eq) and the mixture 
stirred for 30 minutes at room temperature. The reaction mixture was then cooled to -20 °C and a 
solution of 3.20 (5.03 g, 12.2 mmol, 1.0 eq) in THF (36 mL) was added dropwise. The reaction 
mixture was transferred to a 0 °C ice bath and stir red for 1 h. The reaction was quenched by the 
careful dropwise addition of Rochelle's salt (36 mL), followed by 1 h of vigorous stirring at room 
temperature. The mixture was diluted with water and diethyl ether and the layers were separated. 
The aqueous layer was extracted 3x20 mL dichloromethane and the combined organics dried 
over Na2SO4 and concentrated. The mixture was purified with flash column chromatography (2:1 
→ 1:1 Hexanes:Ethyl Acetate) to yield the title compound (2.81 g, 78%) and recovered auxillary 
(1.55 g).  
1H NMR (CDCl3, 500MHz) δ = 7.28 (d, J = 9.0 Hz, 2 H), 6.88 (d, J = 8.6 Hz, 2 H), 5.85 (ddd, J = 
6.2, 10.6, 17.1 Hz, 1 H), 5.36 (d, J = 17.2 Hz, 1 H), 5.21 (d, J = 10.5 Hz, 1 H), 4.67 (d, J = 11.4 
Hz, 1 H), 4.43 (d, J = 11.4 Hz, 1 H), 4.40 (q, J = 5.7 Hz, 1 H), 4.31 (br. s., 1 H), 3.81 (s, 3 H), 3.59 
(s, 3 H), 3.20 (s, 3 H); 13C NMR (CDCl3, 126MHz) δ = 159.6, 136.0, 129.9, 129.3, 117.5, 114.0, 
73.6, 71.9, 61.5, 55.4; IR (film): ṽmax = 3541, 2937, 1662, 1612, 1513 cm
-1; HRMS (ESI): Сalc. for 
C15H22NO5 [MH
+] 296.1498, found 296.1484; []
 = + 34 (c =2 in CH2Cl2). 
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Compound 3.21 Weinreb amide 4.3 (9.48 g, 32.1 mmol, 1.0 eq) was then 
dissolved in dichloromethane (300 mL) and cooled to -78 °C. 2,6-lutidine 
(11.2 mL, 96 mmol, 3.0 eq) and TESOTf (10.9 mL, 48.2 mmol, 1.5 eq) were added dropwise and 
the reaction mixture was stirred for 1 h at -78 °C.  The reaction was quenched with sat. aqueous 
sodium bicarbonate and warmed to room temperature. The layers were separated and the 
aqueous layer extracted with dichloromethane (3x100 mL). The combined organics were dried 
over Na2SO4 and concentrated. The residue was purified by flash column chromatography (4:1 → 
3:1 → 2:1 Hexanes:Ethyl Acetate) to yield the title compound (10.2 g, 77%) as a pale yellow oil. 
1H NMR (CDCl3, 500 MHz): δ = 7.29 (d, J = 8.6 Hz, 2 H), 6.86 (d, J = 8.7 Hz, 2 H), 5.84 (ddd, J = 
6.8, 10.3, 17.2 Hz, 1 H), 5.26 (d, J = 17.1 Hz, 1 H), 5.12 (d, J = 10.4 Hz, 1 H), 4.63 (d, J = 11.8 
Hz, 1 H), 4.51 (d, J = 11.8 Hz, 1 H), 4.47 (t, J = 6.9 Hz, 1 H), 4.35 - 4.26 (m, 1 H), 3.81 (s, 3 H), 
3.50 (br. s., 3 H), 3.14 (br. s., 3 H),  0.95 (t, J = 8.2 Hz, 9 H), 0.62 (q, J = 7.7 Hz, 6 H); 13C NMR 
(CDCl3, 126MHz) δ = 159.3, 137.3, 129.6, 116.7, 113.7, 75.7, 72.2, 55.4, 6.9, 5.0; IR (film): ṽ = 
2954, 1668, 1608, 1513, 1462 cm-1; HRMS (ESI): Calc. for C2H35NO5SiNa [M
+ + Na] 432.2182. 
Found 432.2173; []
 =+9 (c = 1 in CH2Cl2). 
Compound 3.22. To magnesium turnings (1.7 g, 70.8 mmol, 3.0 eq) in 
refluxing THF (50 mL) was added dibromoethane (400 µL, 4.73 mmol, 
0.2 eq) and the mixture refluxed 10 minutes. A solution of freshly prepared (4-bromobut-1-yn-1-
yl)trimethylsilane (2.55) (9.7 g, 47.3 mmol, 2.0 eq,) in THF (100 mL) was then added dropwise 
and the reaction mixture refluxed an additional 1h. In a separate flask, a solution of 3.21 (9.68 g, 
23.6 mmol, 1.0 eq) in THF (50 mL) was cooled to -78 °C. The Grignard solution was then cooled 
to room temperature and transferred to the solution of 3.21 dropwise via cannula and the 
resulting mixture stirred at -78 °C for 30 min, the n at room temperature for an additional 1.5 h. 
The reaction was quenched with sat. aqueous ammonium chloride and diluted with diethyl ether. 
The layers were separated and the aqueous layer extracted with additional diethyl ether. The 
combined organics were washed with water and brine, dried over Na2SO4 and concentrated. The 
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residue was purified by flash column chromatography (9:1 Hexanes:Diethyl ether → 2:1 
Hexanes:Ethyl Acetate) to yield recovered starting material (1.5 g, 15%) the title compound (7.99 
g, 71%, 85% brsm) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.26 (d, J = 9.5 Hz, 2 H), 6.88 (d, J = 9.3 Hz, 2 H), 5.88 (ddd, J = 
6.2, 10.8, 17.1 Hz, 1 H), 5.25 (d, J = 17.2 Hz, 1 H), 5.14 (d, J = 10.5 Hz, 1 H), 4.60 (d, J = 11.7 
Hz, 1 H), 4.42 (d, J = 11.6 Hz, 1 H), 4.38 (dd, J = 4.8, 6.0 Hz, 1 H), 3.82 (s, 3 H), 2.87 (dd, J = 
7.0, 8.7 Hz, 1 H), 2.69 (ddd, J = 6.4, 8.3, 18.0 Hz, 1 H), 2.43 (ddd, J = 2.8, 6.7, 8.2 Hz, 2 H), 0.93 
(t, J = 8.0 Hz, 9 H), 0.58 (q, J = 8.4 Hz, 6 H), 0.14 (s, 9 H); 13C NMR (CDCl3, 126 MHz): δ = 
209.3, 159.6, 137.1, 129.9, 129.5, 116.4, 114.0, 106.2, 87.5, 84.8, 75.0, 73.1, 55.4, 40.1, 13.8, 
6.9, 6.9, 4.9, 4.9, 0.2; IR (film): ṽ = 2956, 2177, 1720, 1637, 1612, 1514, 1250 cm-1; HRMS (ESI): 
C26H42O4Si2Na [M
+ + Na] 497.2519. Found 497.2517; []
 =+15 (c = 1 in CH2Cl2). 
Compound 3.23. The reaction was typically run by separating the 
available 3.22 into batches of roughly 500 mg, then combining for 
purification. Zinc borohydride solution was freshly prepared by adding a solution of zinc chloride 
(1 M in diethyl ether, 5.5 mL, 5.5 mmol, 1.0 eq) to a suspension of sodium borohydride (401 mg, 
10.6 mmol, 1.93 eq) in diethyl ether (30 mL) and stirring the resulting mixture for 2 days. Batches 
of 3.22 (530 mg, 1.12 mmol, 1.0 eq and 611 mg, 1.29 mmol, 1.0 eq) were then dissolved in ether 
(6 mL) and cooled to -50 °C.  An aliquot of the zin c borohydride solution (9 mL, 1.54 mmol, 1.2 eq 
batch 1, 10.3 mL, 1.54 mmol, 1.2 eq batch 2) was then added. The reaction mixture was stirred at 
-50 °C for 30 min., then quenched by the careful ad dition of Rochelle's salt (c. 10 mL). The 
biphasic mixture was warmed to room temperature and stirred vigorously for 1h. The layers were 
separated and the aqueous layer was extracted with diethyl ether. The combined organic phases 
were dried over Na2SO4 and concentrated. The two residues were combined and purified by flash 
column chromatography (9:1 → 7:1 Hexanes:Diethyl Ether) to yield the title compound (708 mg, 
61%) as a colorless oil.  
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1H NMR (CDCl3, 500 MHz): δ = 7.28 (d, J = 7.3 Hz, 2 H), 6.90 (d, J = 8.5 Hz, 2 H), 6.03 (ddd, J = 
5.2, 10.6, 17.2 Hz, 1 H), 5.34 (d, J = 17.2 Hz, 1 H), 5.26 (d, J = 10.6 Hz, 1 H), 4.59 (s, 2 H), 4.39 
(t, J = 4.8 Hz, 1 H), 3.82 (s, 4 H), 3.47 (d, J = 2.5 Hz, 1 H), 3.29 (dd, J = 4.7, 7.8 Hz, 1 H), 2.45 - 
2.36 (m, 1 H), 2.33 (s, 1 H), 1.97 - 1.88 (m, 1 H), 1.64 - 1.58 (m, 1 H), 0.95 (t, J = 8.3 Hz, 9 H), 
0.59 (q, J = 7.6 Hz, 6 H), 0.16 - 0.14 (m, 9 H); 13C NMR (CDCl3, 126 MHz): δ = 159.6, 136.3, 
130.3, 129.8, 116.4, 114.0, 107.8, 84.4, 82.1, 74.3, 73.3, 70.5, 55.4, 32.5, 15.9, 6.9, 4.8, 0.3; IR 
(film): ṽ = 3495, 2955, 2876, 2172, 1640, 1612, 1586, 1514, 1249 cm-1; HRMS (ESI): Calc. for 
C26H44O4NaSi2 [M
+ + Na] 499.2676. Found 499.2675; []
 = ─ 50 (c = 1 in CH2Cl2). 
Compound 4.6. To a solution of 3.23 (1.58 g, 3.3 mmol, 1.0 eq) in 
dichloromethane (30 mL) were added proton sponge (2.13 g, 9,9 mmol, 
3.0 eq) and trimethyloxonium tetrafluoroborate (1.47 g, 9.9 mmol, 3.0 eq) in one portion and the 
reaction mixture was stirred for 1 h at room temperature. The reaction was then quenched with 
brine and diluted with dichloromethane. The layers were separated and the aqueous phase 
extracted three times with dichloromethane. The combined organic layers were filtered through a 
pad of Celite and concentrated, then redissolved in ether and refiltered. The filtrate was 
concentrated and the residue purified by flash column chromatography (9:1 Hexanes:Diethyl 
ether) to yield the title compound (1.33 mg, 82%) as a colorless oil.  
1H NMR (CDCl3, 500 MHz): δ = 7.30 (d, J = 8.6 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.92 (ddd, J = 
6.2, 10.6, 17.1 Hz, 1 H), 5.28 (d, J = 17.2 Hz, 1 H), 5.15 (d, J = 10.5 Hz, 1 H), 4.69 (d, J = 11.4 
Hz, 1 H), 4.63 (d, J = 11.4 Hz, 1 H), 4.19 (t, J = 6.4 Hz, 1 H), 3.81 (s, 3 H), 3.58 (dd, J = 2.3, 6.0 
Hz, 1 H), 3.48 (td, J = 2.5, 9.5 Hz, 1 H), 3.31 (s, 3 H), 2.38 - 2.33 (m, 2 H), 1.86 - 1.77 (m, 1 H), 
1.75 - 1.67 (m, 1 H), 0.95 (t, J = 8.6 Hz, 9 H), 0.59 (q, J = 7.9 Hz, 6 H), 0.16 (s, 9 H); 13C NMR 
(CDCl3, 126 MHz): δ = 159.2, 138.1, 131.3, 129.4, 115.9, 113.7, 113.7, 107.7, 84.6, 81.9, 79.8, 
74.3, 73.7, 57.4, 55.4, 29.2, 16.3, 7.0, 5.1, 5.1, 0.3; IR (film): ṽ = 2955, 2876, 2173, 1729, 1640, 
1614, 1586, 1514, 1463 cm-1; HRMS (ESI): Calc. for C27H46O4Si2Na [M
+ + Na] 513.2832. Found 
513.2836; []
 =-26 (c = 1 in CH2Cl2); []
 = ─ 26 (c = 1 in CH2Cl2). 
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Alkyne 3.18. To a solution of 3.24 (2.02 g, 4.12 mmol, 1.0 eq) in ethanol (50 
mL) was added potassium carbonate (1.71 g, 12.3 mmol, 3.0 eq) in one 
portion and the reaction mixture stirred at room temperature for 3  days, then diluted with diethyl 
ether and washed with water and brinde, then dried over Na2SO4 and concentrated. The residue 
was purified by flash column chromatography (12:1 Hexanes:Diethyl ether) to yield the title 
compound (1.63 g, 94%) as a colorless oil.  
 1H NMR (CDCl3, 500 MHz): δ = 7.29 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.92 (ddd, J = 
6.3, 10.5, 17.1 Hz, 1 H), 5.27 (td, J = 1.5, 17.2 Hz, 1 H), 5.15 (td, J = 1.4, 10.4 Hz, 1 H), 4.68 (d, J 
= 11.5 Hz, 1 H), 4.63 (d, J = 11.4 Hz, 1 H), 4.20 (t, J = 6.1 Hz, 1 H), 3.82 (s, 3 H), 3.78 - 3.74 (m, 
1 H), 3.57 (dd, J = 2.5, 6.0 Hz, 1 H), 3.44 (td, J = 2.6, 9.4 Hz, 1 H), 3.31 (s, 3 H), 2.32 - 2.27 (m, 2 
H), 1.92 (t, J = 2.6 Hz, 1 H), 1.88 - 1.79 (m, 2 H), 1.76 (d, J = 2.7 Hz, 1 H), 0.94 (t, J = 8.0 Hz, 9 
H), 0.59 (q, J = 8.4 Hz, 6 H); 13C NMR (CDCl3, 126 MHz): δ =  159.2, 138.1, 131.2, 129.4, 115.9, 
113.7, 84.8, 81.8, 80.0, 74.4, 73.7, 68.3, 57.4, 55.4, 29.2, 15.0, 7.0, 5.1; IR (film): 2953, 2876, 
2116, 1638, 1613, 1514, 1462, 1378, 1302, 1248 cm-1; HRMS (ESI): Calc. for C24H38O4NaSi [M
++ 
Na] 441.2437. Found 441.2421; []
 = ─ 29 (c = 1 in CH2Cl2). 
Completion of the Revised Southern Hemisphere 3.15 
Coupled products anti-3.26 and syn-3.26. To a -40 °C solution of alkyne 3.18 (294 mg, 0.702 
mmol, 2.6 eq) in THF (3 mL) was added a n-butyllithium (2.4 M in hexanes, 260 µL, 0.67 mmol, 
2.5 eq)  dropwise and the reaction mixture gradually warmed up to -20 °C and stirred at this 
temperature for 30 min, then rcooled to -78 °C and transferred to a precooled -78 °C of aldehyde 
3.17 (205 mg, 0.268 mmol, 1.0 eq) in THF (3 mL) via cannula. The reaction mixture was stirred at 
-78 °C for 30 min, then gradually warmed to -20 °C and quenched with sat. aqueous ammonium 
chloride. After warming to room temperature, the biphasic mixture was diluted with water and 
diethyl ether. The layers were separated and the aqueous layer extracted with diethyl ether. The 
combined organics were dried over Na2SO4 and concentrated. The residue was purified by flash 
column chromatography (9:1 Hexanes:Ethyl acetate) to yield recovered alkyne (151 mg, 83% 
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recovery) and a mixture of propargylic alcohols (282 mg, 89%, c. 1.4:1 ratio favoring anti). The 
diastereomers could be separated using flash column chromatography (7% Ethyl Acetate in 
Hexanes).    
anti-3.26: 1H NMR  (C6D6, 500 MHz) δ = 8.25 - 
8.20 (m, 2 H), 7.33 (d, J = 8.6 Hz, 2 H), 7.16 - 
7.11 (m, 3 H), 6.80 (d, J = 8.7 Hz, 2 H), 6.02 
(ddd, J = 6.1, 10.6, 17.1 Hz, 1 H), 5.68 (t, J = 
8.2 Hz, 1 H), 5.33 (td, J = 1.4, 17.2 Hz, 1 H), 5.10 (td, J = 1.5, 10.5 Hz, 1 H), 4.75 (d, J = 11.5 Hz, 
1 H), 4.68 (d, J = 11.7 Hz, 1 H), 4.64 (s, 1 H), 4.30 (t, J = 6.2 Hz, 1 H), 4.22 (q, J = 7.6 Hz, 1 H), 
4.05 (q, J = 7.4 Hz, 1 H), 3.83 (t, J = 6.8 Hz, 2 H), 3.69 (dd, J = 2.2, 6.3 Hz, 1 H), 3.58 (td, J = 2.3, 
9.4 Hz, 2 H), 3.50 - 3.41 (m, 1 H), 3.29 (s, 3 H), 3.24 (s, 3 H), 2.69 (d, J = 4.8 Hz, 1 H), 2.50 - 
2.37 (m, 2 H), 2.24 - 2.01 (m, 4 H), 1.97 (s, 2 H), 1.92 - 1.83 (m, 2 H), 1.79 - 1.71 (m, 1 H), 1.70 - 
1.63 (m, 1 H), 1.62 - 1.55 (m, 1 H), 1.52 - 1.44 (m, 1 H), 1.43 - 1.25 (m, 8 H), 1.03 - 0.98 (m, 36 
H), 0.62 (q, J = 8.0 Hz, 6 H), 0.22 (s, 3 H), 0.18 (s, 3 H), 0.14 (s, 3 H), 0.13 - 0.12 (m, 3 H), 0.11 
(s, 3 H), 0.08 (s, 3 H); 13C NMR (C6D6, 500 MHz) δ = 167.0, 159.6, 138.5, 133.0, 131.6, 130.8, 
130.2, 129.5, 128.6, 128.2, 127.8, 115.6, 113.7, 85.8, 82.1, 81.1, 80.3, 74.7, 74.5, 74.4, 73.9, 
73.6, 67.4, 66.6, 63.3, 60.4, 57.2, 54.7, 47.7, 44.8, 44.5, 40.5, 40.0, 32.5, 32.1, 30.1, 30.0, 29.8, 
26.2, 24.0, 18.5, 18.2, 15.6, 10.8, 7.1, 5.3, -3.6, -3.8, -4.2, -4.4, -5.1, -5.1; IR (film): ṽ = 3419, 
2928, 2856, 1718, 1613, 1514, 1462, 1381 cm-1; HRMS (ESI): Calc. for C65H114O11Si4Na [M
++ Na] 
1205.7336. Found 1205.7341; []
 = + 5 (c = 1 in CH2Cl2). 
syn-3.26: 1H NMR (CDCl3, 500 MHz): δ = 8.08 
(d, J = 7.0 Hz, 2 H), 7.56 (tt, J = 1.1, 7.2 Hz, 1 
H), 7.44 (t, J = 7.8 Hz, 2 H), 7.26 (d, J = 8.6 Hz, 
2 H), 6.87 (d, J = 8.8 Hz, 2 H), 6.20 (dd, J = 1.5, 
9.4 Hz, 1 H), 5.47 (dd, J = 5.3, 9.1 Hz, 1 H), 5.50 - 5.45 (m, 1 H), 4.60 (d, J = 12.0 Hz, 2 H), 4.37 
(dd, J = 5.5, 9.4 Hz, 2 H), 3.99 - 3.91 (m, 1 H), 3.81 (s, 4 H), 3.79 - 3.67 (m, 3 H), 3.44 (dd, J = 
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3.4, 5.6 Hz, 1 H), 3.41 - 3.37 (m, 2 H), 3.36 - 3.32 (m, 1 H), 3.28 (s, 3 H), 2.45 (d, J = 1.3 Hz, 3 
H), 2.38 (d, J = 6.9 Hz, 1 H), 2.31 - 2.24 (m, 1 H), 2.22 - 2.08 (m, 2 H), 1.95 (ddd, J = 1.9, 9.9, 
14.6 Hz, 1 H), 1.82 - 1.65 (m, 6 H), 1.63 - 1.43 (m, 7 H), 1.36 - 1.28 (m, 1 H), 1.21 - 1.14 (m, 1 H), 
1.08 (d, J = 7.0 Hz, 5 H), 0.94 (t, J = 8.0 Hz, 11 H), 0.90 (s, 9 H), 0.89 (s, 9 H), 0.87 (s, 9 H), 0.58 
(q, J = 7.8 Hz, 6 H), 0.07 (s, 3 H), 0.07 (s, 3 H), 0.05 (s, 3 H), 0.05 (s, 3 H), 0.02 (s, 6 H); 13C 
NMR (CDCl3, 126 MHz): δ = 159.3, 142.0, 132.8, 130.9, 129.9, 129.6, 128.4, 113.8, 96.9, 86.0, 
81.7, 80.5, 79.7, 74.5, 74.1, 73.5, 73.0, 71.1, 67.1, 66.4, 64.6, 60.3, 57.6, 55.4, 47.1, 44.4, 43.4, 
40.2, 38.1, 32.4, 31.9, 29.4, 28.8, 26.1, 24.1, 23.8, 18.5, 18.1, 15.0, 12.2, 6.9, 5.1, -3.7, -3.9, -4.3, 
-4.4, -5.1; IR (film): ṽ = 3455, 2929, 2856, 1719, 1613, 1514, 1463, 1381, 1251 cm-1. []
 = +5 (c 
= 0.5 in CH2Cl2). 
Diols anti-3.27 and syn-3.27. The following procedure for anti-3.27 is representative. To a 0 °C 
solution of anti-3.26 (536 mg, 0.453 mmol, 1.0 eq) in diethyl ether (3.9 mL) was ethyl magnesium 
bromide (3 M in diethyl ether, 1.5 mL, 4.53 mmol, 10 eq). The reaction mixture was then warmed 
to room temperature and stirred for 2 h, at which point TLC analysis showed no further reaction. 
The mixture was therefore re-cooled to 0 °C and que nched by the dropwise addition of saturated 
aqueous ammonium chloride. The mixture was then diluted with diethyl ether and water and the 
layers separated. The aqueous layer was extracted with additional diethyl ether and the 
combined organics dried over Na2SO4 and concentrated. The crude residue was purified by flash 
column chromatography (9:1 → 6:1 → 4:1 Hexanes:Ethyl Acetate) to provide the title compound 
(505 mg, >95%) as well as recovered anti-3.27 (10 mg, 2%). 
anti-3.27: 1H NMR (C6D6, 500 MHz): δ = 7.36 
(d, J = 8.6 Hz, 2 H), 6.82 (d, J = 8.9 Hz, 2 H), 
6.07 (ddd, J = 6.0, 10.6, 17.1 Hz, 1 H), 5.38 (td, 
J = 1.8, 17.2 Hz, 1 H), 5.15 (td, J = 1.6, 10.4 Hz, 
1 H), 4.79 (d, J = 11.3 Hz, 2 H), 4.74 (d, J = 11.6 Hz, 1 H), 4.46 (dt, J = 3.5, 8.4 Hz, 1 H), 4.33 (t, 
J = 6.5 Hz, 1 H), 4.21 - 4.10 (m, 3 H), 3.89 (q, J = 7.5 Hz, 1 H), 3.82 - 3.74 (m, 2 H), 3.72 (dd, J = 
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2.1, 6.4 Hz, 1 H), 3.66 (td, J = 2.7, 9.4 Hz, 1 H), 3.59 (t, J = 11.2 Hz, 1 H), 3.48 - 3.41 (m, 1 H), 
3.31 (s, 3 H), 3.29 (s, 3 H), 2.58 - 2.44 (m, 2 H), 2.20 - 2.09 (m, 2 H), 2.01 - 1.86 (m, 4 H), 1.78 - 
1.70 (m, 3 H), 1.64 (m, 3 H), 1.50 (ddd, J = 2.3, 9.7, 13.4 Hz, 1 H), 1.37 (s, 4 H), 1.18 - 1.11 (m, 1 
H), 1.09 (d, J = 7.0 Hz, 3 H), 1.06 - 0.99 (m, 27 H), 0.91 (s, 9 H), 0.65 (q, J = 8.0 Hz, 6 H), 0.27 (s, 
3 H), 0.25 (s, 3 H), 0.12 (s, 3 H), 0.12 (s, 3 H), 0.09 (s, 3 H), 0.08 (s, 3 H); 13C NMR (C6D6, 500 
MHz): δ =  159.6, 138.6, 131.6, 129.5, 115.7, 113.9, 85.7, 82.3, 81.2, 80.4, 74.8, 74.7, 74.0, 73.6, 
72.2, 69.8, 66.8, 66.5, 60.2, 57.3, 54.7, 45.8, 44.8, 44.6, 40.4, 39.8, 32.6, 31.8, 30.0, 26.2, 26.1, 
25.9, 24.0, 18.4, 18.2, 18.0, 15.7, 13.5, 7.1, 5.3, -3.6, -4.2, -4.4, -4.7, -5.1, -5.2; IR (film): ṽ = 
3434, 2928, 2856, 1612, 1513, 1463 cm-1; HRMS (ESI): Calc. for C58H111O10Si4 [M
+ + H] 
1079.7254. Found 1079.7251; []
 = +6 (c = 0.75 in CH2Cl2). 
syn-3.27: 1H NMR (C6D6, 500 MHz): δ = 7.36 
(d, J = 8.6 Hz, 2 H), 6.83 (d, J = 9.0 Hz, 2 H), 
6.07 (ddd, J = 6.1, 10.6, 17.0 Hz, 1 H), 5.38 (td, 
J = 2.5, 16.4 Hz, 1 H), 5.15 (td, J = 1.4, 10.6 Hz, 
1 H), 4.86 (d, J = 6.8 Hz, 1 H), 4.78 (d, J = 11.6 Hz, 1 H), 4.73 (d, J = 11.4 Hz, 1 H), 4.34 (t, J = 
6.1 Hz, 1 H), 4.26 - 4.20 (m, 1 H), 4.17 (t, J = 8.2 Hz, 2 H), 3.84 - 3.75 (m, J = 3.4 Hz, 2 H), 3.72 
(dd, J = 2.5, 6.3 Hz, 1 H), 3.62 (qd, J = 2.6, 10.5 Hz, 2 H), 3.50 - 3.43 (m, 1 H), 3.33 (s, 3 H), 3.27 
(s, 3 H), 2.54 - 2.41 (m, 2 H), 2.19 - 2.08 (m, 2 H), 1.92 (m, 4 H), 1.86 - 1.72 (m, 3 H), 1.71 - 1.57 
(m, 2 H), 1.52 (ddd, J = 2.1, 9.5, 13.7 Hz, 1 H), 1.45 - 1.32 (m, 4 H), 1.18 (d, J = 6.8 Hz, 3 H), 
1.12 (t, J = 7.0 Hz, 3 H), 1.05 (s, 9 H), 1.04 (s, 9 H), 1.02 (s, 9 H), 0.95 (s, 9 H), 0.66 (q, J = 8.1 
Hz, 6 H), 0.26 (s, 3 H), 0.25 (s, 2 H), 0.14 (s, 3 H), 0.13 (s, 3 H), 0.12 (s, 3 H), 0.11 (s, 3 H); 13C 
NMR (C6D6, 126 MHz): δ = 159.5, 138.6, 131.5, 129.5, 128.5, 115.7, 114.0, 86.1, 82.2, 81.3, 
80.4, 74.7, 73.9, 73.6, 72.2, 69.6, 66.6, 66.4, 65.8, 60.3, 57.2, 54.7, 46.1, 45.9, 44.8, 40.4, 39.8, 
32.6, 31.8, 29.9, 26.2, 26.1, 25.9, 24.0, 18.4, 18.2, 18.0, 15.7, 15.4, 12.9, 7.1, 5.3, -3.7, -4.2, -4.3, 
-4.7, -5.1, -5.2; IR (film): ṽ = 3436, 2928, 2856, 1613, 1514, 1472 cm-1; []
 = ─1.8 (c = 0.73 in 
CH2Cl2). 
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Bisacetal 3.28. Diol syn-3.27 (16 mg, 14.8 µmol, 
1.0 eq) was dissolved in a 2:1 mixture of DMF 
and 2,2-dimethoxypropane (300 µL total volume). 
Catalytic TsOH was added and the reaction mixture stirred overnight, then quenched with 
saturated aq. sodium bicarbonate and diluted with ethyl acetate. The layers were separated and 
the aqueous layer extracted with additional ethyl acetate. The combined organics were dried over 
Na2SO4 and concentrated. The residue was purified by flash column chromatography (4:1 → 2:1 
→ 1:1 Hexanes:Ethyl Acetate) to yield the desired compound (5 mg, ~50%). 
1H NMR (C6D6, 500 MHz): δ = 7.16 (d, J = 8.7 Hz, 2 H), 6.80 (d, J = 8.7 Hz, 2 H), 5.99 (ddd, J = 
4.9, 10.6, 17.2 Hz, 1 H), 5.53 (td, J = 1.8, 17.2 Hz, 1 H), 5.18 (td, J = 1.8, 10.6 Hz, 1 H), 4.50 (d, J 
= 11.2 Hz, 1 H), 4.40 (d, J = 10.9 Hz, 1 H), 4.31 (d, J = 10.5 Hz, 4 H), 3.81 (dt, J = 1.6, 10.3 Hz, 1 
H), 3.74 - 3.67 (m, 1 H), 3.66 - 3.56 (m, 2 H), 3.50 - 3.45 (m, 1 H), 3.44 (d, J = 4.7 Hz, 2 H), 3.32 
(s, 3 H), 3.13 (s, 3 H), 3.09 (s, 2 H), 2.89 (d, J = 6.6 Hz, 1 H), 2.38 - 2.30 (m, 1 H), 2.29 - 2.21 (m, 
1 H), 1.97 - 1.88 (m, 1 H), 1.88 - 1.83 (m, 1 H), 1.82 - 1.69 (m, 5 H), 1.64 - 1.57 (m, 3 H), 1.56 (s, 
3 H), 1.53 (s, 3 H), 1.50 - 1.41 (m, 5 H), 1.39 - 1.34 (m, 4 H), 1.33 (s, 3 H), 0.90 (d, J = 6.7 Hz, 
3H); 13C NMR (C6D6, 126 MHz): δ =  159.8, 138.9, 130.6, 129.8, 115.5, 114.1, 100.4, 99.8, 98.6, 
84.9, 81.4, 80.5, 79.8, 75.2, 74.1, 73.5, 71.9, 70.6, 67.4, 63.4, 62.1, 57.9, 57.6, 54.5, 48.1, 43.4, 
40.8, 39.7, 39.6, 37.8, 32.5, 32.2, 29.7, 25.0, 24.9, 24.7, 24.6, 19.3, 14.8, 12.7; IR (film): ṽ = 
3454, 2933, 1612, 1513, 1379 cm-1; HRMS (ESI): Calc. for C40H62O10Na [M
+ + Na]: 725.4241. 
Found 725.4252; []
 = ─6 (c = 0.4 in CH2Cl2). 
Triols anti-3.29 and syn-3.29. The following procedure for anti-3.29 is representative. To a 
solution of diol anti-3.27 (105 mg, 97.2 µL, 1.0 eq) in DCM/pH 7 buffer (9:1, 15 mL total volume) 
at 0 °C was added DDQ (221 mg, 0.97 mmol, 10 eq) as  a solid in one portion and the reaction 
mixture stirred at 0 °C for 45 minutes, then quench ed with sat. aqueous sodium bicarbonate and 
warmed to room temperature. The layers were separated and the aqueous layer extracted with 
DCM. The combined organic layers were dried over Na2SO4 and  concentrated. The residue was 
OHO
O OO O
OMe
OPMB
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purified by flash column chromatography (3:1 Hexanes:Ethyl Acetate) to yield the title compound 
(91 mg, 97%) as a colorless oil. 
anti-3.29: 1H NMR (C6D6, 500 MHz): δ = 6.07 
(ddd, J = 7.1, 10.3, 17.3 Hz, 1 H), 5.31 (d, J = 
17.2 Hz, 1 H), 5.13 (td, J = 0.8, 10.4 Hz, 1 H), 
4.89 (d, J = 5.4 Hz, 1 H), 4.60 (t, J = 8.4 Hz, 1 
H), 4.54 - 4.50 (m, 1 H), 4.48 (br. s, 1 H), 4.38 - 4.32 (m, 1 H), 4.32 - 4.28 (m, 1 H), 4.27 - 4.22 
(m, 1 H), 3.90 (dt, J = 2.4, 6.5 Hz, 2 H), 3.76 - 3.68 (m, 2 H), 3.60 - 3.48 (m, 2 H), 3.31 (s, 3 H), 
2.64 - 2.52 (m, 3 H), 2.34 - 2.25 (m, 1 H), 2.25 - 2.17 (m, 1 H), 2.14 - 1.98 (m, 4 H), 1.91 - 1.80 
(m, 3 H), 1.80 - 1.68 (m, 2 H), 1.62 (ddd, J = 2.1, 9.8, 11.6 Hz, 1 H), 1.54 - 1.38 (m, 3 H), 1.31 - 
1.21 (m, 1 H), 1.20 - 1.16 (m, 12 H), 1.13 (s, 9 H), 1.10 (t, J = 8.0 Hz, 9 H), 1.03 (s, 9 H), 0.72 (q, 
J = 7.9 Hz, 6 H), 0.40 (s, 3 H), 0.38 (s, 3 H), 0.25 (s, 3 H), 0.24 (s, 3 H), 0.20 (s, 3 H), 0.19 (s, 3 
H); 13C NMR (C6D6, 126 MHz): δ = 139.3, 116.0, 85.9, 81.1, 79.4, 75.0, 74.7, 74.0, 73.5, 72.3, 
69.7, 67.2, 66.4, 60.2, 56.7, 45.8, 44.8, 44.6, 40.4, 39.9, 32.6, 31.8, 28.7, 26.2, 26.1, 25.9, 24.0, 
18.4, 18.2, 18.0, 14.3, 13.7, 7.0, 5.4, -3.6, -4.2, -4.3, -4.7, -5.1, -5.2; IR (film): ṽ = 3441, 2935, 
1640, 1464, 1251 cm-1; HRMS (ESI): Calc. for C50H102O9Si4Na [M
+ + Na] 981.6499. Found 
981.6494; []
 = + 22 (c = 0.75 in CH2Cl2). 
syn-3.29: 1H NMR (C6D6, 500 MHz): δ = 5.98 
(ddd, J = 7.5, 11.0, 17.8 Hz, 1 H), 5.21 (d, J = 
17.2 Hz, 1 H), 5.04 (d, J = 10.4 Hz, 1 H), 4.89 
(d, J = 7.1 Hz, 1 H), 4.41 (dd, J = 3.4, 7.1 Hz, 1 
H), 4.26 - 4.21 (m, 1 H), 4.18 (t, J = 9.3 Hz, 2 H), 3.80 (dt, J = 3.0, 6.8 Hz, 2 H), 3.60 (d, J = 9.0 
Hz, 2 H), 3.50 - 3.43 (m, 1 H), 3.42 - 3.38 (m, 1 H), 3.20 (s, 3 H), 2.43 (dq, J = 2.4, 6.9 Hz, 2 H), 
2.17 (ddd, J = 5.2, 9.4, 14.3 Hz, 1 H), 2.12 - 1.88 (m, 6 H), 1.88 - 1.79 (m, 1 H), 1.83 (ddt, J = 1.3, 
6.2, 15.4 Hz, 1 H), 1.76 (s, 1 H), 1.71 - 1.58 (m, 3 H), 1.52 (ddd, J = 2.6, 9.1, 11.4 Hz, 1 H), 1.45 - 
1.29 (m, 4 H), 1.19 (d, J = 6.8 Hz, 3 H), 1.16 - 1.10 (m, 1 H), 1.06 (s, 9 H), 1.03 (s, 9 H), 1.00 (t, J 
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= 8.2 Hz, 9 H), 0.95 (s, 9 H), 0.62 (q, J = 8.0 Hz, 6 H), 0.26 (s, 6 H), 0.15 (s, 3 H), 0.14 (s, 3 H), 
0.12 (s, 3 H), 0.11 (s, 3 H); 13C NMR (C6D6, 126 MHz): δ =  139.3, 115.9, 86.2, 81.2, 79.4, 75.1, 
74.7, 74.0, 73.6, 72.1, 69.4, 66.6, 66.3, 60.2, 56.6, 46.0, 45.9, 44.8, 40.3, 39.8, 32.6, 31.8, 28.6, 
26.1, 26.1, 25.9, 24.0, 18.4, 18.2, 18.0, 14.2, 12.7, 7.0, 5.4, -3.7, -4.2, -4.3, -4.7, -5.1, -5.2; IR 
(film): ṽ = 3428, 2928, 2856, 1640, 1462, 1254 cm-1; HRMS (ESI): calc. for C50H102O9Si4Na [M
+ + 
Na] 981.6499. Found 981.6497; []
 = + 8 (c = 0.71 in CH2Cl2). 
Southern Hemisphere 3.15 To a solution of triol anti-3.29 
(261 mg, 0.272 mmol, 1.0 eq) in dichloromethane (4.5 mL) 
over 4 Angstrom molecular sieves (~200 mg) was added gold 
catalyst 2.81 (6.5 mg, 8.2 µmol, 0.03 eq) in one portion. The 
reaction mixture was stirred for 1 h, then filtered directly through a pad of silica gel to remove the 
catalyst. The filtrate was then purified by flash column chromatography (2% → 6% → 10% diethyl 
ether in hexanes) to provide the title compound (238 mg, 91%) as a colorless oil.  
1H NMR (C6D6, 500 MHz) δ = 6.49 (ddd, J = 7.8, 10.0, 17.5 Hz, 1 H), 5.68 (dd, J = 2.5, 10.0 Hz, 1 
H), 5.55 (dd, J = 1.6, 10.0 Hz, 1 H), 5.39 (d, J = 17.3 Hz, 1 H), 5.26 (dd, J = 1.7, 10.2 Hz, 1 H), 
4.82 (dd, J = 1.5, 7.8 Hz, 1 H), 4.40 - 4.34 (m, 1 H), 4.33 - 4.27 (m, 1 H), 4.00 - 3.87 (s, 3 H), 3.79 
(ddd, J = 3.0, 6.5, 9.6 Hz, 1 H), 3.70 (t, J = 9.5 Hz, 1 H), 3.63 (dt, J = 5.4, 10.6 Hz, 1 H), 3.58 - 
3.51 (m, 1 H), 3.40 - 3.33 (m, 4 H), 2.23 - 1.93 (m, 8 H), 1.85 - 1.66 (m, 4 H), 1.58 - 1.40 (m, 4 H), 
1.34 - 1.25 (m, 2 H), 1.24 - 1.11 (m, 36 H), 0.99 (d, J = 7.1 Hz, 3 H), 0.83 (dq, J = 4.4, 7.9 Hz, 6 
H), 0.36 (s, 3 H), 0.35 (s, 3 H), 0.33 (s, 3 H), 0.33 (s, 3 H), 0.24 (s, 3 H), 0.23 (s, 3 H); 13C NMR 
(C6D6, 126MHz) δ = 140.4, 133.5, 129.5, 115.4, 93.8, 77.0, 74.5, 74.2, 73.7, 73.5, 72.3, 69.1, 
67.1, 65.8, 60.5, 55.1, 48.1, 45.2, 43.0, 40.5, 34.5, 34.3, 32.3, 32.0, 26.2, 26.1, 24.1, 23.5, 18.5, 
18.3, 18.3, 17.1, 15.5, 7.2, 5.7, -3.1, -3.4, -3.7, -4.1, -5.1; IR (film): ṽmax = 2928, 1658, 1472 cm
-1; 
[]
 = + 14 (c = 0.67 in CH2Cl2). 
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Compound 3.30 To a solution of triol syn-3.29 (4.5 mg, 4.7 
µmol, 1.0 eq) in methanol (200 µL) over 4 Angstrom 
molecular sieves was added the catalyst (0.7 mg, 0.94 µmol, 
0.2 eq) and the reaction mixture stirred for 1.5 h at room 
temperature, then filtered through a plug of silica gel and analyzed directly by NMR spectroscopy. 
No yield was determined.  
1H NMR (C6D6, 500MHz, cryoprobe) δ = 6.04 (ddd, J = 7.0, 10.3, 17.3 Hz, 1 H), 5.24 (td, J = 1.2, 
17.3 Hz, 1 H), 5.04 (qd, J = 1.0, 10.3 Hz, 1 H), 4.55 (dd, J = 3.1, 6.9 Hz, 1 H), 4.42 (t, J = 7.3 Hz, 
2 H), 4.38 (dt, J = 3.5, 9.2 Hz, 1 H), 4.33 - 4.29 (m, 1 H), 4.27 - 4.22 (m, 1 H), 4.11 (d, J = 4.5 Hz, 
1 H), 3.81 (dt, J = 2.0, 6.7 Hz, 3 H), 3.66 (dt, J = 3.5, 7.3 Hz, 1 H), 3.59 (t, J = 10.9 Hz, 1 H), 3.49 
- 3.43 (m, 1 H), 3.43 - 3.39 (m, 1 H), 3.38 (s, 3 H), 2.58 - 2.50 (m, 1 H), 2.49 - 2.43 (m, 2 H), 2.05 
- 1.96 (m, 5 H), 1.95 - 1.85 (m, 3 H), 1.80 - 1.73 (m, 2 H), 1.73 - 1.59 (m, 6 H), 1.43 - 1.38 (m, 1 
H), 1.28 - 1.15 (m, 1 H), 1.07 (m, 27 H), 1.02 (s, 9 H), 0.65 (q, J = 7.4 Hz, 6 H), 0.29 (s, 3 H), 0.26 
(s, 9 H), 0.13 (s, 3 H), 0.12 (s, 3 H); 13C NMR (C6D6, 126MHz, cryoprobe) δ = 158.8, 139.8, 
115.7, 98.8, 81.7, 80.4, 75.2, 74.6, 73.9, 67.9, 67.1, 65.7, 60.2, 56.7, 48.4, 45.4, 44.1, 42.3, 40.5, 
32.7, 31.9, 29.4, 26.1, 24.0, 20.1, 18.5, 18.3, 15.4, 9.4, 7.1, 5.2, -3.6, -3.8, -4.0, -4.3, -5.9; IR 
(film): ṽmax = 3439, 2928, 2856, 1684, 1652, 1506, 1463 cm
-1; []
 = + 33 (c = 0.33 in CH2Cl2). 
Miscellaneous Procedural and Spectral Information 
Aldehyde 3.64: 1H NMR (C6D6, 500MHz,) δ = 9.42 (s, 1 
H), 6.35 (dt, J = 1.3, 7.2 Hz, 1 H), 4.15 - 4.08 (m, 1 H), 
3.92 (quin, J = 6.0 Hz, 1 H), 3.78 (dt, J = 2.2, 6.7 Hz, 2 H), 
3.54 (tt, J = 2.2, 10.1 Hz, 1 H), 3.48 - 3.41 (m, 1 H), 2.38 (t, J = 6.4 Hz, 2 H), 1.91 (qd, J = 6.8, 
13.7 Hz, 1 H), 1.83 (dt, J = 3.3, 7.2 Hz, 2 H), 1.8 (s, 3H), 1.79 - 1.73 (m, 1 H), 1.67 (ddd, J = 1.6, 
6.8, 13.5 Hz, 1 H), 1.63 - 1.59 (m, 1 H), 1.55 (ddd, J = 2.7, 9.0, 13.9 Hz, 1 H), 1.43 - 1.26 (m, 4 
H), 1.21 - 1.07 (m, 2 H), 1.01 (s, 9 H), 1.00 (s, 9 H), 0.96 (s, 9 H), 0.18 (s, 3 H), 0.14 (s, 3 H), 0.11 
(s, 9 H), 0.01 (s, 3 H); 13C NMR (C6D6, 126MHz) δ = 193.7, 148.8, 141.0, 74.8, 73.7, 69.4, 66.8, 
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60.2, 47.0, 45.4, 40.4, 36.8, 32.5, 31.9, 26.1, 25.9, 24.0, 18.4, 18.2, 18.1, 9.7, -3.9, -4.2, -4.3, -
5.2;  IR (film) ṽmax = 2929, 2857, 1693, 1663, 1472 cm
-1; HRMS (ESI): Calc. for C34H71O5Si3 [M
+ + 
H] 643.4609, found 643.4608; []
 = + 7.5 (c = 1.0 in CH2Cl2).   
Ketone 3.66. Coupled product syn-3.26 
(95 mg, 80 µmol, 1.0 eq) in 
dichloromethane (1 mL) was added 
sodium bicarbonate (65 mg, 0.80 mmol, 10 eq) and DMP (68 mg, 0.16 mmol, 2.0 eq) in one 
portion. The reaction mixture was stirred at room temperature for 2 h, then quenched by the 
addition of saturated aqueous sodium bicarbonate (4 mL) and saturated aqueous sodium 
thiosulfate (4 mL). After vigorous stirring for an additional 1 h, the layers were separated and the 
aqueous layer extracted with additional dichloromethane. The combined organics were dried over 
Na2SO4 and concentrated. The crude residue was purified by flash column chromatography (12:1 
→ 9:1 Hexanes:Ethyl Acetate) to provide the title compound (75 mg, 79%) as a colorless oil. 
1H NMR (C6D6, 500MHz) δ = 8.31 - 8.25 (m, 2 H), 7.33 (m, 3 H), 7.14 (d, J = 2.0 Hz, 3 H), 6.83 
(d, J = 8.4 Hz, 2 H), 6.10 (dd, J = 5.8, 10.1 Hz, 1 H), 5.98 (ddd, J = 6.0, 10.7, 17.0 Hz, 1 H), 5.34 
(d, J = 17.3 Hz, 1 H), 5.12 (d, J = 10.5 Hz, 1 H), 4.72 (d, J = 11.6 Hz, 1 H), 4.70 (d, J = 11.5 Hz, 1 
H), 4.28 (t, J = 6.1 Hz, 1 H), 4.25 - 4.14 (m, 2 H), 3.82 (t, J = 6.6 Hz, 2 H), 3.68 (dd, J = 2.0, 6.2 
Hz, 1 H), 3.57 (t, J = 10.2 Hz, 1 H), 3.52 - 3.44 (m, 2 H), 3.32 (m, 4 H), 3.23 (s, 3 H), 2.51 - 2.33 
(m, 2 H), 2.20 (dt, J = 2.3, 13.1 Hz, 1 H), 2.10 - 2.00 (m, 1 H), 1.96 (t, J = 6.8 Hz, 2 H), 1.90 - 1.75 
(m, J = 7.1 Hz, 4 H), 1.68 - 1.58 (m, 2 H), 1.53 (dt, J = 1.8, 11.9 Hz, 1 H), 1.44 - 1.39 (m, 1 H), 
1.37 - 1.30 (m, 2 H), 1.27 (d, J = 7.0 Hz, 3 H), 1.06 (s, 9 H), 1.04 - 0.99 (m, 27 H), 0.64 (q, J = 7.7 
Hz, 6 H), 0.24 (s, 3 H), 0.22 (s, 3 H), 0.18 (s, 3 H), 0.17 (s, 3 H), 0.14 (s, 3 H), 0.13 (s, 3 H); 13C 
NMR (C6D6, 126MHz) δ = 186.6, 165.7, 159.6, 138.2, 132.8, 131.4, 131.0, 130.1, 129.5, 128.5, 
116.0, 113.6, 100.2, 95.4, 81.8, 81.0, 80.1, 74.6, 74.4, 74.0, 73.6, 72.4, 67.5, 66.8, 60.3, 57.1, 
54.7, 52.2, 47.5, 44.9, 40.4, 38.7, 32.5, 32.0, 28.6, 26.2, 26.1, 24.0, 18.4, 18.2, 18.2, 15.7, 11.0, 
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7.1, 5.3, -3.7, -3.8, -4.1, -4.2, -5.1, -5.1; IR (film): ṽmax = 2928, 2856, 2210, 1723, 1675, 1513, 
1472 cm-1; []
 = ─ 18 (c = 1.0 in CH2Cl2).   
Acetal 3.70. To a solution of triol syn-
3.29 (28 mg, 29 µmol, 1.0 eq) in 2,2-
dimethoxypropane (370 µL) was added 
PPTS (0.37 mg, 1.5 µmol, 0.05 eq, stock solution in THF). The reaction mixture was then stirred 
at 36 °C for 4 h. TLC analysis at this stage indica ted full conversion. The reaction mixture was 
concentrated and purified by MPLC (5:1 Hexanes:Diethyl Ether) to provide the title compound (20 
mg, 69%) as a colorless oil.  
1H NMR (C6D6, 500MHz) δ = 5.96 (ddd, J = 7.2, 10.3, 17.3 Hz, 1 H), 5.20 (d, J = 18.4 Hz, 1 H), 
5.02 (d, J = 11.0 Hz, 1 H), 4.38 (dd, J = 3.7, 7.1 Hz, 1 H), 4.33 (d, J = 10.3 Hz, 1 H), 4.26 - 4.16 
(m, 2 H), 3.84 (t, J = 6.8 Hz, 2 H), 3.77 - 3.71 (m, 1 H), 3.62 - 3.56 (m, 1 H), 3.55 - 3.51 (m, 1 H), 
3.51 - 3.44 (m, 1 H), 3.41 - 3.35 (m, 1 H), 3.17 (s, 3 H), 2.43 - 2.38 (m, 3 H), 2.07 - 1.99 (m, 1 H), 
1.98 - 1.83 (m, 7 H), 1.80 - 1.67 (m, 3 H), 1.66 - 1.58 (m, 3 H), 1.44 - 1.25 (m, 11 H), 1.24 - 1.14 
(m, 2 H), 1.07 (s, 9 H), 1.04 (s, 18 H), 1.00 (t, J = 8.2 Hz, 9 H), 0.63 (q, J = 7.2 Hz, 6 H), 0.26 (s, 6 
H), 0.20 (s, 3 H), 0.16 (s, 9 H); 13C NMR (C6D6, 126MHz) δ = 139.2, 115.9, 98.4, 85.3, 79.5, 79.4, 
75.2, 74.5, 74.1, 73.8, 71.6, 67.3, 67.2, 67.1, 65.8, 60.3, 56.6, 48.4, 45.6, 42.9, 40.5, 40.4, 32.6, 
31.9, 30.4, 30.1, 28.9, 26.2, 26.2, 26.1, 25.9, 24.0, 22.9, 19.8, 18.5, 18.3, 18.3, 15.4, 14.4, 14.2, 
13.2, 7.0, 5.4, -3.2, -3.7, -3.8, -4.0, -5.1; IR (film): ṽmax = 3364, 2927, 2856, 1644, 1471 cm
-1; []
 
= + 16 (c = 0.3 in CH2Cl2).   
Carbonate 3.71 A solution of diol syn-
3.27 (34 mg, 31 µmol, 1.0 eq) and 
carbonyl diimidazole (51 mg, 0.31 mmol, 
10 eq) in benzene (600 µL) was heated in a sealed tube to 65 °C for 2.5 hours. The mixture was 
filtered directly through a plug of silica gel and the filtrated evaported. The crude residue was 
dissolved in a dichloromethane/pH 7 buffer mixture (9:1, total volume 4 mL) and cooled to 0 °C. 
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DDQ (70 mg, 0.31 mmol, 10 eq) was added in one portion and the reaction mixture stirred at 0 °C 
for 30 minutes, then quenched by the addition of saturated aqueous sodium bicarbonate and 
warmed to room temperature. The layeres were separated and the aqueous layer extracted with 
additional dichloromethane. The combined organics were washed with water and brine, dried 
over Na2SO4 and concentrated. The crude residue was purified by flash column chromatography 
(9:1 → 6:1 Hexanes:Ethyl Acetate) to provide the title compound (30 mg, >95%) as a colorless 
oil.  
1H NMR (C6D6, 500MHz) δ = 5.94 (ddd, J = 7.2, 10.5, 17.4 Hz, 1 H), 5.21 (td, J = 1.3, 17.3 Hz, 1 
H), 5.05 (d, J = 10.4 Hz, 1 H), 4.38 (dd, J = 3.6, 7.3 Hz, 1 H), 4.24 - 4.18 (m, 2 H), 4.12 (dt, J = 
2.0, 10.3 Hz, 1 H), 3.80 (t, J = 6.6 Hz, 2 H), 3.58 (t, J = 9.6 Hz, 1 H), 3.54 - 3.50 (m, 1 H), 3.49 - 
3.43 (m, 1 H), 3.38 - 3.31 (m, 1 H), 3.18 (s, 3 H), 2.35 (tt, J = 1.8, 7.3 Hz, 2 H), 2.07 - 1.83 (m, 7 
H), 1.78 (ddd, J = 2.3, 10.9, 13.6 Hz, 1 H), 1.72 - 1.57 (m, 5 H), 1.44 - 1.28 (m, 4 H), 1.26 - 1.17 
(m, 2 H), 1.06 (s, 9 H), 1.03 - 0.96 (m, 27 H), 0.70 (d, J = 6.7 Hz, 3 H), 0.63 (q, J = 8.2 Hz, 6 H), 
0.26 (s, 3 H), 0.25 (s, 3 H), 0.19 (s, 3 H), 0.18 (s, 3 H), 0.13 (s, 3 H), 0.12 (s, 3 H); 13C NMR 
(C6D6, 126MHz) δ = 147.0, 139.1, 116.2, 89.2, 79.6, 79.2, 75.6, 75.0, 74.6, 74.1, 73.9, 73.8, 66.8, 
65.9, 65.7, 60.2, 56.6, 48.1, 45.3, 41.4, 40.3, 38.1, 32.4, 31.7, 30.1, 28.3, 26.2, 26.0, 24.0, 18.4, 
18.2, 18.1, 15.5, 14.1, 12.6, 7.0, 5.3, -3.8, -3.9, -4.1, -4.5, -5.1; IR (film): ṽmax = 3375, 2926, 2854, 
1765, 1644, 1422 cm-1; HRMS (ESI): Calc. for C51H101O10Si4 [M
+ + H] 985.6472, found 985.6498; 
[]
 = + 7 (c = 0.33 in CH2Cl2).   
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